‹ÆÑ@ƒŠ@ƒX@ƒg

(1999`2003)

 

 


‰p•¶Œ´’˜˜_•¶

•a‘ԉ𖾕”–åi¶—•”–åj

1.         Satoh Y, Williams MR, Habara Y: Effects of AlF4- and ATP on Intracellular calcium dynamics of crypt epithelial cells in mouse small intestine.  Cell Tissue Res 298: 295-305, 1999

2.         Tachikawa E, Itoh K, Kudo K, Harada K, Kashimoto T, Hirota Y: Effects of interferons on cortisol production in bovine adrenal fasciculata cells stimulated by adrenocorticotropin.  J Pharm Pharmacol 51: 465-473, 1999

3.         Tachikawa E, Kudo K, Harada K, Kashimoto T, Miyate Y, Kakizaki A, Takahashi E: Effects of ginseng saponins on responses induced by various receptor stimuli.  Eur J Pharmacol 369: 23-32, 1999

4.         Onodera S, Hicks TP: Evolution of the motor system: Why the elephantfs trunk works like a humanfs hand.  Nueroscientist 5: 217-222, 2000

5.         Tachikawa E, Takahashi M, Kashimoto T: Effects of extract and ingredients isolated from Magnolia obovata Thungberg on catecholamine secretion from bovine adrenal chromaffin cells.  Biochem Pharmacol 60: 433-440, 2000

6.         Cui Z-J, Habara Y, Satoh Y: Photodynamic modulation of adrenergic receptors in the isolated rat hepatocytes.  Biochem Bioph Res Co 277: 705-710, 2000

7.         Mori S, Saino T, Satoh Y: Effect of low temperatures on compound 48/80-induced intracellular Ca2+ changes and exocytosis of rat peritoneal mast cells.  Arch Histol Cytol 63: 261-270, 2000

8.         Shinohe Y, Saino T: Effects of ATP on intracellular calcium dynamics of the perineurium of peripheral nerve bundles.  Histochem Cell Biol 114: 497-504, 2000

9.         Kumagai M, Saino T: Effects of ATP on intracellular calcium dynamics of neurons and satellite cells in rat superior cervical ganglia.  Histochem Cell Biol 115: 285-292, 2001

10.     Fujita R, Kimura S, Kawasaki S, Takashima K, Matsumoto M, Hirano H, Sasaki K: ATP suppresses the K+ current responses to FSH and adenosine in the folliculer cells of Xenopus oocyte.  Jpn J Physiol 51: 491-500, 2001

11.     Kimura S, Kawasaki S, Takashima K, Sasaki K: Physiological and pharmacological characteristics of quisqualic acid-induced K+-current response in the ganglion cells of Aplysia.  Jpn J Physiol 51: 511-521, 2001

12.     Yokota Y, Nara K, Miura H, Kimura S, Kawasaki S, Somei K: Dual roles of protein kinase C in regulation of synaptic transmission on the bullfrog sympathetic ganglia.  J Iwate med Assoc 53: 31-41, 2001

13.     Gesase AP, Satoh Y: Sexual differences effects of castration on secretory mode and intracellular calcium ion dynamics of golden hamster harderian gland.  Cell Tissue Res 304: 81-90, 2001

14.     Warashina A, Satoh Y: Modes of secretagogue-induced [Ca2+]i responses in individual chromaffin cells of the perfused rat adrenal medulla.  Cell Calcium 30: 395-401, 2001

15.     Masumiya H, Kase J, Kawanishi T, Hayakawa T, Miyata S, Sato Y, Nakamura R, Tanaka H, Shigenobu K: Effect of T-type and L-type Ca2+ channel blockade on early phase Ca2+ transients in rat atrial and ventricular cardiomyocytes.  Bioimages 9: 87-93, 2001

16.     Hashikura S, Satoh Y, Cui ZJ, Habara Y: Photodynamic action inhibits compound 48/80-induced exocytosis in rat peritoneal mast cells.  Jpn J Vet Res 49: 239-247, 2001

17.     Tanaka H, Masumiya H, Sekine T, Kase J, Kawanishi T, Hayakawa T, Miyata S, Sato Y, Nakamura R, Shigenobu K: Involvement of Ca2+ waves in excitation-contraction coupling of rat atrial cardiomyocytes.  Life Sci 70: 715-726, 2001

18.     Tachikawa E, Kudo K, Nunokawa, M, Kashimoto T, Takahashi E, Kitagawa S: Characterization of ginseng saponin ginsenoside-Rg3 inhibition of catecholamine secretion in bovine adrenal chromaffin cells.  Biochem Pharmacol 62: 943-951, 2001

19.     Tachikawa E, Mizuma K, Kudo K, Kashimoto T, Yamato S, Ohta S: Characterization of the functional subunit combination of nicotinic acetylcholine receptors in bovine adrenal chromaffin cells.  Neurosci Lett 312: 161-164, 2001

20.     Ogawa T, Hagihara K, Suzuki M, Yamaguchi Y: Brevican in the developing hippocampal fimbria: differential expression in myelinating oligodendrocytes and adult astrocytes suggests a dual role for brevican in central nervous system fiber tract development.  J Comp Neurol 432: 285-295, 2001

21.     Takahashi S, Hitomi J, Satoh Y, Takahashi T, Asakura H, Ushiki T: Fine structure of the mouse portal vein in relation to its peristaltic movement.  Arch Histol Cytol 65: 71-82, 2002

22.     Saino T, Matsuura M, Satoh Y: Application of real-time confocal microscopy to intracellular calcium ion dynamics in rat arterioles.  Histochem Cell Biol 117: 295-305, 2002

23.     Takashima K, Kawasaki S, Kimura S, Fujita R, Sasaki K: Blockade of ionotropic receptor responses by progesterone in the ganglion cells of Aplysia.  Neurosci Res 43: 119-125, 2002

24.     Kudo K, Tachikawa E, Kashimoto T: Inhibition by pregnenolone sulfate of nicotinic acetylcholine response in adrenal chromaffin cells.  Eur J Pharmacol 456: 19-27, 2002

25.     Kitagawa S, Tachikawa E, Kashimoto T: Transbilayer transport of a propyltrimethylammonium derivative of diphenylhexatriene (TMAP-DPH) in bovine blood platelets and adrenal chromaffin cells. J Pharm Pharmacol 54: 1631-1636, 2002

26.     Saino T, Matsuura M, Satoh Y: Comparison of the effect of ATP on intracellular calcium ion dynamics between rat testicular and cerebral arteriole smooth muscle cells.  Cell Calcium 32: 153-16, 2002

27.     Kubo-Watanabe S, Satoh Y, Saino T: Adenosine-5'-triphosphate-induced intracellular calcium changes through gap-junctional communication in the corneal epithelium.  Jpn J Ophthalmol 46: 479-487, 2002

28.     Kubo-Watanabe S, Goto S, Saino T, Tazawa Y, Satoh Y: ATP-induced [Ca2+]i changes in the human corneal epithelium.  Arch Histol Cytol 66: 63-72, 2003

29.     Gesase A, Satoh Y: Apocrine secretory mechanism: recent findings and unresolved problems.  Histol Histopathol 18: 597-608, 2003

30.     Suzuki M, Obara K, Sasaki Y, Sasaki K, Matoh H, Nunosawa F: Comparison of perivascular astrocytic structure between white matter and gray matter of rats.@Brain Res (in press)

31.     Kawasaki S, Kimura S, Fujita R, Sasaki K: The small GTP-binding protein RhoA regulates serotonin-induced Na+ current response in the neurons of Aplysia.  Neurosci Res (in press)

32.     Tanaka H, Sato K, Saito Y, Yamashita T, Agoh M, Okunishi J, Tachikawa E, Suzuki K: Insect Diapause-specific peptide from the leaf beetle has consensus with a putative iridovirus peptide.  Peptides (in press)

33.     Tachikawa E, Kudo K, Hasegawa H, Kashimoto T, Sasaki K, Miyazaki M, Taira H, Lidstrom JM: In vitro inhibition of adrenal catecholamine secretion by steroidal metabolites of ginseng saponins. Biochem Pharmacol (in press)

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

34.     Fukudo S, Abe K, Itoyama Y, Mochizuki S, Sawai T, Hongo M: Psychophysiological stress induces heat shock cognate protein 70 messenger RNA in the hippocampus of rats.  Neuroscience 91: 1205-1208, 1999

35.     Kawamura T, Inada K, Nara N, Wakusawa R, Endo S: Influence of methylprednisolone on cytokine balance during cardiac surgery.@Crit Care Med 27: 545-548, 1999

36.     Yamada Y, Endo S, Nakae H, Kamei Y, Taniguchi S, Ishikura H, Tanaka T, Taki K, Inada K: Nuclear matrix protein levels in burn patients with multiple organ dysfunction syndrome.  Burns 25: 705-708, 1999

37.     Nossik D, Kaplina E, Nossik N, Kalinina L, Tsutsumi R, Miura Y, Sera K, Itoh C, Sato S, Lvov D: A Fe3+/DNA complex induces an anti-human immunodeficiency virus factor(s) in CD4+ lymphocyte cell lines.  Acta Virologica 43: 25-30, 1999

38.     Kato S, Tsutsumi R, Sato S: Nucleotide sequence of the 5' nontranslated and virion polypeptides regions of coxsackievirus B6.  Microbiol Immunol 43: 871-883, 1999

39.     Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Ukitsu M, Genda Y: The methylation status of cytosines in a tau gene promoter region alters with age to downregulate transcriptional activity in human cerebral cortex.  Neurosci Lett 275: 89-92, 1999

40.     Utsugisawa K, Nagane Y, Tohgi H, Yoshimura M, Ohba H, Genda Y: Changes with aging and ischemia in nicotinic acetylcholine receptor subunit alpha7 mRNA expression in postmortem human frontal cortex and putamen.  Neurosci Lett 270: 145-148, 1999

41.     Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Ukitsu M: Local variation in expression of pro- and antithrombotic factors in vascular endothelium of human autopsy brain.  Acta Neuropathol 98: 111-118, 1999

42.     Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Genda Y, Ukitsu M: Reduction with age in methylcytosine in the promoter region-224 approximately-101 of the amyloid precursor protein gene in autopsy human cortex.@Brain Res Mol Brain Res 70: 288-292, 1999

43.     Utsugisawa K, Tohgi H, Yoshimura M, Nagane Y, Ukitsu M: Quantitation of nicotinic acetylcholine receptor subunits alpha 4 and beta 2 messenger RNA in postmortem human brain using a non-radioactive RT-PCR and CCD imaging system.  Brain Res Protoc 4: 92-96, 1999

44.     Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Ukitsu M, Genda Y: Decrease with age in methylcytosines in the promoter region of receptor for advanced glycated end products (RAGE) gene in autopsy human cortex.  Brain Res Mol Brain Res 65: 124-128, 1999

45.     Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C: Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis.  Neurosci Lett 260: 204-206, 1999

46.     Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C: Alteration of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and patients with Alzheimer's disease.  Neurosci Lett 269: 52-54, 1999

47.     Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C: Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis.  Ann Neurol  46:129-131, 1999

48.     Matsuno H, Sawai T, Nezuka T, Uzuki M, Tsuji H, Nishimoto N and Yoshizaki K: Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model.  Arthritis Rheum 41: 2014-2021, 1999

49.     Takahashi Y, Kasahara T, Sawai T, Rikimaru A, Mukaida N, Matsushima K, Sasaki T: The participation of IL-8 in the synovial lesions at an early stage of rheumatoid arthritis.  Tohoku J Exp Med 188: 75-87, 1999

50.     Uzuki M, Watanabe T, Katsura Y, Sawai T: Quantitative histochemical study of hyaluronic acid binding protein and the activity of uridine diphosphoglucose dehydrogenase in the synovium of patients with rheumatoid arthritis.  Anal Quant Cytol Histol 21: 75-80, 1999

51.     Hishinuma T, Nakamura H, Sawai T, Uzuki M, Itabashi Y, Mizugaki M: Microdetermination of prostaglandin E2 in joint fluid in rheumatoid arthritis patients using gas-chromatography /selected ion monitoring.  Prostag Oth Lipid M 58: 179-186, 1999

52.     Watanabe M, Sawai T: Alteration of cross-linking amino acids of elastin in human aorta in association with dissecting aneurysm: Analysis using high performance liquid chromatography.  Tohoku J Exp Med 187: 291-303, 1999

53.     Watanabe M, Takahashi M, Sawai T: Unusual renal involvement of polymyositis complicated with malignant hypertension.  Jap J Rheumatol 9: 381-390, 1999

54.     Kaneko C, Mizunashi K, Tanaka M, Uzuki M, Kikuchi M, Sawai T, Goto M: Relationship between Ca-dependent change of serum PTH and extracellular Ca2+-sensing receptor expression in parathyroid adenoma.  Calcif Tissue Int 64: 271-272, 1999

55.     Sawai T, Goto K, Watanabe M, Endoh W, Ogata K, Nagura H: Constructing a local district telepathology network in Japan.  Anal Quant Cytol Histol 21: 81-84, 1999

56.     Osaki T, Omotezako M, Nagayama R, Hirata M, Iwanaga S, Kasahara J, Hattori J, Ito I, Sugiyama H, Kawabata S: Horseshoe crab hemocyte-derived antimicrobial polypeptides, tachystatins, with sequence similarity to spider neurotoxins.  J Biol Chem 274: 26172-26178, 1999

57.     Kitada M, Mizoguchi A, Tohyama K, Ohtsubo A, Fujimoto E, Chakrabortty S, Ide C: Comparison of the axonal and glial reactions between the caudal and rostral border in the cryoinjured dorsal funiculus of the rat spinal cord.  Restract Neurol Neurosci 14: 251-263, 1999

58.     Maruyama Y, Abe T, Tohgi H, Naoi M: An endogenous MPTP-like dopaminergic neurotoxin, N-methyl(R)salsolinol, in the cerebrospinal fluid decreases with progression of Pakinson's disease. Neurosci Lett 262: 13-16, 1999

59.     Yoshida M, Igarashi A, Suwendra P, Inada K, Masri SM, Komang K, Suda H, Maria TA, Puta ABN, Takikawa Y, Maesawa S, Yoshida H, Chiba M: The first report on human cases serologically diagnosed as japanese enchephalitis in Indonesia.  Southeast Asian J Trop Med Public Heath 30: 698-706, 1999

60.     Suzuki M, Asahara H, Endo S, Inada K, Doi M, Kuroda K, Ogawa A: Increased levels of nitrite/nitrate in the cerebrospinal fluid of patients with subarachnoid hemorrhage.  Neurosurg Rev 22: 96-98, 1999

61.     Kasai T, Endo S, Inada K, Yamada Y, Wakabayashi G, Niimi M, Ishikura H, Tanaka T: Nitrite/Nitrate and type II phospholipase A2 increase in patients with multiple organ dysfunction syndrome.  Crit  Care  Shock 2: 82-86, 1999

62.     Shibata M, Ueshima K, Harada M, Nakamura M, Hiramori K, EndoS, Mukaida H, Suzuki T, Suzuki T, Inada K: Effect of magnesium sulfate pretreatment and significance of matrix metalloproteinase-1 and interleukin-6 levels in coronary reperfusion therapy for patients with acute myocardial infarction. Angiology 50: 573-58, 1999

63.     Yamada Y, Endo S, Shibata M, Kikuchi M, Nakae H, Wakabayashi G, Tanaka T, Taki K, Inada K: Interleukin 1 receptor antagonist and interleukin 10 levels clearly reflect hemodynamics during septic shock.  Crit Care Shock 2: 27-31, 1999

64.     Jia Q, Ohka S, Iwasaki K, Tohyama K, and Nomoto A: Isolation and molecular characterization of a poliovirus type 1 mutant that replicates in the spinal cords of mice.  J Virol 73: 6041-6047, 1999

65.     Kubo Y, Suzuki M, Kudo A, Yoshida K, Suzuki T, Ogasawara K, Ogawa K, Kurose A, Sawai T: Thrombin inhibitor ameliorates secondary damage in rat brain injury: Suppression of inflammatory cells and vimentin-positive astrocytes.  J Neurotrauma 17: 163-172, 2000

66.     Kurose A, Beppu T, Miura Y, Suzuki M, Ogawa A, Arai H, Kubo Y, Sugawara A, Sawai T: Desmoplastic cerebral astrocytoma of infancy intermingling with atypical glial cells.  Pathol Int 50: 744-749, 2000

67.     Nakae H, Endo E, Yamada Y, Inada K: Bound and soluble adhesion molecule and cytokine levels in patients with severe burns.  Burns 26: 139-14, 2000

68.     Takakuwa T, Endo S, Shirakura Y, Yokoyama M, Tamatani M, Tohyama M, Aozasa K, Inada K: Interleukin-10 gene transfer improves the survival rate of mic inoculated with Escherichia coli.  Crit Care Med 28: 26859-2689, 2000

69.     Kawamura T, Nara N, Kadosaki M, Inada K, Endo S: Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery.  Crit Care Med 28: 2201-2208, 2000

70.     Nishikawa Y, Suzuki M, Kuwata N, Ogawa A: Microvascular decompression for treating glossopharyngeal neuralgia complicated by sick sinus syndrome.  Acta Neurochir 142: 351-352, 2000

71.     Miura M, Endo S, Inada K, Inoue Y, Yamada Y, Fujino Y, Baba E, Wakabayashi G, Katsuya H, Sato N, Sato S: Tumor necrosis factor-a and nitrite/nitrate (NOx) levels in patients with acute pancreatitis.  Crit Care Shock 4: 189-194, 2000

72.     Tohgi H, Utsugisawa K, Nagane Y: Hypoxia-induced expression of C1q, a subcomponent of the complement system, in cultured rat PC12 cells.  Neurosci Lett 291: 151-154,  2000

73.     Utsugisawa K, Nagane Y, Obara D, Tohgi H: Increased expression of alpha7 nAChR after transient hypoxia in PC12 cells.  Neuroreport 11: 2209-2212, 2000

74.     Tohgi H, Utsugisawa K, Nagane Y: Protective effect of nicotine through nicotinic acetylcholine receptor alpha 7 on hypoxia-induced membrane disintegration and DNA fragmentation of cultured PC12 cells.  Neurosci Lett 285: 91-94, 2000

75.     Nagane Y, Utsugisawa K, Tohgi H: PCR amplification in bisulfite methylcytosine mapping in the GC-rich promoter region of amyloid precursor protein gene in autopsy human brain.  Brain Res Protoc 5: 167-171, 2000

76.     Utsugisawa K, Nagane Y, Tohgi H: Marked increase in CD44-highly positive cells in hyperplastic thymuses from patients with myasthenia gravis.  Muscle Nerve 23: 507-513, 2000

77.     Tohgi H, Abe T, Takahashi S, Yonezawa H, Utsugisawa K: Pathogenesis of vascular dementia of Binswanger Type (VDBT).  J Stroke Cerebrovasc Dis 9: 45-46, 2000

78.     Kurose A, Oyama K, Murakami Y, Ohyama K, Segawa I, Sawai T: Dilated cardiomyopathy in Noonan syndrome: A first autopsy case.  Hum Pathol 31: 764-767, 2000

79.     Pan LH, Yamauchi K, Sawai T, Nakadate T, Kojima Y, Takahashi N, Adachi K, Kameyama A, Inoue H: Inhibition of binding between E- and P-selectins, and SLeX molecule suppresses the inflammatory response in hypersensitivity pneumonitis in mice.   Am J Respir Crit Care Med  161:  1689-1697, 2000

80.     Nagaoka I, Hirota S, Yomogida S, Ohwada A, Hirata M: Synergistic actions of antibacterial neutrophil defensins and cathelicidins.  Inflamm Res 49: 73-79, 2000

81.     St Swierzko A, Kirikae T, Kirikae F, Hirata M, Cedzynski M, Ziolkowski A, Hirai Y, Kusumoto S, Yokochi T, Nakano M: Biological activities of lipopolysaccharides of Proteus spp. and their interactions with polymyxin B and an 18-kDa cationic antimicrobial protein (CAP18)-derived peptide.  J Med Microbiol 49: 127-138, 2000

82.     Arakawa N, Endo S, Nakamura M, Saito S, Inada K, Ogawa M, Hiramori K: Increased plasma group II phospholipase A2 concentrations in patients with acute myocardial infarction: correlation with tumor necrosis factor-alpha.  Cardiology 94: 106-110, 2000

83.     Nakae H, Endo S, Kikuchi M, Yamada Y, Shibata M, Ishikura H, Tanaka T, Wakabayashi G, Kawamura T, Inada K, Sato S: Nitrite/Nitrate (Nox) levels and hemodynamics during septic shock. Surg Today 30: 683-688, 2000

84.     Endo S, Inada K, Yamada Y, Wakabayashi G, Ishikura H, Tanaka T, Sato S: Interleukin 18 (IL-18) levels in patients with sepsis.  J Med 31: 15-20, 2000

85.     Ozaki M, Tohyama K, Kishida H, Buonanno A, Yano R, Hashikawa T: Roles of neuregulin in synaptogenesis between mossy fibers and cerebellar granule cells.  J Neurosci Res 59: 612-623, 2000

86.     Kawamura T, Inada K, Nara N, Endo S: The authors reply.  Crit Care Med 28: 3374, 2000

87.     Endo S, Inoue Y, Fujino Y, Yamada Y, Sato N, Wakabayashi G, Sakamoto T, Ishikura H, Tanaka T, Inada K, Sato S: Soluble fas and soluble fas L levels in patients with acute pancreatitis.  Res Com Chem Path Phar 108: 179-186, 2000

88.     Kudo A, Suzuki M, Kubo Y, Watanabe M, Yoshida K, Doi M, Kuroda K, Ogawa A: Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin.@Cerebrovasc Dis 10: 424-430, 2000

89.     Sapp E, Kegel KB, Aronin N, Hashikawa T, UchiyamaY, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M: Early and progressive accumulation of reactive microglia in the Huntington's disease brain.  J Neuropathol Exp Neurol 60: 161-172, 2001

90.     Uzuki M, Sasano H, Muramatsu Y, Totsune K, Oki Y, Takahashi K, Iino K, Sawai T: Urocortin in the synovial tissue of patients with rheumatoid arthritis.  Clin Sci 100: 577-589, 2001

91.     Pan LH, Yamauchi K, Uzuki M, Nakanishi T, Takigawa M, Inoue H, Sawai T: Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in idiopathic pulmonary fibrosis.  Eur Respir J  17: 1220-1227, 2001

92.     Zang Y, Tohyama K, Winterbottom JK, Haque NSK, Schachner M, Lieberman AR, Anderson PN,: Correlation between putative inhibitory molecules at the dorsal root entry zone and failure of dorsal root axonal regeneration.  Mol Cellular Neurosci 17: 444-459, 2001

93.     Hirano N, Haga S, Sada Y, Tohyama K: Susceptibility of rats of different ages to inoculation with swine haemagglutinating encephalomyelitis virus (Coronavirus) by various routes.  J Comp Pathol 125: 8-14, 2001

94.     Hirano N, Tohyama K, Ootani N, Hashikawa T: Infection of hemagglutinating encephalomyelitis virus (HEV) at the visual pathways of rats.  Adv Exp Med Biol 494: 149-154, 2001

95.     Hirano N, Tohyama K, Taira H, Hashikawa T: Spread of hemagglutinating encephalomyelitis virus (HEV) in the CNS of rats inoculated by intranasal route.   Adv Exp Med Biol 494: 127-132, 2001

96.     Mihara M, Utsugisawa K, Konno S, Tohgi H: Isolated lesions limited to the bilateral substantia nigra on MRI associated with influenza A infection.   Eur Neurol 45: 290-291, 2001

97.     Nagane Y, Utsugisawa K, Obara D, Tohgi H: NKT-associated markers and perforin in hyperplastic thymuses from patients with myasthenia gravis.  Muscle Nerve 24: 1359-1364, 2001

98.     Yamauchi K, Tanifuji Y, Pan LH, Yoshida T, Sakurai S, Goto S, Kuroda S, Kobayashi H, Inoue H: Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics.  J Asthma 38: 51-57, 2001

99.     Matsuno H, Yudoh K, Uzuki M, Kimura T: The SCID-HuRAg mouse as a model for rheumatoid arthritis.@Modern Rheumatol 11: 6-9, 2001

100.  Nakao K, Shibusawa M, Ishihara A, Yoshizawa H, Tsunoda A, Kusano M, Kurose A, Makita T, Sasaki K: Genetic changes in colorectal carcinoma tumors with liver metastases analyzed by comparative genomic hybridization and DNA ploidy.  Cancer 91: 721-726, 2001

101.  Kurose A, Yoshida W, Yoshida M, Sawai T: Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis.  Cytometry 44: 349-354, 2001

102.  Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I: Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D2 production from mast cells.   Eur J Immunol 31: 1066-1075, 2001

103.  Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M: Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60: 161-172, 2001

104.  Ohka S, Ohno H, Tohyama K, Nomoto A: Basolateral sorting of human poliovirus receptor alpha involves an interaction with the mu 1B subunit of the clathrin adaptor complex in polarized epithelial cells.  Biochem Biophy Res Com 287: 941-948, 2001

105.  Sawai T, Uzuki M: Dynamics of hyaluronate in patients with rheumatoid arthritis.  Connective Tissue 33: 253-259, 2001

106.  Hatori M, Ohtani H, Yamada N, Uzuki M, Kokubun S: Synchronous multifocal osteosarcoma with lymphatic spread in the lung: an autopsy case report.  Jpn J Clin Oncol 31: 562-566, 2001

107.  Shibata C, Kobari M, Tsuchiya T, Arai K, Anzai R, Takahashi M, Uzuki M, Sawai T, Yamazaki T: Pancreatectomy combined with superior mesenteric-portal vein resection for adenocarcinoma in pancreas.   World J Surg 25: 1002-1005, 2001

108.  Nakazawa F, Matsuno H, Yudoh K, Katayama R, Sawai T, Uzuki M, Kimura T: Methotrexate inhibits rheumatoid synovitis by inducing apoptosis.@J Rheumatol 28: 1800-1808, 2001

109.  Umeda H, Kawamorita K, Suyama K: High-performance liquid chromatographic quantification of allysine as bis-p-cresol derivative in elastin.   Amino Acids 20: 187-199, 2001

110.  Umeda H, Nakamura F, Suyama K: Oxodesmosine and isooxodesmosine, candidates of oxidative maetabolic intermediates of pyridinium cross-linking in elastin.   Arch Biochem Biophys 385: 209-219, 2001

111.  Umeda H, Takeuchi M, Suyama K: Two new elastin cross-links having pyridine skeleton.   J Biol Chem 276: 12579-12587, 2001

112.  Nakae H, Endo S, Inoue Y, Fujino Y, Onodera M, Sakamoto T, Tanaka T, Inada K, Sato S: Chronological changes in the serum levels of endothelin-1 in patients with acute pancreatitis.  Crit Care Shock 4: 1441-1444, 2001

113.  Nakae H, Endo S, Sato N, Wakabayashi G, Inada K, Sato S: Involvement of soluble adhesion molecules in acute pancreatitis.    Eur Surg Res 33: 377-382, 2001

114.  Sano H, Kumagai J, Sawai T: Experimental fascial patch autografting for the supraspinatus tendon defect-remodeling process of the grafted fascia and the insertion into bone-.    J Shoulder Elb Surg 11: 166-173, 2002

115.  Yoshida M, Ichinohe S, Uzuki M, Yoshida W, Sawai T, Shimamura T: Development of large pseudocysts adjacent to the knee joint in rheumatoid arthritis.-Assessment of radiological and histopathological approaches.  Modern Rheumatol  12: 128-133, 2002

116.  Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, Yonezawa T, Saeki Y, Panayi GS, Pitzalis C, Kimura T: The role of TNF-ƒ¿ in the pathogenesis of inflammation and joint destruction in RA: A study using a human RA / SCID mice chimera.   Rheumatology 41: 329-337, 2002

117.  Matsuno H, Yudoh K, Uzuki M, Nakazawa F, Sawai T, Yamaguchi N, Olsen BR, Kimura T: Treatment with angiogenesis inhibitor endostatin represents a novel therapeutic approach in patients with rheumatoid arthritis.  J Rheumatol 29: 890-895, 2002

118.  Matsuno H, Yudoh K, Nakazawa F, Sawai T, Uzuki M, Nishioka K, Yonehara S, Nakayama J, Ohtsuki M, Kimura T: Anti-rheumatic effects of humanized anti-Fas monoclonal antibody in human RA/SCID mice chimera.   J Rheumatol 29: 1609-1614, 2002

119.  Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M, Ogawa A, Sawai T: Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma.   Neuro Res 24: 677-683, 2002

120.  Utsugisawa K, Nagane Y, Obara D, Tohgi H: Over-expression of ƒ¿7 nicotinic acetylcholine receptor prevents G1-arrest and DNA fragmentation in PC12 cells after hypoxia.   J Neurochem 81: 497-505, 2002

121.  Munakata R, Utsugisawa K, Nagane Y, Yamagata M, Oikawa M, Obara D, Tohgi H: The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis.   Eur Neurol  48: 115-117, 2002

122.  Utsugisawa K, Nagane Y, Obara D, Tohgi H: Over-expression of ƒ¿7 nicotinic acetylcholine receptor induces sustained ERK phosphorylation and N-cadherin expression in PC12 cells.  Mol Brain Res 106: 88-93, 2002

123.  Obara D, Utsugisawa K, Nagane Y, Tohgi H: Hypoxic condition interferes with phosphorylation of Akt at Thr308 in cultured rat PC12 cells.   Neurosci Lett 332: 167-170, 2002

124.  Nakae H, Endo S, Yamada Y, Sato K, Akasaka T, Makabe H, Kaku L, Wakabayashi G, Inada K, Sato S: Interleukin 11 and stem cell factor levels in patients with disseminated intravascular coagulation: a report of four cases.@Crit Care Shock 5: 126-129, 2002

125.  Nakae H, Endo S, Yamada Y, Aoki H, Inoue Y, Kuroda K, Wakabayashi G, Tajimi K, Inada K, Sato S: Evaluation of chronological changes in protein C activity and TNF-a and NOx levels in sepsis: a report of four cases.    Crit Care Shock 5: 33-36, 2002

126.  Konno D, Ko J-A, Usui S, Hori K, Maruoka H, Inui M, Fujikado, Tano Y, Suzuki T, Tohyama K, et al.: The postsynaptic density and dendritic raft localization of PSD-Zip70, which contains an N-myristoylation sequence and leucine-zipper motifs.    J Cell Sci 115: 4695-4706, 2002

127.  Hayashi S, Osawa T, Tohyama K: Comparative observations on corneas, with special reference to Bowman's layer and Descemet's membrane in mammals and amphibian.   J Morphol 254: 247-258, 2002

128.  Izumiyama T, Hama H, Miura M, Hatakeyama A, Suzuki Y, Sawai T, Saito T: Frequency of broncho-bronchiolar disease in rheumatoid arthritis: an examination by high-resolution computed tomography. Mod Rheumatol  12: 311-317, 2002

129.  Naganawa S, Sato S, Nossik D, Takahashi K, Hara T, Tochikubo O, Kitamura K, Honda M, Nakasone T: First report of CRF03_AB recombinant HIV type 1 in injecting drug users in Ukraine.   AIDS Res Hum Retrov 18: 1145-1149, 2002

130.  Utsugisawa K, Nagane Y, Yonezawa H, Obara D, Kondoh R, Tohgi H: Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells.  Muscle Nerve 27: 245-248, 2003

131.  Utsugisawa K, Nagane Y, Obara D, Kondoh R, Yonezawa H, Tohgi H: Interleukin-2 production by peripheral blood mononuclear cells from patients with myasthenia gravis.   Eur Neurol 49: 160-163, 2003

132.  Nagane Y, Utsugisawa K, Obara D, Yamagata M, Tohgi H: Dendritic cells in hyperplastic thymuses from patients with myasthenia gravis.   Muscle Nerve 27: 582-589, 2003

133.  Yoshida W, Uzuki M, Kurose A, Yoshida M, Nishida J, Shimamura T, Sawai T: Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis.   Hum Pathol 34: 65-73, 2003

134.  Miura Y, Kurose A, Kondo M, Maruyama A, Shibata Y, Kanno H, Sawai T: Claer cell myoepithelial carcinoma of the breast.   Tohoku J Exp Med 200: 103-109, 2003

135.  Pan L-H, Ito H, Kurose A, Yamauchi K, Inoue H, Sawai T: Pulmonary lymphangioleiomyomatosis. Tohoku J Exp Med 199: 119-126, 2003

136.  Inada K, Tajkahashi K, Ichinohe S, Suda H, Tsuchiya M, Takahashi J, Matsuura S, Kasai T, Yoshida M, Endo S, Sato S: A silkworm larvae plasma test for detecting peptidoglycan in cerebrospinal fluid is useful for the diagnosis of bacterial meningitis.  Mircrobiol Immunol 47: 701-707, 2003

137.  Hiranno N, Nomura R, Tawara T, Tohyama K: Neurotropism of swine haemagglutinating encephalomyelitis virus (coronavirus) in mice depending upon age and route of infection.   J Comp Pathol (in press)

138.  Koike Y, Uzuki M, Kokubun S, Sawai T: Inflammatory cells infiltration improves the lumbar disc hernia.   Spine (in press)

139.  Yoshino O, Matsuno H, Nakamura H, Yudoh K, Abe Y, Sawai T: The role of Fas-mediated apoptosis after traumatic spinal cord injury.   Spine (in press)

140.  Ogawa Y, Ohtsuki M, Uzuki M, Sawai T, Onozawa Y, Nakayama J, Yonehara A, Kimua T, Matsuno H: Induction of apoptosis to activated CD4+ T cells suppresses osteoclastogenesis in rheumatoid arthritis.   Arthritis Rheum (in press)

141.  Sawai T: Possible another important function of VEGF related to polyneuropathy.   Internal Med (in press)

 

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

142.  Ogasawara K, Koshu K, Yoshimoto T, Ogawa A: Transient hyperemia immediately after rapid decompression of chronic subdural hematoma.   Neurosurgery 45: 484-489, 1999

143.  Takahashi S, Tohgi H, Yonezawa H, Obara S, Yamazaki E: The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease.   J Neurol Sci 167: 56-61, 1999

144.  Beppu T, Yoshida Y, Arai H, Wada T, Suzuki M, Ogawa A, Hakozaki S, Kubo N: A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas.   J Neuro-Oncol 49: 213-218, 2000

145.  Ogasawara K, Ogawa A, Doi M, Konno H, Suzuki M, Yoshimoto T: Prediction of acute embolic stroke outcome after local intraarterial thrombolysis: Value of pretreatment and posttreatment 99mTc-Ethyl cysteinate dimer single photon emission computed tomography.  J Cereb Blood Flow Metab 20: 1579-1586, 2000

146.  Kudo A, Suzuki M, Kubo Y, Watanabe M, Yoshida K, Doi M, Kuroda K, Ogawa A: Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm.@Cerebrovascular Diseases 10: 424-430, 2000

147.  Ogasawara K, Ogawa A, Okuguchi T, Kobayashi M, Suzuki M, Yoshimoto T: Postoperative hyperperfusion syndrome in elderly patients with chronic subdural hematoma.  Surg Neurol 54: 155-159, 2000

148.  Ogawa A, Suzuki M, Ogasawara K: Aneurysms at nonbranching sites in the supraclinoid portion of the internal carotid artery: internal carotid artery trunk aneurysms.   Neurosurgery 47: 578-586, 2000

149.  Suzuki M, Otawara Y, Doi M, Ogasawara K, Ogawa A: Neurological grades of patients with poor-grade subarachnoid hemorrhage improve after short-term pretreatment.   Neurosurgery 47: 1098-1105, 2000

150.  Abe M, Otawara Y, Suzuki M, Tomitsuka N, Ogawa A, Hongo S, Abe M: Sonic detection system for cervical and intracranial vascular disease.   Neurosurg Rev 23: 90-93, 2000

151.  Sasaki M, Oikawa H, Tamakawa Y, Takahashi S, Tohgi H: Disorganized unilateral cerebellar folia: a mild form of cerebellar cortical dysplasia.   Neuroradiology 43: 151-155, 2001

152.  Oikawa H, Sasaki M, Tamakawa Y, Kamei A: MR findings of Papez circuit in mesial temporal sclerosis. Neuroradiology 43: 205-210, 2001

153.  Ogasawara K, Ogawa A, Ezura M, Yoshimoto T: Dynamic and static 99mTc-ECD SPECT imaging of subacute cerebral infarction: Comparison with 133Xe SPECT.   J Nucl Med 42: 543-547, 2001

154.  Ogasawara K, Ogawa A, Konno H, Shibanai K, Doi M, Kuroda K, Yoshimoto T: Combination of early and delayed single-photon emission tomography imaging using technetium-99m ethyl cysteinate dimer immediately after local intraarterial thrombolysis.   Eur J Nucl Med 28: 498-505, 2001

155.  Ogasawara K, Yasuda S, Beppu T, Kobayashi M, Doi M, Kuroda K, Ogawa A: Brain PET and technetium-99m-ECD SPECT imaging in Lhermitte-Duclos disease.   Neuroradiology 43: 993-996, 2001

156.  Inoue T, Shimizu H, Yoshimoto T, Kabasawa H: Spatial functional distribution in the corticospinal tract at the corona radiata: A three-dimensional anisotropy contrast study.   Neurol Med-Chir 41: 293-299, 2001

157.  Mikami C, Suzuki M, Tsuiki K, Ogawa A:  Effect of nicardipine and magnesium on cerebral infarction-Brain surface perfusion technique.   Cerebrovasc Dis 11: 44-50, 2001

158.  Ogasawara K, Ogawa A, Ezura M, Konno H, Suzuki M, Yoshimoto T: Brain single-photon emission CT studies using 99mTc-HMPAO and 99mTc-ECD early after recanalization by local intraarterial thrombolysis in patients with acute embolic middle cerebral artery occlusion.   Am J Neuroradiol 22: 48-53, 2001

159.  Inoue K, Kawashima R, Sugiura M, Ogawa A, Schormann T, Zilles K, Fukuda H: Activation on the ipsilateral posterior parietal cortex during tool use: A PET study.   Neuro Image 10: 1469-1475, 2001

160.  Ogasawara K, Beppu T, Yasuda S, Kobayashi M, Yukawa H, Ogawa A: Blood fiow and oxygen metabolism in a case of Lhermitte-Duclos Disease: results of positron emission tomography.@J Neuro-Oncol  55: 59-61, 2001

161.  Suzuki M, Doi M, Otawara Y, Ogasawara K, Ogawa A: Intrathecal administration of nicardipine hydrochloride to prevent vasospasm in patients with subarachnoid hemorrhage.   Neurosurg Rev 24: 180-184, 2001

162.  Ogasawara K, Yoshida K, Otawara Y, Kobayashi M, Yasuda S, Doi M, Ogawa A: Cerebral blood flow imaging in arteriovenous malformation complicated by normal perfusion pressure breakthrough.   Surg Neurol 56: 380-384, 2001

163.  Suzuki M, Doi M, Otawara Y, Ogasawara K, Ogawa A: Intrathecal administration of nicardipine hydrochloride to prevent vasospasm in patients with subarachnoid hemorrhage.   Neurosurg Rev 24: 180-184, 2001

164.  Tohgi H, Takahashi S, Abe T, Utsugisawa K: Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis.   Eur Neurol 46: 1-10, 2001

165.  Sasaki M, Oikawa H, Yoshioka K, Tamakawa Y, Konno H, Ogawa A: Combining time-resolved and single-phase 3D techniques in contrast-enhanced carotid MR angiography.   Magn Reson Med Sci  1: 1-6, 2002

166.  Takahashi S, Yonezawa H, Takahashi J, Kudo M, Inoue T, Tohgi H: Selective reduction of diffusion anisotropy in white matter of Alzheimer disease brains measured by 3.0 Tesla magnetic resonance imaging.   Neurosci Lett 332: 45-48, 2002

167.  Ogasawara K, Konno K, Yasuda S, Yukawa H, Ogawa A: Very early and standard Tc-99m ethyl cysteinate dimer SPECT imaging in a patient with reperfusion hyperemia after acute cerebral embolism.   Clinical Nucl Med 27: 105-108, 2002

168.  Suzuki M, Kudo A, Sugawara A, Yoshida K, Kubo Y, Suzuki T, Ogasawara K, Doi M, Ogawa A: Amino acid concentrarions in the blood of the jugular vein and peripheral artery after traumatic brain Injury: Decreased release of glutamate into the jugular vein in the early phase.   J Neurotrauma 19: 285-292, 2002

169.  Matsuura H, Inoue T, Konno H, Sasaki M, Ogasawara K, Ogawa A: Quantification of susceptibility artifacts produced from various biomaterials for neurosurgical implants in 3.0-tesla magnetic resonance imaging.   J Neurosurg 12: 1472-1475, 2002

170.  Oikawa H, Sasaki M, Tamakawa Y, Ehara S, Tohyama K: The substantia nigra in Parkinson disease: proton density weighted spin-echo and fast.   Am J Neuroradiol 23: 1747-175, 2002

171.  Ogasawara K, Ogawa A, Terasaki K, Shimizu H, Tominaga T, Yoshimoto T: Use of cerebrovascular reactivity in patients with symptomatic major cerebral artery occlusion to predict 5-year outcome: comparison of xenon-133 and iodine-123-IMP single-photon emission computed tomography.   J Cereb Blood Flow Metab 22: 1142-1148, 2002

172.  Iwata R, Pascali C, Bogni A, Flumoto S, Terasaki K, Yanai K: [18F]Fluoromethyl triflate: a novel and reactive [18F]fluoromethylating agent: preparation and application to the on-column preparation of [18F]fluorochpline.   Appl Radiat Isot 57: 347-352, 2002

173.  Beppu T, Kamada K, Yoshida Y, Arai H, Ogasawara K, Ogawa A: Change of oxygen pressure in glioblastoma tissue under various conditions.  J Neuro-Oncol  58: 47-52, 2002

174.  Ogasawara K, Ogawa A, Yoshimoto T: Cerebrovascular reactivity to acetazolamide and outcome in patients with symptomatic internal carotid or middle cerebral artery occlusion a xenon-133 single-photon emission computed tomography study.   Stroke 33: 1857-1862, 2002

175.  Ogasawara K, Yasuda S, Yukawa H, Yamagata M, Kin M, Ogawa A: Atypical finding of brain Tc-99m-ECD SPECT imaging in herpes simplex encephalitis.   Ann Nucl Med 16: 347-350, 2002

176.  Otawara Y, Ogasawara K, Ogawa A, Kogure T: Dissecting aneurysms of the bilateral vertebral arteries with subarachnoid hemorrhage: Report of three cases.   Neurosurg 50: 1372-1375, 2002

177.  Otawara Y, Ogasawara K, Ogawa A, Sasaki M, Takahashi K: Evaluation of vasospasm after subarachnoid hemorrhage by use of multislice computed tomograhpic angiography.   Neurosurg 51: 939-943, 2002

178.  Akabane A, Jokura H, Ogasawara K, Takahashi K, Sugai K, Ogawa A, Yoshimoto T: Rapid development of interanidal aneurysm with perifocal brain edema in an unruptured cerebral arteriovenous malfoemation.   J Neurosurg 97: 1436-1440, 2002

179.  Suzuki M, Kawamura S, Watanabe H, Sakai A: Late-onset psychosis with agenesis of the corpus callosum.   Psychogeriatrics 2: 187-190, 2002

180.  Yoshioka Y, Oikawa H, Ehara S, Inoue T, Ogawa A, Kambara Y, Itazawa S, Kubokawa M: Noninvasive estimation of temperature and pH in human lower leg muscles using 1H nuclear magnetic resonance spectroscopy.   Spectroscopy 16: 183-190, 2002

181.  Inoue T, Ogasawara K, Konno H, Ogawa A, Kabasawa H: Diffusion tensor imaging in patients with major cerebral artery occlusive disease.   Neurol Med Chir 43: 421-426, 2003

182.  Beppu T, Inoue T, Shibata Y, Kurose A, Arai H, Ogasawara K, Ogawa A, Nakamura S, Kabasawa H: Measurement of fractional anisotropy using diffusion tensor MRI in supratentorial astrocytic tumors. J Neuro-Oncol 63: 109-116, 2003

183.  Kashimura H, Inoue T, Ogasawara K, Ogawa A: Preoperative evaluation of neural tracts using three-dimensional anisotropy contrast imaging.   Neurosurgery 52: 1226-1229, 2003

184.  Yoshioka K, Niinuma H, Ohira A, Nasu K, Kawakami T, Sasaki M, Kawazoe K: MR angiography and CT angiography of the artery of Adamkiewicz: noninvasive preoperative assessment of thoracoabdominal aortic aneurysm.   Radiographics 23: 1215-122, 2003

185.  Sasoh M, Ogasawara K, Kuroda K, Okuguchi T, Terasaki K, Yamadate K, Ogawa A: Effects of EC-IC bypass surgery on cognitive impairment in patients with hemodynamic cerebral ischemia.   Surg Neurol 59: 455-460, 2003

186.  Ogasawara K, Okuguchi T, Sasoh M, Kobayashi M, Yukawa H, Terasaki K, Inoue T, Ogawa A: Qualitative versus quantitative assessment of cerebrovascular reactivity to acetazolamide using iodine-123-N-Isopropyl-p-Iodoamphetamine SPECT in patients with unilateral major cerebral artery occlusi.   Am J Neuroradiol 24: 1090-1095, 2003

187.  Ogasawara K, Ito H, Sasoh M, Okuguchi T, Kobayashi M, Yukawa H, Terasaki K, Ogawa A: Quantitative measurement of regional cerebrovascular reactivity to acetazolamide using 123I-N-isopropyl-p-iodoamphetamine autoradiography with SPECT: validation study using H215O with PET. J Nucl Med 44: 520-525, 2003

188.  Ogasawara K, Noda A, Yasuda S, Kobayashi M, Yukawa H, Ogawa A: Effect of calcium antagonist on cerebral blood flow and oxygen metabolism in patients with hypertension and chronic major cerebral artery occlusion: a positron emission tomography study.   Nucl Med Commun 24: 71-76, 2003

189.  Beppu T, Kamada K, Nakamura R, Oikawa H, Takeda M, Fukuda T, Arai H, Ogasawara K, Ogawa A: A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas.   J Neuro-Oncol  61: 161-170, 2003

190.  Kuroda K, Kanbara Y, Inoue T, Ogawa A: Analysis of NMR-CT images to detect the xylem dysfunction and lesiona in tree trunks.   IAWA Jounal 23: 469-470, 2003

191.  Ogasawara K, Yukawa H, Kobayashi M, Mikami C, Konno H, Terasaki K, Inoue T, Ogawa A: Prediction and Monitoring of cerebral hyperfusion after carotid endarterectomy by using single-photon emission computerized tomography scanning.   J Neurosurg 99: 504-510, 2003

192.  Shouzushima M, Tsutsumi R, Sato S, Terasaki K, Izumisawa M, Sato H, Shoji S, Sakamaki K: Quantification of  11C-methionine uptake during proliferation of cultured human cancer cells. Rdioisotopes 52: 10-16, 2003

193.  Sasaki M, Inoue T, Tohyama K, Ehara S, Ogawa A: High field MRI: current concepts on clinical and microscopic imaging.   Magn Reson Med Sci, 2003 (in press)

194.  Sasaki M, Oikawa H, Ehara S: Clinical Impact of 16-row Multislice CT on the Central Nervous System Imaging.  Diagnostic Imaging, 2003 (in press)

195.  Oikawa H, Sasaki M, Ehara S, Abe H: Substantia innominata: MR findings in Parkinson disease. Neuroradiology, 2003 (in press)

196.  Mikami C, Inoue T, Ogasawara K, Ogawa A: Medullary streaks in a patient with atherosclerotic internal carotid artery occlusion: Case report.   Surg Neurol (in press)

197.  Inoue T, Ogasawara K, Beppu T, Ogawa A: Three-Dimensional Anisotropy Contrast Imaging of Gliomatosis Cerebri: Two Case Reports.   Surg Neurol  (in press)

198.  Sasaki T, Funaki Y, Shozushima M, Terasaki K: Effect of anoxia on choline uptake and release of acetylcholine in brain slices estimated with a bioradiographic technique using [11C] choline. Radioisotopes (in press)

199.  Shozushima M, Tsutsumi R, Terasaki K, Sato S, Nakamura R, Sakamaki K: Augmentation effects of lymphocyte activation by antigen-presenting.   Ann Nucl Med (in press)

200.  Ito N, Hanawa A, Suzuki K, Nabeshima N, Nagai Y, Natsuhori M, Ishikawa T, Hatakeyama S, Futatsugawa S,Terasaki K, Sakamoto Y: External dose estimation of the human related to Veterinary Nuclear Medicine of companion animals.   Radioisototes (in press)

201.  Terasaki K, Takahashi K, Sasaki M, Shozushima M, Iwata R: Adaptation of an automated [11C]methylation system for the loop method using [11C] methyl triflate.   Radioisotopes (in press)

 


‰p•¶‘àE•ª’S’˜‘

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         Kawasaki S, Kimura S, Fujita R, Takashima K, Sasaki K, Sato M: Facilitatory effect of calmodulin-dependent protein kinase on the K+-current responses to dopamine, acetylcholine, and Phe-Met-Arg-Phe-NH2 in the ganglion cells of Aplysia, pp 97-100, Snow Synaptic Responses and Modulation, Kuba K, Higashida H, Brown D, Yoshioka T ed, Springer, Amsterdam, 1999

2.         Onodera S: Evolution of the motor system: why the elephant's trunk works like a human's hand. Neuroscientist 5: 217-226, 1999

3.         Saino T, Satoh Y: Application of real-time confocal laser scanning microscopy to observe living cells in tissue specimens.   Microscopy (in press)

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

4.         Sawai T, Uzuki M: Serum hyaluronic acid level is a good marker for evaluating the process of joint destruction in rheumatoid arthritis, pp 273-277, Excerpta Medica International Congress Series (ICS), Endo M ed, Elsevier Science BV, Amsterdam, 2001

5.         Uzuki M, Sawai T: A comparison of the affinity of sodium hyaluronate of various molecular weights for degenerated cartilage: a histochemical study using hyaluronic acid binding protein, pp 279-284, Excerpta Medica International Congress Series (ICS), Endo M ed, Elsevier Science BV, Amsterdam, 2001

6.         Hirano N, Tohyama K, Taira H, Hashikawa T: Swine coronavirus (HEV) as a transneuronal tracer for analyzing polysynaptic pathways in the CNS of laboratory animal, pp 41-42, Animal Research and Welfare, Association for Laboratory Animal ed, Lab Anim Ltd., London, 2001

 

 


‘ÛƒVƒ“ƒ|ƒWƒEƒ€

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         Satoh Y, Miyata S, Saino T: Dynamic morphology by real-time digital imaging analysis: with special reference to the intracellular calcium ion dynamics, XV Congress of IFA, 1999, 9, Rome (Italy)

2.         Satoh Y: Real time confocal microscopy for dynamic morphology of living tissue specimens, 15th International Morphological Sciences, 2000, 9, Kyoto

3.         Satoh Y: Real time confocal microscopy for dynamic morphology of living tissue specimens. 15th International Morphological Sciences, 15th International Morphological Sciences, 2000, 9, Kyoto

4.         Satoh Y, Saino T: ATP-induced intracellular calcium changes in the peripheral nervous system, The Joint JAAA-AAAA Symposium, 2001, 4, Kochi

5.         Nakagawa H, Tanigawa T, Tomita K, Tomihara Y, Araki Y, Tachikawa E: Recent studies in sea urchin venomes, International Symposium on Toxins and Natural Products in Honor of Professor Anthony T. Tu, 2002, 11, Naha

6.         Tachikawa E, Nagaoka Y, Iida  Fujita T, Nakagaw H: Trichosporin- an ƒ¿-aminoisobutyric acid-containing peptide isolated from Trichoderma polysporum, forms Ca2+-permeable channels and results in Ca2+ influx into cells, International Symposium on Toxins and Natural Products in Honor of Professor Anthony T. Tu, 2002, 11, Naha

7.         Satoh Y, Saino T, Goto S: Confocal microscopy for dynamic morphology of living tissue/cells: with special reference to [Ca2+]i changes induced by ATP, 6th Joint Meeting of the JSHC and HCS, 2003,7, Sheattle

8.         Kudo K, Tu AT, Tachikawa E, Kashimoto T: Characterization of hyaluronidase isolated from Agkistrodon contortrix contortrix (Southern copperhead) venom, International Symposium on Toxins and Natural Products in Honor of Professor Anthony T. Tu, 2003, 11, Naha

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

9.         Inada K: The role of anti-inflammatory cytokines in sepsis, The 5th National Congress of Indonesian Tropical and Infectious Diseases Research Society, 1999, 11, Makassar (Indonesia)

10.     Tohgi H, Abe T, Takahashi S, Yonezawa H, Utsugizawa K: Pathogenesis of vascular dementia of Binswanger type, International Stroke Society Regional Meeting, 1999, 4, Yokohama

 

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

11.     Sasaki M: Multidetector-row CT in central nervous system: clinical impact on cerebrovascular disorders, 2nd International Symposium on Multidetector-row CT, 2002, 9, Tokyo

12.     Sasaki M: CT in the assessment of perfusion in stroke patients, Advanced Imaging Multidisciplinary Symposia: International Neuroimaging Symposium, 2003, 6, Tokyo

 


‰p•¶Proceedings

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         Watanabe M, Doi M, Tsuiki K, Suzuki M, Sasaki K, Ogawa A: Involvement of protein tyrosine kinase activation in the mechanism of cerebral vasospasm, Cerebral Vasospasm, 1999

2.         Doi M, Watanabe M, Tsuiki K, Suzuki M, Sasaki K, Ogawa A:  Mechanism of the mutual augmenting effect of spasmogenic agents, Cerebral Vasospasm, 1999

3.         Tachikawa E, Hasegawa H, Kudo K, Kashimoto T, Miyate Y, Kakizaki, A, Takahashi, K, Takahashi E: Inhibitory effects of ginseng saponins metabolized in digestive tracts on adrenal secretion of catecholamines in vitro, Advances in Ginseng Research 2002, 2002, 10, Seoul

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

4.         Uzuki M, Sasano H, Totsune K, Takahashi K, Sawai T: Urocortin (UCN) and corticotropin-releasing factor (CRF) receptors in the synovial tissue of patients with rheumatoid arthritis (RA), Arthritis Rheum, 1999

5.         Yoshida M, Uzuki M, Kurose A, Ichinohe S, Sawai T, Shimamura T: Abundant localization of matrix metalloproteinase 9 and its inhibitor in osteoclasts and osteoblasts at sites of the excessive bone resorption in rheumatoid arthritis, Arthritis Rheum, 2000

6.         Yoshida W, Uzuki M, Yoshida M, Nishida J, Sato T, Hosaka M, Shimamura T, Sawai T: Histological and cellular characterization of pigmented villonodular synovitis, Arthritis Rheum, 2000

7.         Uzuki M, Matsuno H, Yudoh K, Nakazawa F, Katayama R, Kimura T, Sawai T: Apoptotic chondrocyte death and matrix metalloproteinases in rheumatoid arthritis, Arthritis Rheum, 2000

8.         Tsuchihashi Y, Okada Y, Ogushi Y, Mazaki T, Tsutsumi Y, Sawai T: The current status of medicolegal issues surrounding telepathology and telecytology in Japan, Journal of Telemedicine & Telecare, 2000

9.         Nakae H, Endo S, Kikuchi M, Yamada Y, Shibata M, Inada K, Inada H: Nitrite / Nitrate levels reflect hemodynamics during septic shock, 5th World Congress on Trauma, Shock, Inflammation and Sepsis, 2000

10.     Yoshida M, Uzuki M, Yoshida W, Itoh T, Ichinohe S, Sawa T, Shimamura T: Abundant expression of matrix metalloproteinase 9 and osteoclast differentiation factor mRNA in osteoclasts and osteoblasts at sites of punnus bone interface in rheumatoid arthritis, Arthritis Rheum, 2001

11.     Ouchi N, Uzuki M, Yoshida M, Shimamura T, Sawai T: Cartilage destruction is partly induced by the internal proteolytic enzymes and apoptotic phenomenon of chondrocytes in polychondritis, Arthritis Rheum, 2001

12.     Matsuno H, Yudoh K, Nakazawa F, Uzuki M, Sawai T, Otsuki M, Ogawa Y, Nishioka, Kimura T: Treatment with novel humanaized anti-Fas monoclonal antibody in rheumatoid arthritis, Arthritis Rheum, 2001

13.     Tanaka M, Fujii K, Tsuji M, Funaki K, Ueno Y, Tanabe N, Hayashi H, Sawai T, Ito Y, Nishizawa T, Sawai T: Early immune reaction to type II collagen and cartilage degeneration in MRL/Mp-lpr mouse, Arthritis Rheum, 2001

14.     Uzuki M, Kaiyama J, Miyoshi T, Sawai T: Three hyaluronan synthases, HAS1, HAS2, HAS3 and hyaluronan synthetic activity in the synovial tissue of patients with rheumatoid arthritis, Arthritis Rheum, 2002

15.     Yoshida M, Uzuki M, Yoshida W, Ouchi N, Koyama A, Ichinohe S, Sawai T, Shimamura T: Expression of matrix metalloproteinase 9 and osteoclast differentiation factor mRNA in osteoclasts and osteoblasts in rheumatoid arthritis, Scandinavian Journal of Rheumatology, 2002

16.     Ouchi N, Uzuki M, Yoshida M, Yoshida M, Shimamura T, Sawai T: Cartilage destruction is partly induced by the internal proteolytic enzymes and apoptotic phenomenon of chondrocytes in polychondritis, Scandinavian Journal of Rheumatology, 2002

17.     Yoshida W, Uzuki M, Ouchi N, Yoshida M, Shimamura T, Sawai T: Examination of gelatinolytic activity in rheumatoid arthritis synovium using in situ zymography and image analyzer, Scandinavian Journal of Rheumatology, 2002

18.     Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, Yonezawa T, Saeki Y, Panayi GS, Pizalis C: The role of TNF-ƒ¿ in the pathogenesis of inflammation and joint destruction in Human RA/SCID mice chimera, Arthritis Rheum, 2002

19.     Munakata T, Uzuki M, Yoshida M, Shimamura T, Sawai T: Interleukin (IL)-18 concentration in synovial fluid represents a positive correlation between the number of inflammatory cells especially lymphocytes and macrophages, in RA synovium, Arthritis Rheum, 2002

19.

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

20.     Inoue T, Shimizu H, Kumabe T, Yoshimoto T, Kabasawa H: Imaging the corticospinal tract by diffusion weighted magnetic resonance imaging in patients with brain tumors, Proc Intl Soc Mag Reson Med, 2000

21.     Inoue T, Shimizu H, Nakasato N, Kumabe T, Yoshimoto T, Kabasawa H: Comparative study of MRI and MEG for objective indentification of the central sulcus in patients with brain tumors, Proc Intl Soc Mag Reson Med, 2000

22.     Inoue T, Ogawa A, Shimizu H, Ogasawara K: Spatial functional distribution in the corticospinal tract at the corona radiata: a 3DAC study, Proc ISMRM, 2001

 

 


‘ÛŠw‰ï

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         Tachikawa E, Kudo K, Harada K, Kashimoto T, Takahashi E: Inhibitory effects of ginsenosides, ginseng saponins on various receptor stimulation-responses, Society for Neuroscience 29th Annual Meeting, 1999, 10, Miami (USA)

2.         Fukushima T, Shingai R, Marshall J, Sakata K, Ichinose M, Ogurusu T, Tachikawa E: Ion permeability of willardine-induced response in kainate receptor GLUR(G)/KA-2, Society for Neuroscience 30th Annual Meeting, 2000, 11, New Orlens (USA)

3.         Shinohe Y, Kumagai M, Saino T, Satoh Y: Effects of ATP and its analogues on [Ca2+]i dynamics of perineurium in the rat sciatic nerve, 40th American Society for Cell Biology Annual Meeting, 2000, 12, San Francisco (USA)

4.         Shinohe Y, Kumagai M, Saino T, Satoh Y: Effects of ATP on intracellular calcium dynamics of perineurium in the rat sciatic nerve, 15th International Morphological Sciences, 2000, 9, Kyoto

5.         Kumagai M, Shinohe Y, Saino T, Joh S, Satoh Y: Effects of ATP on intracellular calcium dynamics of neurons and satellite cells in rat superior cervical ganglion, 15th International Morphological Sciences, 2000, 9, Kyoto

6.         Watanabe S, Miyata S, Saino T, Tazawa Y, Satoh Y: Communication through [Ca2+]i dynamics in rabbit corneal epithelium, 15th International Morphological Sciences, 2000, 9, Kyoto

7.         Saino T, Matsuura M, Satoh Y: Effect of ATP on intracellular calcium ion dynamics of smooth muscle cells in testicular and cerebral arterioles of rats, 15th International Morphological Sciences, 2000, 9, Kyoto

8.         Miyata S, Sato Y: The imaging of nitric oxide on neonatal rat cardiomyocytes, 15th International Morphological Sciences, 2000, 9, Kyoto

9.         Kumagai M, Shinohe Y, Saino T, Joh S, Satoh Y: Measurements of intracellular calcium in superior cervical ganglion of rats, 40th American Society for Cell Biology Annual Meeting, 2000, 12, San Francisco

10.     Kawasaki S, Kimura S, Fujita R, Takashima K, Sasaki K: Regulatory role of monomeric G-protein RhoA on the serotonin-induced Na+-current response in the ganglion cells of Aplysia, The 34th World Congress of the International Union of Physiological Sciences, 2001, 8, Christchurch (New Zealand)

11.     Kimura S, Kawasaki S, Fujita R, Takashima K, Sasaki K: CaM-kinase II and protein phosphatase 2A reciprocally regulate quisqualic acid-induced K+-current response in the identified neurons of Aplysia, The 34th World Congress of the International Union of Physiological Sciences, 2001, 8, Christchurch (New Zealand)

12.     Fujita R, Hirano H, Kawasaki S, Kimura S, Matsumoto M, Sasaki K, Takashima K: Stimulation of P2-receptor suppresses the K+-current responses to FSH and adenosine in the follicular cells of Xenopus oocyte, The 34th World Congress of the International Union of Physiological Sciences, 2001, 8, Christchurch (New Zealand)

13.     Nishikawa Y, Koji T, Kawasaki S, Kimura S, Doi M, Ogawa A, Sasaki K: Role of Rho-kinase in the serotonin-induced contraction in the middle cerebral artery of bovine, The 34th World Congress of the International Union of Physiological Sciences, 2001, 8, Christchurch (New Zealand)

14.     Koji T, Nishikawa Y, Doi M, Kawasaki S, Kimura S, Ogawa A, Sasaki K: Prolonged contraction induced by stimulation of receptor for cyclicthromboxane A2 in the middle cerebral artery of bovine, The 34th World Congress of the International Union of Physiological Sciences, 2001, 8, Christchurch (New Zealand)

15.     Matsuura M, Saino T, Satoh Y: Effect of ATP on Intracellular Calcium Concentration Dynamics of Arterioles of Heart of Golden Hamster, 41st American Society for Cell Biology Annual Meeting, 2001, 12, Washington DC

16.     Satoh Y,  Watanabe S, Saino T, Tazawa Y, Tohyama K: ATP-induced intracellular calcium increase of human corneal epithelium, 41st American Society for Cell Biology Annual Meeting, 2001, 12, Washington DC

17.     Kudo K, Tachikawa E, Kashimoto T, Harada K: Pregnenolone sulfate, a neuropeptide, inhibits catecholamine secretion stimulated by acetylcholine in cultured bovine adrenal chromaffin cells, Society for Neuroscience 31st Annual Meeting, 2001, 11, San Diego

18.     Saino T, Matsuura M, Satoh Y: Dipyridamole Inhibits ATP-induced smooth muscle contraction in testicular and cerebral arterioles of rats, 41st American Society for Cell Biology Annual Meeting, 2001, 12, Washington DC

19.     Matsuura M, Saino T, Satoh Y: Effect of ATP on Intracellular Calcium Concentration Dynamics of Arterioles of Heart of Golden Hamster, 41st American Society for Cell Biology Annual Meeting, 2001, 12, Washington DC

20.     Sasaki K,  Kawasaki S, Kimura S, Takashima K: D1-receptor-induced current response reverses from inward to outward after the injection of guanosine thiotriphosphate in the ganglion cells of Aplysia, The 3rd International Symposium on the Study of Brain Function, 2002, 5, Fukuoka

21.     Fujita R, Kimura S, Kawasaki S, Takashima K, Matsumoto M, Hirano H, Sasaki: Suppressing action of P2Y-receptor stimulation on the K+-current response to adenosine and FSH in the follicular cells of Xenopus Laevis oocyte, The 3rd International Symposium on the Study of Brain Function, 2002, 5, Fukuoka

22.     Ogasawara M, Yamauchi K, Satoh Y,  Maeyama K: Molecular mechanism of intracellular translocation of histamine N-methyltransferase, 42nd American Society for Cell Biology Annual Meeting, 2002, 12, San Francisco

23.     Suzuki M, Matoh K, Sasaki Y, Ikemoto K, Nishimura A, Nishi K: Neuroanatomical basis of the white matter disease,@XII World Congress of Psychiatry, 2002, 8, Yokohama

24.     Matsuura M, Saino T, Satoh Y: ATP-induced contraction of coronary arterioles in golden hamster is accompanied with Ca2+ influx via P2X ion channel type receptors, 42nd American Society for Cell Biology Annual Meeting, 2002, 12, San Francisco

25.     Satoh Y,  Saino T, Goto S, Tohyama K: Photodamage of Harderian gland cells containing porphyrins is resulted from production of nitricoxide, 42nd American Society for Cell Biology Annual Meeting, 2003, 12, San Francisco

26.     Saino T, Matsuura M, Satoh Y: Dipyridamole inhibits ATP-induced smooth muscle contractions in testicular and cerebral arterioles of rats, 42nd American Society for Cell Biology Annual Meeting, 2003, 12, San Francisco

27.     Matsuura M, Saino T, Satoh Y: ATP-induced contraction of coronary arterioles in golden hamster is accompanied with Ca2+ influx via P2X ion channel type receptors, 42nd American Society for Cell Biology Annual Meeting, 2003, 12, San Francisco

28.     Fujita R, Kimura S, Kawasaki S, Hirano H, Matsumoto M, Sasaki K: Inhibition of K+-current responses to FSH and adenosine by stimulation of P2Y-receptor in the follicular cells of Xenopus oocyte, 6th IBRO World Congress of Neuroscience, 2003, 7, Praque (Czech Republic)

29.     Kawasaki S, Kimura S, Fujita R, Matsumoto M, Sasaki K: Reversal of D1 receptor-induced current response from inward to outward after the injection of GTP-analogue in the ganglion cells of Aplysia, 6th IBRO World Congress of Neuroscience, 2003, 7, Praque (Czech Republic)

30.     Koji T, Kimura S, Nishikawa Y, Kawasaki S, Doi M, Ogawa A, Sasaki K: Regulatory Role of Rho- and PI 3-kinase in the slowly developing contraction induced by thromboxane A2 receptor in the middle cerebral artery of bovine, 6th IBRO World Congress of Neuroscience, 2003, 7, Praque (Czech Republic)

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

31.     Kumagai J, Kawamata T, Sano H, Sato K, Sawai T: Histopathology of the torn rotator cuffs, 3rd Academic Congress of the Asian Shoulder Association, 1999, 10, Bali

32.     Pan LH, Yamauchi K, Yoshida K, Nakanishi T, Takigawa M, Uzuki M, Mouri T, Ito H, Shikanai T, Inoue H, Sawai T: Expression of connective tissue growth factor (CTGF) in pulmonary fibrosis, 1999 International Conference, 1999, 4, San Diego

33.     Uzuki M, Sasano H, Totsune K, Takahashi K, Sawai T: Urocortin (UCN) and corticotropin-releasing factor (CRF) receptors in the synovial tissue of patients with rheumatoid arthritis (RA), American College of Rheumatology 63rd Annual Scientific Meeting, 1999, 11, Boston

34.     Hirano N, Tohyama K, Hashikawa T: Hemagglutinating encephalomyelitis virus HEV (coronavirus) infects the CNS of laboratory animals through transneuronal pathways, XIth International Congress of Virology, 1999, 8, Sydney

35.     Hirano N, Tohyama K, Hashikawa T: Swine coronavirus (HEV) as a transneuronal tracer analysing polysynaptic pathways in the CNS of laboratory anumals, ICLAS and 7th FELASA Joint Meeting, 1999, 5, Plama de Malllorca

36.     Sapp E, Kegel KB, Aronin N, Tohyama K, Uchiyama Y, Bhide P, VonSattel IP, Difiglia M: Microglia accumulate in the HD stratum and cortex, 29th Annual Meeting, Society for Neuroscience, 1999, 10, USA

37.     Inada K, Endo S, Sato S: Activation of granulocytes by shiga-like toxins and its possible role in pathogenesis of hemolytic uramic syndrome, 3rd Asia Pacific Conference on Travel Health, 2000, 7, Denpasar (Indonesia)

38.     Ichinohe N, Tsutsumi R, Sasaki M, Shimooki O, Takahashi K, Inada K, Chida S, Sato S: Specific and nonspecific antibody responses to lipopolysaccharide (LPS) in enterohemorrhagic E. Coli infection, 4th International symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli infections, 2000, 10, Kyoto

39.     Inada K, Sato S, Endo S: Activation of granulocytes with vero toxins: A possible role of the activation for pathogenesis of hemolytic uremic syndrome caused by enterohemorrhagic E. Coli, 4th International symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli infections, 2000, 10, Kyoto

40.     Sawai T, Uzuki M: Increased levels of circulating hyaluronate in the sera of patients with rheumatoid arthritis with special reference to joint destruction, The 4th Meeting of Hirosaki International Forum of Medical Science, 2000, 10, Hirosaki

41.     Uzuki M, Sawai T: Hyaluronic acid (HA) with high molecular weight shows high affinity to degenerated cartilage in tissue sections, The 4th Meeting of Hirosaki International Forum of Medical Science, 2000, 10, Hirosaki

42.     Yoshida M, Uzuki M, Kurose A, Ichinohe S, Sawai T, Shimamura T: Abundant localization of matrix metalloproteinase 9 and its inhibitor in osteoclasts and osteoblasts at sites of the excessive bone resorption in rheumatoid arthritis, American College of Rheumatology 64th Annual Scientific Meeting, 2000, 10, Philadelphia

43.     Yoshida W, Uzuki M, Yoshida M, Nishida J, Sato T, Hosaka M, Shimamura T, Sawai T: Histological and cellular characterization of pigmented villonodular synovitis, American College of Rheumatology 64th Annual Scientific Meeting, 2000, 10, Philadelphia

44.     Uzuki M, Matsuno H, Yudoh K, Nakazawa F, Katayama R, Kimura T, Sawai T: Apoptotic chondrocyte death and matrix metalloproteinases in rheumatoid arthritis, American College of Rheumatology 64th Annual Scientific Meeting, 2000, 10, Philadelphia

45.     Sawai T,  Ashihara T, Itoh H, Itoh M, Tsuchihashi Y, Nakamura S, Mukai K, Watanabe M: Telepathology in Japan; its history, present state and future, IAP NAGOYA 2000, 2000, 10, Nagoya

46.     Sawai T: Medicolegal and administrative issues of telepathology in Japan, ’nˆæˆã—ÂƃeƒŒƒpƒ\ƒƒW[‚ÉŠÖ‚·‚é‹ž“s‘ÛƒtƒH[ƒ‰ƒ€, 2000, 10, ‹ž“s

47.     Ishii K, Tohyana K, Sasaki N, Hashikawa T: Distribution of microglila and macrophages in developing rat brain using immunohistochemical labeling methods, 30th Annual Meeting, Society for Neuroscience, 2000, 11, New Orleans (USA)

48.     Tohyama K, Murate M, Yamazaki Y, Hirata M, Hashikawa T: Cationic anti-microbial protein-like immunoactivity in astrocytes of rat brain, 30th Annual Meeting, Society for Neuroscience, 2000, New Orleans (USA)

49.     Hirano N, Tohyama K, Taira H, Hashikawa T: Spread of hemagglutinating encephalomyelitis virus in the CNS of rats inoculated intranasal route, VIIth International Symposium on Nidoviruses, 2000, 5, Lake Harmony (USA)

50.     Hirano N, Ootani N, Tohyama K, Hashikawa T: Infection of hemagglutinating encephalomyelitis virus (HEV) at the visual pathways of rats, VIIth International Symposium on Nidoviruses, 2000, 5, Lake Harmony (USA)

51.     Hirano N, Tohyama K, Taira H, Hashikawa T: Trans-synaptic infection of CNS neurons in rats after intranasal inoculation of swine hemagglutinating encephalomyelitis virus, 19th Annual Meeting, American Society for Virilogy, 2000, 7, Fort Collins (USA)

52.     Hirano N, Tohyama K, Taira H, Hashikawa T: Pathogenicity of swine hemagglutinating encephalomyelitis virus (HEV) for rats, 11th Federation of Asian Veterinary Association Congress, 2000, 11, Taipei (Taiwan)

53.     Kumagai J, Sato K, Kawamata T, Komatsuda T, Sawai T: Pathogenesis of rotator interval lesions in younger and older age groups, 8th International Congress of Surgery of the Shoulder, 2001, 4, Cape Town

54.     Suzuki M, Obara K, Kitabatake A, Kawamura S, Mato K, Yasuda S, Ito K: Is perivascular glial structure related to the pathogenesis of white matter disease?  10th Congress of the International Psychogeriatric Association, 2001, 9, Nice

55.     Yoshida M, Uzuki M, Yoshida W, Itoh T, Ichinohe S, Sawai T,  Shimamura T: Abundant expression of matrix metalloproteinase 9 and osteoclast differentiation factor mRNA in osteoclasts and osteoblasts at sites of punnus bone interface in rheumatoid arthritis, American College of Rheumatology 64rd Annual Scientific Meeting, 2001, 11, San Francisco

56.     Ouchi N, Uzuki M, Yoshida M, Shimamura T, Sawai T: Cartilage destruction is partly induced by the internal proteolytic enzymes and apoptotic phenomenon of chondrocytes in polychondritis, American College of Rheumatology 64rd Annual Scientific Meeting, 2001, 11, San Francisco

57.     Matsuno H, Yudoh K, Nakazawa F, Uzuki M, Sawai T,  Otsuki M, Ogawa Y, Nishioka K, Kimura T: Treatment with novel humanaized anti-Fas monoclonal antibody in rheumatoid arthritis, American College of Rheumatology 64rd Annual Scientific Meeting, 2001, 11, San Francisco

58.     Sasaki N, Kurose A, Yamauchi K, Inoue H, Sawai T: Endothelial cell apoptosis is a possible mechanism of pulmonary hypertension in patients with mixed connective tissue disease, 98th International Conference of American Thoraic Society, 2002, 5, Atlanta (USA)

59.     Yoshida M, Uzuki M, Yoshida W, Ouchi N, Koyama A, Ichinohe S, Sawai T,  Shimamura T: Expression of matrix metalloproteinase 9 and osteoclast differentiation factor mRNA in osteoclasts and osteoblasts in rheumatoid arthritis, 29th Scandinavian Congress of Rheumatology, 2002, 8, Tromso (Norway)

60.     Ouchi N, Uzuki M, Yoshida M, Yoshida M, Shimamura T, Sawai T: Cartilage destruction os partly induced by the internal proteolytic enzymes and apoptotic phenomenon of chondrocytes in polychondritis, 29th Scandinavian Congress of Rheumatology, 2002, 8, Tromso (Norway)

61.     Yoshida W, Uzuki M, Ouchi N, Yoshida M, Shimamura T, Sawai T: Examination of gelatinolytic activity in rheumatoid arthritis synovium using in situ zymography and image analyzer, 29th Scandinavian Congress of Rheumatology, 2002, 8, Tromso (Norway)

62.     Hirano N, Tohyama K, Taira H, Hashikawa T: Susceptibility of mice of diffrent ages to inoculation with swine HEV by various routes, XIIth International Congress of Virology, 2002, 7, Paris (France)

63.     Tohyama K, Nishiyama H, Hanasaki T, Nakamura M, Itohara S, Hashikawa T: S100B may not be essential for regeneration of peripheral nerve axons, 32th Annual Meeting, Society for Neuroscience, 2002, 11, Orlando (USA)

64.     Anderson PN, Pavlides M, Rezajool K, Stallcup WB, Tohyama K, Lieberman AR: NG2 expression increases following injury to the spinal cord or peripheral nerves, 32th Annual Meeting, Society for Neuroscience, 2002, 11, Orlando (USA)

65.     Uzuki M, Kaiyama J, Miyoshi T, Sawai T: Three hyaluronan synthases, HAS1, HAS2, HAS3 and hyaluronan synthetic activity in the synovial tissue of patients with rheumatoid arthritis, American College of Rheumatology 66th Annual Scientific Meeting, 2002, 10, New Orleans

66.     Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T,  Yonezawa T, Saeki Y, Panayi GS, Pizalis C: The role of TNF-ƒ¿ in the pathogenesis of inflammation and joint destruction in Human RA/SCID mice chimera, American College of Rheumatology 66th Annual Scientific Meeting, 2002, 10, New Orleans

67.     Munakata T, Uzuki M, Yoshida M, Shimamura T, Sawai T: Interleukin (IL)-18 concentration in synovial fluid represents a positive correlation between the number of inflammatory cells especially lymphocytes and macrophages, in RA synovium, American College of Rheumatology 66th Annual Scientific Meeting, 2002, 10, New Orleans

68.     Kumagai J, Sawai T: Tendon insertion into bone-anatomy and its surgical reconstruction-, 4th Academic Congress of the Asian Shoulder Association, 2002, 10, Seoul

69.     Ouchi N, Uzuki M, Kanno H, Yoshida M, Shimamura T, Sawai T: Cartilage destruction in polychondritis is induced by internal factors as well as inflammatory reaction around cartilage, 5th Pan-Pacific Connective Tissue Societies Symposium, 2003, 6, Ube

70.     Uzuki M, Itano N, Kimata K, Kaiyama J, Miyoshi T, Yoshida M, Sawai T: Three hyaluronan synthases, HAS1, HAS2, HAS3 in the synovial tissue of patients with rheumatoid arthritis, 5th Pan-Pacific Connective Tissue Societies Symposium, 2003, 6, Ube

71.     Itoh Y, Uzuki M, Fujii K, Sawai T: Connective Tissue Growth Factor (CTGF) mRNA expressed especially in RA synovium in early Stage, 5th Pan-Pacific Connective Tissue Societies Symposium, 2003, 6, Ube

72.     Yoshida M, Ichinohe S, Uzuki M, Ouchi N, Yoshida W, Sawai T,  Shimamura T: Pathogenesis of large bone cysts adjacent to the knee joint in rheumatoid arthritis, 4th Annual European Congress of Rheumatology, 2003, 6, Lisbon

73.     Yoshida W, Uzuki M, Ouchi N, Yoshida M, Shimamura T, Sawai T: Examination of gelatinolytic activity in rheumatoid arthritis synovial tissue using newly developed in situ zymography and image analyzer, 4th Annual European Congress of Rheumatology, 2003, 6, Lisbon

 

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

74.     Oikawa H, Tamakawa Y: The Evaluation of the difference between Alzheimer type dementia and vascular dementia using proton magnetic resonance spectroscopy, RSNA 85th Scientific Assembly and Annual Meeting, 1999, 11, Chicago

75.     Sasaki M, Oikawa H, Ehara S, Tamakawa Y: Ventral thalamus and subthalamic nucleus: MR findings using optimized fast short inversion-time inversion-recovery technique, RSNA 86th Scientific Assembly and Annual Meeting, 2000, 11, Chicago

76.     Sasaki M, Oikawa H, Ehara S, Tamakawa Y: Magnetization transfer MR imaging of the hippocampus and entorhinal cortex in early Alzheimer disease: evaluation with high-resolution fast spin-echo and fast STIR techniques, RSNA 86th Scientific Assembly and Annual Meeting, 2000, 11, Chicago

77.     Sasaki M, Oikawa H, Ehara S, Tamakawa Y: Substantia nigra at 3 Tesla MR imaging using dual-echo spin-echo and fast short inversion-time inversion-recovery techniques, American Society of Neuroradiology (ASNR) 39th Annual Meeting, 2001, 4, Boston

78.     Sasaki M, Oikawa H, Ehara S, Tamakawa Y: Internal structures of cerebral gray matter at 3 Tesla: MR imaging using fast short inversion-time inversion-recovery technique, Radiological Society of North America (RSNA) 87th Scientific Assembry and Annual Meeting, 2001, 11, Chicago

 


˜a•¶Œ´’˜˜_•¶

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         “n•Ó”üŠì—YC“y”ìŽçC—é–Ø—Ï•ÛC²X–ؘa•FC¬ì²: PKC ‚ÌŠˆ«‰»‚É‚æ‚鎑±«‚Ì”]ŒŒŠÇŽûk‚É‚¨‚¯‚é protein kinase cascade ‚ÌŠÖ—^D”]ŒŒŠÇ¹k14: 167-173, 1999

2.         “y”ìŽçC“n•Ó”üŠì—YC—§–ØŒõC®–ìLC—é–Ø—Ï•ÛC²X–ؘa•FC¬ì²: ”]ŒŒŠÇ¹k‚¨‚æ‚Ñ”]ŒŒŠÇ‚ÌŽûk‚É‚¨‚¯‚é protein kinases ‚ÌŠÖ—^D”]ŒŒŠÇ¹k14: 40-49, 1999

3.         ¼ì‘׳C“y”ìŽçC“n•Ó”üŠì—YC—é–Ø—Ï•ÛC¬ì²C–Ø‘ºáÁŒáC²X–ؘa•F: ƒXƒtƒBƒ“ƒSƒŠƒ“Ž‰Ž¿sphingosylphosphorylcholine‚É‚æ‚é”]ŒŒŠÇ‚ÌŽ‘±“IŽûk‚Ì”­¶‹@˜D”]ŒŒŠÇ¹k15: 226-229, 2000

4.         “y”ìŽçC ¼ì‘׳C “n•Ó”üŠì—YC—é–Ø—Ï•ÛC¬ì²C–Ø‘ºáÁŒáC²X–ؘa•F: Rho kinase activator ‚É‚æ‚é Žûk‚ɑ΂·‚éŠeŽí”]ŒŒŠÇŠg’£–ò‚Ì—}§Œø‰ÊD”]ŒŒŠÇ¹k15: 242-246, 2000

5.         “n•Ó”üŠì—YC“y”ìŽçC¼ì‘׳C—é–Ø—Ï•ÛC¬ì²Cìè•qC²X–ؘa•F: ”]ŒŒŠÇ‚ÌŽ‘±«Žûk‚É‚¨‚¯‚éRho kinase inhibitor Y-27632‚Ì—}§Œø‰ÊD”]ŒŒŠÇ¹k15: 247-250, 2000

6.         Ö–ì’©KC¼‰Y½C²“¡—mˆê: ‚‘¬‹¤Å“_ƒŒ[ƒU[Œ°”÷‹¾‚ð—p‚¢‚½×“®–¬‚É‚¨‚¯‚é×–E“àƒJƒ‹ƒVƒEƒ€”Z“x•Ï“®‚̉摜‰ðÍDzŠÂ§Œä21: 10-16, 2000

7.         ¼ì‘׳CKŽ¡F—TC“y”ìŽçCìè•q: ƒZƒƒgƒjƒ“‚É‚æ‚Á‚Ĉø‚«‹N‚±‚³‚ꂽƒEƒV”]ŒŒŠÇ•½ŠŠ‹ØŽûk‚É‚¨‚¯‚éRho-kinase ‚É‚æ‚é‘‹­‹@\DŠâŽèˆãŽ53: 117-127, 2001

8.         ¼ì‘׳C“y”ìŽçCKŽ¡F—TC“n•Ó”üŠì•vCìè•qC–Ø‘ºáÁŒáC¬ì²: ƒXƒtƒBƒ“ƒSƒŠƒ“Ž‰Ž¿Sphingosylphosphorylcholine‚É‚æ‚é”]ŒŒŠÇ‚ÌŽ‘±“IŽûk‚É‚¨‚¯‚éRho kinase‚ÌŠÖ—^D”]ŒŒŠÇ¹k16: 283-286, 2001

9.         “y”ìŽçC¼ì‘׳C“n•Ó”üŠì•vCKŽ¡F—TC¬ì²Cìè•qC–Ø‘ºáÁŒáC²X–ؘa•F: Myosin light chain phosphataseŠˆ«‚Ì’²ß‚É‚æ‚é”]ŒŒŠÇ‚ÌŽûk§Œä‹@\D”]ŒŒŠÇ¹k16: 290-293, 2001

10.     KŽ¡F—TC¼ì‘׳C“y”ìŽçC–Ø‘ºáÁŒáCìè•qC²X–ؘa•FC¬ì²: ƒgƒƒ“ƒ{ƒLƒTƒ“‚`‚QŽó—e‘ÌŽhŒƒ‚Å”­¶‚·‚鎑±«‚Ì”]ŒŒŠÇŽûk‚É‚¨‚¯‚éRho-kinase‚É‚æ‚éŽûk‘‹­‹@\D”]‘²’†‚ÌŠO‰È29: 61-65, 2001

11.     KŽ¡F—TC¼ì‘׳Cìè•qC–Ø‘ºáÁŒá: ƒEƒV’†‘å”]“®–¬‚̃gƒƒ“ƒ{ƒLƒTƒ“‚`‚QŽó—e‘ÌŽhŒƒ‚Å”­¶‚·‚éŠÉ™‚ÈŽûk‰ž“š‚Ì‘‹­‹@\DŠâŽèˆãŽ54: 137-150, 2002

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

12.     ŒF’JƒCì–”•ü–›C²–씎‚C²“¡Ž–¤CàVˆä‚ŽuCΈäG’‰: äF”‘a•”‘¹‚Ì•a‘Ô\10‘ã`20‘ã‚ÌÇ—á‚ɂ‚¢‚Ä\DŒ¨ŠÖß23: 385-389, 1999

13.     ‰““¡dŒúCŠ‹¼Œ’Cˆî“c·–ç: ‘Sg«‰ŠÇ”½‰žÇŒóŒQ‚É‚¨‚¯‚銴õÇ‚¨‚æ‚ÑdÇ“xf’f‚Æ‚µ‚ẴvƒƒJƒ‹ƒ`ƒgƒjƒ“’l‘ª’è‚̈Ӌ`DŠ´õÇŽ97: 197-204, 1999

14.     àVˆä‚ŽuC‰FŒŽ”ü˜a: –«ŠÖ߃ŠƒEƒ}ƒ`iRAj‚Ì•a—D ƒJƒŒƒ“ƒgƒeƒ‰ƒs[17: 41-48, 1999

15.     ‰FŒŽ”ü˜a: Ú’…•ªŽq‚ÌV‚µ‚¢“WŠJD×–E31: 19-20, 1999

16.     ¼–씎–¾C—V“¹˜a—YC’†‘ò•s“ñ—YC•ÐŽR—ŒbC‰FŒŽ”ü˜aC–Ø‘º—FŒú: V‚µ‚¢“®•¨ƒ‚ƒfƒ‹‚ÌŠJ”­D×–E31: 24-29, 1999

17.     ¬¼“c’C˜YC²“¡Ž–¤C¬“‡’‰ŽmCŒF’JƒCàVˆä‚Žu: Š£á«—¼Œ¨ŠÖ߉Š‚¨‚æ‚ÑŒ¨•ô‰ºŠŠ‰t•ï‰Š‚Ì‹¾Ž‹‘œDŠÖß‹¾  24: 69-75, 1999

18.     •£Œ°C‹g“c“nC‹g“c¹–¾CàVˆä‚Žu:  –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ”|—{×–E‚Ì×–EŒv—ÊŠw“I‰ðÍ \ pacritaxel‚É‚æ‚é×–E“®‘Ԃ̕ω» \D Cytometry Res  9: 85-88, 1999

19.     –Ø‘º—FŒúC’†‘ò•s“ñ—YC¼–씎–¾CàVˆä‚ŽuC‰FŒŽ”ü˜a: ŠÖ߉Š‚É”º‚¤“j‰óDRAƒZƒ‰ƒs[ 5: 40-48, 1999

20.     ì–”•ü–›CŒF’JƒC²–씎‚C²“¡Ž–¤C¬¼“c’C˜YC¬d’CàVˆä‚Žu: ”½•œ«Œ¨ŠÖß‘O•û’E‰P‚Ì‘¹ŠÖßO‚Ì•a—‘gD‘œDŒ¨ŠÖß23: 236-266, 1999

21.     ‹g“c¹–¾CˆêŒË’啶C@‘œF‰ÀC“ˆ‘º³C‰FŒŽ”ü˜aC•£Œ°C‹g“c“nCàVˆä‚Žu:  RA‚Ì‹‘圔XŽî‚É‚¨‚¯‚éMMP‚Æ‚»‚Ì‘jŠQy‘f‚Ì”­Œ»‚ɂ‚¢‚ÄDŠâŽèˆãŽ51: 661, 1999

22.     Šâè^‹|C‰FŒŽ”ü˜aC“n•Ó‚Ý‚©C”~“c‰pKC{ŽR‹ŽOCˆ¢•”ŒhŽqCàVˆä‚Žu: ƒqƒg”x“®–¬‚̃Gƒ‰ƒXƒ`ƒ“‰Ë‹´ƒAƒ~ƒmŽ_iƒfƒXƒ‚ƒVƒ“CƒCƒ\ƒfƒXƒ‚ƒVƒ“j‚Ì’è—ʉ»‚ÌŽŽ‚Ýi‘æ1•ñjDŠâŽèˆãŽ51: 441-452, 1999

23.     àN—§‰ØCŽR“àL•½: ”x×–E‘BDŒÄ‹z‚ÆzŠÂ47: 899-905, 1999

24.     ˆÉ“¡ŒOŽ÷C‘ºˆäˆê”ÍCΓc—zŽ¡C~Mˆê˜YC“cŒû‰ëŠCC•£Œ°: ‰¡–ä‹Ø“÷Žî‚Ì‚Ñ‚Ü‚ñ«œ‘ZDŠâŽèˆãŽ51: 573-576, 1999

25.     •£Œ°CàVˆä‚Žu: AIDS‚Ì•a—FƒƒVƒAAIDSƒZƒ“ƒ^[‚̃GƒCƒY–UŒŸ—á‚ɂ‚¢‚ÄDŠâŽèˆãŽ 51: 662, 1999

26.     ‰Á“¡‚³‚­‚çC’ç—æŽq: ƒRƒNƒTƒbƒL[ƒEƒCƒ‹ƒX‚a6i‚b‚u‚a‚Uj‚Ì5'”ñ–|–ó—̈æ‹y‚уLƒƒƒvƒVƒbƒh’`”’—̈æ‚Ì‚ƒ‚c‚m‚`‰–Šî”z—ñŒˆ’è‚ÉŠÖ‚·‚錤‹†DŠâŽèˆãŽ51: 89-104, 1999

27.     ’†‰®•×CŽ›“‡‰ë“TCˆî“c·–ç: ˆÝŠàŠ³ŽÒŒŒ‰t‚Ìex vivo”|—{‚É‚¨‚¯‚éè÷—±‹…‚̃Cƒ“ƒ^[ƒƒCƒLƒ“-‚PƒŒƒZƒvƒ^[ƒAƒ“ƒ^ƒSƒjƒXƒgiIL-1rajŽY¶”\’ቺDŠâŽèˆãŽ  51: 537-554, 1999

28.     ˆî“c·–çC‰““¡dŒú: ƒŠƒ€ƒ‹ƒXŽŽ–ò‚ð—p‚¢‚½ŒŒ’†ƒGƒ“ƒhƒgƒLƒVƒ“‚¨‚æ‚уÀ-ƒOƒ‹ƒJƒ“’è—Ê‚É‚¨‚¯‚éƒJƒCƒlƒeƒBƒbƒN–@‚Å‚Ì“ÁˆÙ”½‰ž‚Æ”ñ“ÁˆÙ”½‰ž‚Ì”»•ÊDˆãŠw‚Æ–òŠw 42: 885-897, 1999

29.     àVˆä‚ŽuC‰FŒŽ”ü˜aC“n•Ó‚Ý‚©: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[jEƒeƒŒƒpƒ\ƒƒW[‚ÌŒ»ó‚Æ–â‘è“_DŠO‰È61: 613-618, 1999

30.     àVˆä‚ŽuC“n•Ó‚Ý‚©C‰FŒŽ”ü˜a: ƒeƒŒƒpƒ\ƒƒW[i‰“Šu•a—f’fjŽÀ—p‰»‚Æ–â‘è“_DŒŸ¸‚Æ‹Zp27: 85-88, 1999

31.     ŽO‰YNGC•£Œ°CŽÄ“c—S“ñC•Ê•{‚–¾CàVˆä‚Žu: ¶‘¤“ª—t‚É”­¶‚µ‚½Dysembryoplastic neuroepithlial tumor iDNTj ‚Ì1Ç—áDf’f•a—17: 120-122, 2000

32.     ²–씎‚CŒF’JƒCàVˆä‚Žu: Ž©‰Æ‘å‘Ú‹Ø–Œpatch–@‚É‚¨‚¯‚éäF‘gD‚¨‚æ‚ÑäFœ•t’…•”‚ÌÄŒ`¬‰ß’öDŒ¨ŠÖß24: 253-258, 2000

33.     쑺—@, —é–Ø –ž, –k”©Œ°_, ¬Œ´ƒPƒCŽq: ƒtƒ‰ƒNƒgƒOƒ‰ƒtƒB•Ï–@‚É‚æ‚é‘å”]”’Ž¿‚̃OƒŠƒAŽ²õŠÔ‘ŠŒÝŠÖŒW‚Ì3ŽŸŒ³“IŠÏŽ@D”]‚̉Ȋw22: 329-338, 2000

34.     ¬–ì’¼”V, —é–Ø–ž, ¬Œ´ƒPƒCŽq, –k”©Œ°_: ‘å”]”’Ž¿ŒŒŠÇŽüˆÍ‚̃OƒŠƒA\‘¢ \ ŠD”’Ž¿‚Ì‚»‚ê‚Æ‚Ì”äŠrD˜V”N¸_ˆãŠw11: 539-547, 2000

35.     ŽO‰YNGC•£Œ°CàVˆä‚ŽuC‹g“c_ŽqCˆäã—m¼: –Ɖu—}§—Ö@‚ª‘tŒ÷‚µ‚½‚à‚Ì‚Ì”x•¡‡Š´õ‚Ì•¹”­‚É‚æ‚莀–S‚µ‚½Wegener“÷‰èŽîÇ‚Ì1Ç—áD—Õ°ƒŠƒEƒ}ƒ` 12: 143-149, 2000

36.     “n•Ó“O—YCàVˆä‚ŽuC²“¡¬C‰FŒŽ”ü˜aC—¢Œ©i: • •”‘å“®–¬áŽi“W‚É‚¨‚¯‚éMatrix metalloproteinases ‚Ì–ðŠ„D –¬ŠÇŠw40: 505-510, 2000

37.     •£Œ°CàVˆä‚Žu: ”ñ’èŒ^“I‚ÈS‹ØÇ‚Ì2—áD•a‰@•a—17: 86, 2000

38.     ŒÃ‰Æ‘ô–çC—«¯¯CH“¡½Ž¡C‚‹´MDC—é–Ø—BŽiC•l“c˜aˆê˜YCŽO‰YNG: ‹ó’°‚Ö’¼ÚZ‚µ‚½”A–ŒŠÇŽîᇂÌ1—áD”å”AŠíŠO‰È13: 297-299, 2000

39.     ¼–씎–¾C’†‘ò•s“ñ—YC—V“¹˜a—YC‰FŒŽ”ü˜aCàVˆä‚ŽuC–Ø‘º—FŒú: RA‚ÌŠÖߓj‰ó‚É‚¨‚¯‚éƒAƒ|ƒg[ƒVƒXDƒŠƒEƒ}ƒ`‰È  23: 275-281, 2000

40.     àN—§‰ØCàVˆä‚Žu: üˆÛ‰»”x‚Æconnective tissue growth factoriCTGFjD•ªŽqŒÄ‹zŠí•a4: 89i433j-91i435j, 2000

41.     ˆÉ“¡Œ[CŒ‹é–L•FCΓcˆê•FC²“¡‹§C•Ð‘q–FŽ÷C•½àV‘åC–ì“c—TC“¡“c’¼FC“y‰®—_CŽR苧C‰FŒŽ”ü˜aCàVˆä‚Žu: Ž‰–b‘gD‚¨‚æ‚уuƒ‹ƒ“ƒlƒ‹‘B‚ðŽå‘Ì‚Æ‚·‚é\“ñŽw’°ƒuƒ‹ƒ“ƒlƒ‹‘B‰ßŒëŽî‚Ì1—áD“úÁ•a‰ïŽ97: 449-454, 2000

42.     àVˆä‚Žu:  ŒŒŠÇ‰Š‚Ì•ª—Þ‚Æ‘gDŠw“I“Á’¥DÅVˆã55: 2663-267, 2000

43.     “n•Ó“O—YCàVˆä‚ŽuC²“¡¬C—¢Œ©i: • •”‘å“®–¬áŽ‚É‚¨‚¯‚éMatrix metalloproteinasesiMMP-2‚ÆMMP-9j‚Ì”­Œ»‚Æ’†–Œ’e«üˆÛ•ö‰ó‚Æ‚ÌŠÖ˜AD“úŒŒŠÇŠO‰ïŽ9: 539-54, 2000

44.     àVˆä‚ŽuC‰FŒŽ”ü˜a: •úŽËüƒvƒ[ƒuD•a—‚Æ—Õ°18i—ÕŽž‘Š§j: 258-262, 2000

45.     àVˆä‚Žu: ‰ä‚ª‘‚É‚¨‚¯‚éƒeƒŒƒpƒ\ƒƒW[‚ÌŒ»óDVˆã—Ã27i•Êûj 29-32, 2000

46.     ‰FŒŽ”ü˜aCàVˆä‚Žu: d‘gD‚É‚¨‚¯‚é–Ɖu‘gD‰»ŠwD•a—‚Æ—Õ°18i—ÕŽž‘Š§j: 57-62, 2000

47.     ’·‰ªŒ÷CœA“c‘ŽqCùì“ÖŽqC‘å˜a“c–¾•FC•½“c—¤³: D’†‹…‚ÌŽE‹Ûƒyƒvƒ`ƒhdefensin ‚Æcathelicidin‚Ì‹¤“¯ì—pD‰ŠÇ20: 131, 2000

48.     ‰““¡dŒúC²“¡M”ŽCˆî“c·–ç: ƒEƒŠƒiƒXƒ^ƒ`ƒ“‚É‚æ‚éƒTƒCƒgƒJƒCƒ“ŽY¶‚ÌCüDTherapeutic Res 21: 1921-1923, 2000

49.     àVˆä‚Žu: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚ÌŒ»ó‚Æ–â‘è“_Dˆã‚Ì‚ ‚ä‚Ý194: 120-126, 2000

50.     àVˆä‚ŽuC‰FŒŽ”ü˜aC“n•Ó‚Ý‚©: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚ÌŒ»ó‚Æ–â‘è“_D—Õ°•a—48: 458-462, 2000

51.     àVˆä‚ŽuC‰FŒŽ”ü˜a: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j¡Œã‚ÌŒ©’Ê‚µD—Õ°ŒŸ¸44: 965-969, 2000

52.     “Œ•ŸŽ›Šô•vC”ª–Ø—RŽqC“y‹´N¬CàVˆä‚Žu: •Ä‘‰“Šuˆã—Êw‰ïƒeƒŒƒpƒ\ƒƒW[@SIG‚É‚æ‚éƒeƒŒƒpƒ\ƒƒW[—Õ°‰^—pƒKƒCƒhƒ‰ƒCƒ“DVˆã—Ã1: 138-141, 2000

53.     ›Œ´~C—é–Ø—Ï•ÛCàVˆä‚ŽuC¬ì²: Rƒgƒƒ“ƒrƒ“ÜiƒAƒ‹ƒKƒgƒƒoƒ“j‚̃‰ƒbƒg‚Ì‘¹”]‚É—^‚¦‚é‰e‹¿ \ ŒŒŠÇ‚É‚¨‚¯‚éÚ’…•ªŽqiintercellular adhesionmolecule(ICAM-1)‚Ì”­Œ»‚ÆMac-1—z«×–E‚ÌZ \D‰ŠÇEĶ21: 63-69, 2001

54.     àVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`iRAj‚Ì•a‘Ô‚Ì•a—Šw“I‰ðÍ \ “Á‚É“îœEœ”j‰ó‚ɂ‚¢‚Ä \DŠâŽèˆãŽ53: 99-109, 2001

55.     @‘œF‰ÀC‰FŒŽ”ü˜aC“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚éInterleukiniILj-18‚Ì“®‘ÔDƒŠƒEƒ}ƒ`41: 625-634, 2001

56.     ‘å‹v•Û‹±ŽqCŒ‹é–L•FC²“¡‹§CΓcˆê•FC–…”öd°C¼‰iŒú¶C–쑺”üŽ÷ŽqC“àŠCŒ‰C—é–ØŒhC•½àV‘åC–ì“c—TC“¡“c’¼FCàVˆä‚ŽuC‰FŒŽ”ü˜aCœA“c½ˆê: ˆÝ•ÇŠO«‚É—LŒs«”­ˆç‚µ‚½ˆÝGIST‚Ì1—áD“úÁ•a‰ïŽ98: 822-826, 2001

57.     ŽO‰YNGC•£Œ°CŽÄ“c—S“ñCàVˆä‚ŽuC²“¡—F—ºCˆäã—m¼: œ‘ˆÙŒ`¬ÇŒóŒQ‚ÌŒo‰ß’†‚É–«Epstein-BarrƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚é‚Æl‚¦‚ç‚ê‚錌‹…æÃHÇŒóŒQ‚ÆŽíX‚ÌŽ©ŒÈR‘Ì‚Ìã¸‚ðŽ¦‚µ‚½1Ç—áD—Õ°ƒŠƒEƒ}ƒ`13: 137-143, 2001

58.     ŽO‰YNGC•£Œ°CŽÄ“c—S“ñC‰ª“cMˆê˜YCàVˆä‚Žu: ‰E”x’†—t‚É”­¶‚µ‚½d‰»«ŒŒŠÇŽî‚Ì1—á.f’f•a—18: 263-265, 2001

59.     “c‘º‘¥’jC‰FŒŽ”ü˜aC¼–{•s“ñ•vC—ÍŠÛöC‘•ª³ˆêCàVˆä‚Žu: ‹}‘¬”j‰óŒ^ŒÒŠÖßÇiRDCj‚Ìœ”j‰ó•”ˆÊ‚É‚¨‚¯‚éUrokinase-Type Plasminogen ActivatoriuPAj‚¨‚æ‚ÑuPA ReceptoriuPARj‚Ì”­Œ»‚Æœ”j‰ó‚ÌŠÖ˜ADƒŠƒEƒ}ƒ`41: 851-857, 2001

60.     —é–Ø—zŽqCŒIŒ´‰pŽqC–Ø”¦ŒjC”©ŽR–¾CòŽR•ü­C‰FŒŽ”ü˜aCàVˆä‚Žu: Ä”­«‘½”­“Š‚Ì2Ç—áD“ú“à‰ïŽ90: 2088-2092, 2001

61.     ‰““¡‰p•FC•Ê•{‚–¾CrˆäŒ[ŽjC¬Š}Œ´–MºC—é–Ø‹C—é–Ø—Ï•ÛC¬ì²CÄ“¡—§‰ØCàVˆä‚Žu: ŠC–ÈÖ¬“´•”ƒAƒXƒyƒ‹ƒMƒ‹ƒX“÷‰èŽî‚Ì1—áD”]_ŒoŠO‰È29: 325-329, 2001

62.     ‹g“c_ŽqC–Ñ—˜FC•“cWC—é–؇CŽR“àL•½Cˆäã—m¼CÄ“¡—§‰ØCàVˆä‚Žu:  SjögrenÇŒóŒQ‚ÉBOOP•a•Ï‚ð‡•¹‚µ‚½1—áD“ú“à‰ïŽ90: 329-331, 2001

63.     ŒF’JƒC²“¡Ž–¤Cì–”•ü–›C²–씎‚CΈäG’‰CàVˆä‚Žu: äF”‘a•”‘¹‚Ì•a‘Ô \ 30‘ãˆÈ~‚ÌÇ—á‚ɂ‚¢‚Ä \DŒ¨ŠÖß25: 213-216, 2001

64.     ˆî“c·–çC‰““¡dŒú: ¶‘Ì”½‰ž‚©‚ç‚Ý‚½”Mi3jDMed Post 39: 33-46, 2001

65.     ‰““¡dŒúCŽR“c—T•FCˆî“c·–ç: ¶‘Ì”½‰ž‚©‚ç‚Ý‚½”Mi5jDMed Post 39: 269-278, 2001

66.     ‰““¡dŒúCŽR“c—T•FC’†‰iŽmŽt–¾Cˆî“c·–ç: ¶‘Ì”½‰ž‚©‚ç‚Ý‚½”Mi6jDMed Post 39: 29-38, 2001

67.     Š‹¼Œ’C‰““¡dŒúCˆî“c·–çC²“¡¬‘å: ƒCƒ€ƒmƒNƒƒ}ƒgƒOƒ‰ƒtƒB[–@‚É‚æ‚éƒvƒƒJƒ‹ƒ`ƒgƒjƒ“’l‘ª’è‚Ì—L—p«‚ÌŒŸ“¢DMed Post 39: 77-79, 2001

68.     ‰““¡dŒúCˆî“c·–ç: ”sŒŒÇ‚Ì•a‘ÔŒ`¬‚ÉŠÖ‚·‚éƒTƒCƒgƒJƒCƒ“‚Ì–ðŠ„D‰ŠÇ‚ƖƉu9: 96-103, 2001

69.     ‰““¡dŒúCŽR“c—T•FC’†‰iŽmŽt–¾CŠFìK—mC”óŒû_•¶Cˆî“c·–ç: ¶‘Ì”½‰ž‚©‚ç‚Ý‚½”Mi7jDMed Post 39: 31-42, 2001

70.     ’†‰iŽmŽt–¾C‰““¡dŒúCŽR“c—T•FCˆî“c·–ç: ¶‘Ì”½‰ž‚©‚ç‚Ý‚½”Mi8jDMed Post 40: 23-36, 2001

71.     ’†‰iŽmŽt–¾C‰““¡dŒúCˆäã‹`”ŽC“¡–ì–õ‹vCŽR“c—T•FC²“¡Œõ‘¾˜YCÔârŽ÷C‹g‘º•¶FCˆî“c·–çC²“¡¬‘å: PMX‚ðŽ{s‚µ‚½”sŒŒÇ«‘½‘ŸŠí•s‘S‚ÌŒŒ’†ƒGƒ“ƒhƒgƒLƒVƒ“CƒTƒCƒgƒJƒCƒ“CNOx’l‚ÌŒŸ“¢DƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇ‹~–½Ž¡—ÃŒ¤‰ïŽ5: 30-35, 2001

72.     ˆî“c·–çC‹v•Û‹^“Þ”üC‰““¡dŒúC²“¡¬‘å: ŋ߂̃Gƒ“ƒhƒgƒLƒVƒ“‘ª’è–@‚Ì–â‘è“_DƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇ‹~–½Ž¡—ÃŒ¤‰ïŽ5: 9-12, 2001

73.     àVˆä‚ŽuC‰FŒŽ”ü˜aCŽÄ“c—S“ñCŠâè^‹|CŽO‹{²mC“¡ì”ŽNC’†“‡—m: ¶ŒŸ‘œ‚Æ—Õ°ŠŒ©‚©‚çHypereosinophilic SyndromeiHESj‚ª‹^‚í‚ꂽǗáD –¬ŠÇŠw42: 193-196, 2002

74.     àVˆä‚Žu: u“ú–{ƒeƒŒƒpƒ\ƒƒW[Œ¤‹†‰ïv‚Ì”­‘«‚ɂ‚¢‚ÄD•a—‚Æ—Õ°20: 220-221, 2002

75.     ˆÉ“¡’C‰FŒŽ”ü˜aC“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`ŒŒ´CŠÖ߉t’†‚ÌMatrix MetalloproteinaseiMMPj-13‚Ì“®‘ÔDƒŠƒEƒ}ƒ`42: 60-69, 2002

76.     ‰FŒŽ”ü˜aC•½“c–œç‘ãCàVˆä‚Žu: ŠÖߎ¾Š³‚É‚¨‚¯‚é–Ɖu‘gD‰»Šw‚Æin situ hybridization.   J Hard Tissue Biol 10: 141-148, 2002

77.     ‹g“c“nC‰FŒŽ”ü˜aC“ˆ‘º³CàVˆä‚Žu: In situ zymography‚ð—p‚¢‚½–«ŠÖ߃ŠƒEƒ}ƒ`ŠŠ–Œ‘gD‚É‚¨‚¯‚éƒ[ƒ‰ƒ`ƒ“•ª‰ð”\‚ÌŒŸ“¢DŠâŽèˆãŽ54: 95-105, 2002

78.     ²X–ØMlC¬—Ñ“NlC•£Œ°CàVˆä‚Žu: äPŒ´•a‚Ì•a—D‘Ž‡—Õ°51: 2213-2219, 2002

79.     Š‹‘×FC•Ê•{‚–¾CŽÄ“àˆê•vC¬Š}Œ´–M–¾C¬ì²C•£@Œ°: èò•”–À‘–_ŒoŒ´”­malignant peripheral nerve sheath tumoriMPNSTj‚Ì1—áD”]_ŒoŠO‰È30: 523-526, 2002

80.     ’†‰iŽmŽt–¾C‰““¡dŒúCŽR“c—T•FCˆî“c·–ç: ¶‘Ì”½‰ž‚©‚ç‚Ý‚½”MÇi9jDMed Post 40: 29-42, 2002

81.     ’†‰iŽmŽt–¾C‰““¡dŒúCŽR“c—T•FCˆî“c·–ç: ¶‘Ì”½‰ž‚©‚ç‚Ý‚½”MÇi10jDMed Post 40: 25-36, 2002

82.     ‘å“à’¼‹vC¬—Ñ“NlCàVˆä‚Žu: RA‚É‚¨‚¯‚éœE“j‰ó‚Ì•a—D THE BONE  16: 2002-2009, 2002

83.     àN—§‰ØC•Ê•{‚–¾C•£Œ°CŽR“àL•½C›Œ´~C¬ì²CàVˆä‚Žu: Neoplastic cells and proliferating endothelial cells express connective tissue growth factoriCTGFj in glioblastom.  ŠâŽèˆãŽ54: 322-323, 2002

84.     ¬—Ñ“NlC•£Œ°CàVˆä‚Žu: ƒOƒŠƒI[ƒ}‚É‚¨‚¯‚éconnective tissue growth factor‚Ì”­Œ»‚Æ‚»‚ÌŒŒŠÇV¶‚Æ‚ÌŠÖ˜ADŠâŽèˆãŽ54: 323, 2002

85.     ‰FŒŽ”ü˜aCù–ìŒöLC‘º¼N¬C‚‹´˜aLCŒËP˜alC‰«—²CàVˆä‚Žu: CRFƒtƒ@ƒ~ƒŠ[_Œoƒyƒvƒ`ƒh‚Æ‚»‚ÌŽó—e‘̂̉ŠÇ«Ž¾Š³‚É‚¨‚¯‚é”­Œ»DŠâŽèˆãŽ54: 323, 2002

86.     ›Œ´~C—é–Ø—Ï•ÛCàVˆä‚ŽuC¬ì²: Rƒgƒƒ“ƒrƒ“ÜiƒAƒ‹ƒKƒgƒƒoƒ“j‚̃‰ƒbƒg‚Ì‘¹”]‚É—^‚¦‚é‰e‹¿@ŒŒŠÇ‚É‚¨‚¯‚éÚ’…•ªŽqintercellular ahesion moleculeiICAM-1j‚Ì”­Œ»‚ÆMac-1—z«×–E‚ÌZDŠâŽèˆãŽ54: 323-324, 2002

87.     ²X–ØMlC•£Œ°Cˆäã—m¼CàVˆä‚Žu: ¬‡«Œ‹‡‘gD•a‚ɇ•¹‚·‚é”x‚ŒŒˆ³Ç‚ɑ΂·‚éR“à”ç×–ER‘Ì‚ÌŠÖ—^‚ɂ‚¢‚ÄD ƒŠƒEƒ}ƒ`42: 885-894, 2002

88.     àVˆä‚ŽuC‰FŒŽ”ü˜aCˆÉ“¡‹gŒ«CŠâè^‹|C‹yìáÁˆê: ”x“®–¬‚ɉÁ—îŠw“I•Ï‰»‚Í‘¶Ý‚·‚éH –¬ŠÇŠw‰ïŽiin pressj

89.     àVˆä‚ŽuC‰FŒŽ”ü˜aCˆÉ“¡‹gŒ«C“c’†^ŠóC‘å“àC“ñ: “gD‚Ì“Á«‚Æ‚»‚Ì”j‰ó‹@\D•a—‚Æ—Õ°iin pressj

 

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

90.     ²X–Ø^—: MRI‚É‚æ‚éƒAƒ‹ƒcƒnƒCƒ}[•a‚̉摜‰ðÍD˜V”NŠú’s•ðŒ¤‰ïŽ11: 59-61, 1999

91.     ˆäãŒhC¬ì²C´…G–¾C‹g–{‚Žu: ˆÙŠ«ŠD”’Ž¿‚É‚¨‚¯‚é‹ÇŠ_ŒoüˆÛ‚ÌŠgŽU‹­’² MRI i3DACj‚É‚æ‚錟“¢DCI Œ¤‹†22: 259-262, 2000

92.     ¼ì‘׳C“y”ìŽçC“n•Ó”üŠì—YC—é–Ø—Ï•ÛC¬ì²: ƒXƒtƒBƒ“ƒSƒŠƒ“Ž‰Ž¿ Sphyngosylphosphorylcholine ‚É‚æ‚é”]ŒŒŠÇ‚ÌŽ‘±“IŽûk‚Ì”­¶‹@˜D”]ŒŒŠÇ¹k12: 226-229, 2000

93.     “n•Ó”üŠì—YC“y”ìŽçC¼ì‘׳C—é–Ø—Ï•ÛC¬ì²Cìè@•qC²X–ؘa•F: ”]ŒŒŠÇ‚ÌŽ‘±“IŽûk‚ɑ΂·‚é Rho kinase inhibitor Y-27632 ‚Ì—}§Œø‰ÊD”]ŒŒŠÇ¹k15: 247-250, 2000

94.     ‹g“c—YŽ÷C¬ì²C•“c´ŽiC˜a“cŽiCŽçŒû®C—é–Ø—Ï•Û: ”íŠkoŒŒ‚ɑ΂·‚é“àŽ‹‹¾‰ºŒŒŽî‹zˆøpD”]‘²’†22: 605-609, 2000

95.     ‘åŠÔX^ˆêC‹g“c—YŽ÷C—é–Ø—Ï•ÛC¬ì²C”óŒûh: ŠâŽèŒ§‚É‚¨‚¯‚é‚­‚à–Œ‰ºoŒŒ‚Ì”­Çó‹µ@•½¬3”N‚©‚çD”]‘²’†22: 623-627, 2000

96.     ŽÄ“àˆê•vC•Ê•{‚–¾CrˆäŒ[ŽjC¬Š}Œ´–MºC“y”ìŽçC¬ì²: ‘o“à”dŽí‚𗈂µ‚½craniopharyngioma‚Ì1Ç—áDVŠƒˆã‰ïŽ114: 500, 2000

97.     ‰““¡‰p•FCŠÖ”Ž•¶C›Œ´FsC–p‰ir: ‰º‚‘Ì”^ᇂÌ1—áDVŠƒˆã‰ïŽ114: 500, 2000

98.     éF–›C¬•Û“àŽåÅF’†•_ŒoŒnŒ´”­«ˆ««ƒŠƒ“ƒpŽî‚ɑ΂µHigh Dose Methotrexate iHDMTXj—Ö@‚ðs‚Á‚½1Ç—áDVŠƒˆã‰ïŽ114: 497-498, 2000

99.     ˆäãŒhC’†—¢M˜aCŒG•”rGC‹g–{‚ŽuC´…G–¾CŽÐ–{”Ž: fMRI‚ð—p‚¢‚½Œ¾Œê—DˆÊ”¼‹…‚Ì“¯’èDVŠƒˆã‰ïŽ114: 496, 2000

100.  Ø‘Ö“TGCç—tCC“ú‚“O—YFƒ‚ƒ„ƒ‚ƒ„•a‚ɇ•¹‚µ‚½”j—ô”]“®–¬áŽ‚ÉŠJ“ªªŽ¡p‚ðs‚Á‚½1—áD VŠƒˆã‰ïŽ114: 490, 2000

101.  •Ê•{‚–¾C¬—ѳ˜aCrˆäŒ[ŽjC®–ìLC¬Š}Œ´–MºC“y”ìŽçC¬ì²C¬—ѽˆê˜Y: High-fiow bypass ‚ð—p‚¢‚Ä“Eop‚ðs‚Á‚½ŠC–ÈÖ¬“´ZÒõŽî‚Ì1—áD“Œ–k”]Žîᇌ¤‰ïŽ4: 58, 2001

102.  ¼ì‘׳CKŽ¡F—TC“y”ìŽç: ƒZƒƒgƒjƒ“‚É‚æ‚Á‚Ĉø‚«‹N‚±‚³‚ꂽƒEƒV”]ŒŒŠÇ•½ŠŠ‹ØŽûk‚É‚¨‚¯‚é Rho-kinase ‚É‚æ‚é‘‹­‹@\DŠâŽèˆãŽ53: 117-127, 2001

103.  ‘¾“cŒ´N¬C¬Š}Œ´–MºC“y”ìŽçC¬ì²: Permanent symptomatic vasospasm‚ÌŒŸ“¢D ”]ŒŒŠÇ¹k16: 222-225, 2001

104.  ¼ì‘׳C“y”ìŽçCKŽ¡F—TC“n•Ó”üŠì—YCìè•qC–Ø‘ºáÁŒáC¬ì²C²X–ؘa•F: ƒXƒtƒBƒ“ƒSƒŠƒ“Ž‰Ž¿ Sphingosylphosphorylcholine ‚É‚æ‚é”]ŒŒŠÇ‚ÌŽ‘±“IŽûk‚É‚¨‚¯‚é Rho Kinase‚ÌŠÖ—^D”]ŒŒŠÇ¹k16: 283-286, 2001

105.  “y”ìŽçC¼ì‘׳C“n•Ó”üŠì—YCKŽ¡F—TC¬ì²Cìè•qC–Ø‘º^ŒáC²X–ؘa•F: Myosin light chain phosphataseŠˆ«‚Ì’²ß‚É‚æ‚é”]ŒŒŠÇ‚ÌŽûk§Œä‹@\D ”]ŒŒŠÇ¹k 16: 290-293, 2001

106.  ‹g“c—YŽ÷: ”]ŒŒŠÇáŠQDŽ¡—Ã83: 113-119, 2001

107.  ‰““¡‰p•FC•Ê•{‚–¾CrˆäŒ[ŽjC¬Š}Œ´–MºC—é–Ø‹C—é–Ø—Ï•ÛC¬ì²CÄ“¡—§‰ØCàVˆä‚Žu: ŠC–ÈÖ¬“´•”ƒAƒXƒyƒ‹ƒMƒX“÷‰èŽî‚Ì1—áDNeurol Surg 29: 325-329, 2001

108.  ‹g“cŒ¤“ñC—é–Ø—Ï•ÛCH“¡–¾C¬ì²: ƒNƒ‚–Œ‰ºoŒŒŒã‚Ì”]ŒŒŠÇ¹k‚ɑ΂·‚éRƒgƒƒ“ƒrƒ“Ü‚ÌŽ¡—ÃŒø‰Ê‚ÉŠÖ‚·‚錤‹† \ Z“§ˆ³ƒ|ƒ“ƒv‚É‚æ‚鎑±‘‰to“à“Š—^–@‚ð—p‚¢‚Ä \D”]_ŠOƒWƒƒ[ƒiƒ‹10: 104-109, 2001

109.  ˆ¢•”[áC^£’q•FC‰““¡‰p—YC¬ì²: Ž‹‘©ŠÇŠJ•úp‚ª—L—p‚Å‚ ‚Á‚½2—áD“ú‹~‹}ˆã‰ïŽ12: 67-70, 2001

110.  ¬Š}Œ´–Mº: ”]zŠÂ‘ãŽÓ‚ÌŠî‘bDƒuƒŒƒCƒ“ƒi[ƒVƒ“ƒO17: 10-16, 2001

111.  ²X–Ø^—: MRI‚É‚æ‚éƒAƒ‹ƒcƒnƒCƒ}[•a‚̉摜f’fD˜V”NŠú’s•ðŒ¤‰ïŽ12: 24-26, 2001

112.  “n•Ó”üŠì—YC‹v•Û’¼•FC” è½ŽiCŒK“c’m”VC–åŠÔM”ŽC¬ì²: “ªŠW“à capillary hemangioma ‚Ì1—áDNeurol  Surg 29: 1049-1054, 2001

113.  ˆÀ“cd: ¸_•ª—ô•a‚É‚¨‚¯‚鉹ŠyŒ¶’®‚ÌÓ”C•”ˆÊDŠâŽèˆãŽ54: 189-193, 2002

114.  ²X–Ø^—C¼‰iŒåC•yàVLsC‰“ŽRe“ñ˜YC‹Êì–FtC¬ì”Ž”V: 3 Tesla‘•’u‚ð—p‚¢‚½ƒCƒkCƒlƒR”]‚ÌMRŠŒ©D“úŽ¥ˆãŽ22: 30-31, 2002

115.  ‹Tˆä~C²X–Ø^—CÔâ^“Þ”üCç“cŸˆê: Ž¥‹C‹¤–‰摜‚ňÙí‚ð”F‚ß‚½EBƒEƒCƒ‹ƒX”]Ç‚É‚æ‚é•sŽv‹c‚Ì‘‚̃AƒŠƒXÇŒóŒQ‚Ì1—áD”]‚Æ”­’B34: 348-35, 2002

116.  Š‹‘×FC•Ê•{‚–¾CŽÄ“àˆê•vC¬Š}Œ´–MºC¬ì²C•£Œ°: èò•”–À‘–_ŒoŒ´”­malignant peripheral nerve sheath tumor iMPNSTj‚Ì1—áDNeurol  Surg 5: 523-526, 2002

117.  ã–ìˆçŽqC“¡Œ´r˜YC¼“c_ˆêC‹T“c¹ŽuC“yˆäÍ’jCˆäãŒhC¬ì²: ‚RŽŸŒ³—̈æŠg’£–@‚ð—p‚¢‚½”]MRI‰æ‘œ‚©‚ç‚ÌŽîᇗ̈撊oDMŠw‹Z•ñ11: 23-28, 2002

118.  ²X–Ø‹P•vCrˆäŒ[ŽjCˆ¢•”[áC㙌›KC›ˆä•ÛC¬Š}Œ´–MºC’†‘ºáÁˆêC¬ì²: •@‘¤”¼–Ó‚ð’悵‚½ˆÆã•”ˆÙŠ«‰º‚‘Ì‘BŽî‚Ì1—áD”]_ŠOƒWƒƒ[ƒiƒ‹12: 124-128, 2003

119.  ¼–{‰p–¾C˜a“cŽiC•“c´ŽiC‹g“c—YŽ÷C‰œŒû‘ìC¬Š}Œ´–MºC¬ì²C•½‰êŒbC‚‹´–¾: “ªŠWŠOŒã‚ÉŠg‘å‚ð‚Ý‚½ƒxƒ‹ƒKo‚Ì1—áDNeurol Surg  31: 297-301, 2003

120.  ‹g“c—YŽ÷C•“c´ŽiC˜a“cŽiC‰œŒû‘ìC‰““¡dŒúC¬ì²: ‹~‹}ŠO—ˆ‚É‚¨‚¯‚é‹Ù‹}ú“ªp \ dÇ‹}«d–Œ‰ºŒŒŽî‚ÌŽ¡—Ã¬Ñ \D“ú‹~‹}ˆã‰ïŽ14: 179-186, 2003

 


˜a•¶‘à

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         ²“¡—mˆê: ‹¤Å“_Œ°”÷‹¾‚ð—p‚¢‚½¶‘gD‚̃Cƒ[ƒWƒ“ƒO \ “Á‚É×–E“àƒJƒ‹ƒVƒEƒ€ƒCƒIƒ““®‘Ԃ̉Ž‹‰»‚ɂ‚¢‚ÄD “dŒ°ŽGŽ34: 217-219, 1999

2.         ²X–ؘa•F: ‚f’`”’‚̉îÝ‚·‚é×–E“àî•ñ“`’B‹@\‚ƃVƒOƒiƒ‹’`”’ƒŠƒ“Ž_‰»‚É‚æ‚é’²ßDŠâŽèˆãŽ51: 327-344, 1999

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

3.         ˆî“c·–çC‰““¡dŒú: ƒGƒ“ƒhƒgƒLƒVƒ“‚ÌŽ¾Š³‚É‚¨‚¯‚é–ðŠ„D“úW’†ˆãŽ6: 337-345, 1999

4.         àVˆä‚ŽuC‰FŒŽ”ü˜a: ƒŠƒEƒ}ƒ`‚Ì•a— \ “®•¨ƒ‚ƒfƒ‹‚Ì•a‘ԉ𖾂Ǝ¡—Âւ̉ž—p \D•a—‚Æ—Õ°17i—ÕŽž‘Š§j: 321, 1999

5.         àVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`iRAjŒ¤‹†‚ÌV‚µ‚¢“®Œü \ “ÁW‚ÉŠñ‚¹‚Ä \D×–E31: 2-3, 1999

6.         àN—§‰ØCŽR“àL•½: üˆÛ‰è×–E‚Æ”xƒŠƒ‚ƒfƒŠƒ“ƒODˆã‚Ì‚ ‚ä‚Ý3i•ÊûEŒÄ‹zŠíŽ¾Š³j: 91-94, 1999

7.         ‰““¡dŒúCŽR“c—T•FCˆäã‹`”ŽCˆî“c·–çC²“¡M”ŽC쑺—²Ž}: ƒTƒCƒgƒJƒCƒ“‚ƃXƒeƒƒCƒh—Ö@D ICU‚ÆCCU 23: 845-851 1999

8.         ‰““¡dŒúCŽR“c—T•FCˆî“c·–ç: ”sŒŒÇD‹~‹}ˆãŠw23: 1481-1485, 1999

9.         ‰““¡dŒúC’JŒû”ÉCˆî“c·–çC쑺—²Ž}C²“¡M”Ž: ‘½‘ŸŠí•s‘S‚Ì•a‘Ô¶—‚Æf’fD—Õ°“§Í15: 1379-1386, 1999

10.     ‰““¡dŒúCŽR“c—T•FCˆäã‹[”ŽCˆî“c·–ç: ‹~‹}ƒZƒ“ƒ^[‚É‚¨‚¯‚銴õÇ‚Ìf’f‚ÆŽ¡—ÃDŠ´õ–hŽ~9: 9-14, 1999

11.     ‰““¡dŒúCˆî“c·–ç: SIRS‚ƃGƒ“ƒhƒgƒLƒVƒ“ŒŒÇD Lis 6: 854-858, 1999

12.     ˆî“c·–çC‰““¡dŒú: ƒGƒ“ƒhƒgƒLƒVƒ“‚Ì’è—Ê–@DLis 6: 838-844, 1999

13.     ‰““¡dŒúCŽR“c—T•FC’JŒû”ÉCˆî“c·–ç: RƒƒfƒBƒG[ƒ^—Ö@D ICU‚ÆCCU 23: 351-356, 1999

14.     ‰““¡dŒúCŠ‹¼Œ’CŽR“c—T•FC’JŒû”ÉC²“¡M”ŽC”ì“cŒ\‰îC’r“cŒ’ˆê˜YCˆî“c·–ç: systemic inflammatory response syndrome‚É‚¨‚¯‚銴õÇf’f‚¨‚æ‚ÑdÇ“x‚ÌŽw•W‚Æ‚µ‚ẴvƒƒJƒ‹ƒ`ƒgƒjƒ“’l‘ª’è‚̈Ӌ`DNP‚ƖƉu  8: 1-6, 1999

15.     ‰““¡dŒúCŽR“c—T•FCˆî“c·–ç: dÇ•a‘Ԃł̃Gƒ“ƒhƒgƒLƒVƒ“ŒŒÇ‚ɑ΂·‚é‘ÎôDW’†Ž¡—Ã11: 169-174, 1999

16.     àVˆä‚Žu: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚ÌŒ»‹µ‚Æ–â‘è“_D“úˆã‰ï‘‰ï25‰ñ‰ïŽ3: 448, 1999

17.     àVˆä‚ŽuC‰FŒŽ”ü˜a: ƒŠƒEƒ}ƒ`‚Ì•a— \ “®•¨ƒ‚ƒfƒ‹‚Ì•a‘ԉ𖾂Ǝ¡—Âւ̉ž—p \D•a—‚Æ—Õ  17: 321, 1999

18.     ˆî“c·–ç: ƒGƒ“ƒhƒgƒLƒVƒ“‚Ì‘ª’è–@‚ð‚ß‚®‚Á‚ÄDƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇŽ¡—ÃŒ¤‰ïŽ  43: 177-196A2000

19.     ‰““¡dŒúCˆî“c·–ç: SIRS‚ƃGƒ“ƒhƒgƒLƒVƒ“ŒŒÇDŒ»‘ãˆã—à  32i‘Š§IIIj: 79-84, 2000

20.     ˆî“c·–çC‰““¡dŒú: ”sŒŒÇ‚Ì—Õ°f’fƒKƒCƒhƒ‰ƒCƒ“‚Æ‚µ‚ẴvƒƒJƒ‹ƒVƒgƒjƒ“D —ÕŒŸ  44: 679-680, 2000

21.     ‰““¡dŒúCŽR“c—T•FCˆî“c·–çC쑺—²Ž}C²“¡M”Ž: ‰ŠÇ«ƒƒfƒBƒG[ƒ^[iƒTƒCƒgƒJƒCƒ“‘¼jD W’†Ž¡—Ã12: 247-252, 2000

22.     àVˆä‚Žu: ƒeƒŒƒpƒ\ƒƒW[‚Ì—L—p«‚Æ–â‘è“_DVˆã—Ã308: 80-83, 2000

23.     ‰FŒŽ”ü˜aCàVˆä‚Žu: ƒeƒŒƒpƒ\ƒƒW[‚ÌŒ¤‹†–ʂւ̉ž—pDˆã‚Ì‚ ‚ä‚Ý195: 503-510, 2000

24.     ‰“ŽRe“ñ˜Y: ƒ~ƒNƒƒOƒŠƒA \ Œ`‘Ô“I“Á«‚Æ‹@”\D×–E32: 4-8, 2000

25.     àVˆä‚ŽuCˆä“¡‹v—YC“y‹´N¬CŠJŒ´¬ˆò: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚ÌŒ»ó‚Æ¡Œã‚Ì–â‘è“_ ƒeƒŒƒpƒ\ƒƒW[‘S‘’²¸‚©‚çDVˆã—Ã326: 95-99, 2002

26.     àVˆä‚Žu: ‰“Šuˆã—Â͂ǂ±‚Ü‚Åi‚Þ‚©DŒŽŠ§–òŽ–  44: 226i816j-232i822j, 2002

27.     ˆÉ“¡‹gŒ«CàVˆä‚Žu: ŠÖ߉Š‚Ì•a—Šw“IŠî‘bD—Õ°‰æ‘œ18: 30-243, 2002

28.     ‰FŒŽ”ü˜aC¼–{•s“ñ•vCàVˆä‚Žu: ƒŠƒEƒ}ƒ`«Ž¾Š³‚Ì•a—ŠwDƒŠƒEƒ}ƒ`‰È27: 93-100, 2002

29.     àVˆä‚Žu: ‘•]uƒJƒ‰[ƒAƒgƒ‰ƒX@•a—‘gD‚ÌŒ©•û‚ÆŠÓ•Êf’fi‘æ4”ÅjDˆã‚Ì‚ ‚ä‚Ý 202: 142, 2002

30.     ‰“ŽRe“ñ˜Y: ––½_ŒoˆÚA‚ÌŽÀŒ±Žè‹ZD Organ Biol 10: 59-66, 2003

 

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

31.     ²X–Ø^—C‹y씎•¶C‹Êì–Ft: MRI‚É‚æ‚éŠD”’Ž¿“à\‘¢‚Ì•`oD—Õ°•úü44: 1229-1234, 1999

32.     ²X–Ø^—: _ŒoŒn‚ÌMRŽB‘œ–@D“úŽ¥‹C‹¤–ˆã‰ïŽ19: 503-519, 1999

33.     ²X–Ø^—C‹y씎•¶C‹g‰ª–M_C‹Êì–Ft: _ŒoŠ´õǂ̉摜f’fD_Œ¤‚Ìi•à  43: 26-34, 1999

34.     ²X–Ø^—C‹Tˆä~: JoubertÇŒóŒQDBrain Med  12: 429-431, 2000

35.     —é–Ø‹: Ò’ÅEÒ‘Ž¾Š³DƒuƒŒƒCƒ“ƒi[ƒVƒ“ƒO17: 35-42, 2001

36.     ¬Š}Œ´–MºC¬ì²: èò“®–¬•a•ÏD“úˆã‰ïŽi“Á•Ê†; ”]ŒŒŠÇáŠQ‚Ì—Õ°j125: 253-258, 2001

37.     ²X–Ø^—: ŠC–ÈÖ¬“´AspergillusÇDBrain Med 13: 93-95, 2001

38.     ²X–Ø^—: 3 Tesla MR‰æ‘œ‚É‚¨‚¯‚鎋°‰ºŠjC• ‘¤Ž‹°‚̳í‰ð–UDˆã‚Ì‚ ‚ä‚Ý196: 747-748, 2001

39.     ²X–Ø^—C‹y씎•¶C‹Êì–Ft: ‚Ä‚ñ‚©‚ñ‚ÉŠÖ—^‚·‚é”]\‘¢‚̳í‰ð–UD‰æ‘œf’f 21: 126-132, 2001

40.     ²X–Ø^—: ¡‚·‚®¸_‰È—Õ°‚ÉŽg‚¦‚é”]ƒCƒ[ƒWƒ“ƒO  \ ƒAƒ‹ƒcƒnƒCƒ}[•aD¸_‰ÈŽ¡—à 16: 1011-1015, 2001

41.     ²X–Ø^—C•Ê•{‚–¾: ãó‰èˆÙŒ`¬«_Œoã”çŽîá‡DBrain Med  13: 193-195, 2001

42.     •“c´Ži: ¬lC‚—îŽÒ‚Ì“ª’ÉDŽ¡—à 83: 12-18, 2001

43.     •“c´Ži: ˆÓŽ¯áŠQDŽ¡—à 83: 225-230, 2001

44.     ‹g“c—YŽ÷: ”]‘²’†‚Ì•a—E•a‘ÔD ƒuƒŒƒCƒ“ƒi[ƒVƒ“ƒO 214: 10-24, 2001

45.     ˆäãŒhC¬ì²C´…G–¾ CŒG•”rGC‹g–{‚Žu: Func Tool‚ðŽg—p‚µ‚½”]‹@”\‰ð͉摜DGE today  6: 17-19, 2001

46.     ¬ì²: “ªŠWŠO \ “àƒoƒCƒpƒXp‚Í—LŒø‚ÈŽ¡—Ö@‚½‚肤‚é‚©D“ú–{‚Ì’§íFJET study.   EBMƒWƒƒ[ƒiƒ‹2: 50-54, 2001

47.     ˆäãŒhC¬ì²:  V‚µ‚¢f’f–@ fMRI, 3DACDƒuƒŒƒCƒ“ƒi[ƒVƒ“ƒO 17: 55-59, 2001

48.     ²X–Ø^—C‹g‰ª–M_: Š´õ«”]“®–¬áŽDBrain Med 13: 299-301, 2001

49.     ²X–Ø^—: 3 Tesla MRI‚ÌŒ»ó‚Æ¡ŒãD‰f‘œî•ñƒƒfƒBƒJƒ‹33: 958-962, 2001

50.     ¬Š}Œ´–MºC¬ì²: ”]“®–¬áŽ‚ÌŽèpDClin Neurosci  19: 27-29, 2001

51.     ¬ì²: JET study Group,  ”]‘²’†‚ÌŠO‰È‚É‚¨‚¯‚éEBM-JET study‚ð’†S‚ÉD”]_ŠOƒWƒƒ[ƒiƒ‹10: 596-603, 2001

52.     ¬Š}Œ´–MºC¼ì‘׳: ŒÝ‚¢‚ɉe‹¿‚·‚éS‘Ÿ‚Æ”]DƒuƒŒƒCƒ“ƒi[ƒVƒ“ƒO 18: 17-21, 2001

53.     ¬Š}Œ´–MºC¬ì²: •W€Ž¡—ÂÆÅVŽ¡—à \ ƒƒŠƒbƒgEƒfƒƒŠƒbƒg@Œz•”“àèò“®–¬‹·óÇDClin Neurosc  20: 110-111, 2001

54.     ²X–Ø^—: ŠC”n‘ÌC‘Ñó‰ñC”]—ÀDMedicin  38: 32-37, 2001

55.     ¬Š}Œ´–MºC¬ì²: 1.   Ä”­‚ð–h‚®@“ÁWQ4@Ä”­—\–h‚Ì‚½‚ß‚Ì”]ŒŒŠÇ‚̃oƒCƒpƒXŽèp‚ÆC‚»‚ÌŒø‰Ê‚ÍH  –ˆ“úƒ‰ƒCƒt1: 27-28, 2002

56.     “y”ìŽçC¬ì²: ”]‘²’†‹}«Šú‚̃}ƒ“ƒjƒg[ƒ‹—Ö@DClin Neurosci  20: 168, 2002

57.     ®–ìLC¬ì²: ŒŒsÄŒšp‚͂ǂ̂悤‚ÈꇂÉl—¶‚·‚ׂ«‚©D“à‰È 89: 667-673, 2002

58.     ²X–Ø^—: 3 Tesla MRI‚É‚æ‚鎋°‰ºŠj‚Ì“¯’èD”]‚̉Ȋw 24: 451-456, 2002

59.     ²X–Ø^—: ƒAƒ‹ƒcƒnƒCƒ}[•a‚̉摜f’fD¸_Ž 104: 455-457, 2002

60.     ²X–Ø^—: 3T‘•’u‚Ì—Õ°‰ž—p‚̉”\«DInnervision 17: 58-60, 2002

61.     ²X–Ø^—: ”]_ŒoŒn‚Ì‚¨‚¯‚éƒ}ƒ‹ƒ`ƒXƒ‰ƒCƒXCT‚Ì—L—p«‚Æ–â‘è“_D’f‘w‰f‘œŒ¤‰ïŽ 29: 88-94, 2002

62.     ²X–Ø^—: ”]_Œo—̈æ‚É‚¨‚¯‚éMDCT‚ÌŒ»óD Vˆã—Ã334: 82-84, 2002

63.     •Ê•{‚–¾CˆäãŒhC•£Œ°C‰FŒŽ”ü˜aCrˆäŒ[ŽjC¬Š}Œ´–MºC’†‘ºáÁˆêC¬ì²: Diffusion tensor MRI‚É‚æ‚é¯×–EŒnŽîᇂÌfractional anistoropy (FA) ’lD‰æ‘œf’f  9: 291-295, 2002

64.     ˆäãŒhC¬ì²: Functional MRI. Clin  Neurosc 20: 1047-1050, 2002

65.     ¬Š}Œ´–MºC¬ì²F“ªŠWŠO’Åœ“®–¬‹·óE•ÂÇ«Ž¾Š³‚ɑ΂·‚錌sÄŒšpD”]_ŠO‚Š‚|‚Ž‚‚’‚•11: 783-788, 2002

66.     ˆäãŒhC¬ì²: V‚µ‚¢Ž¡—ÃKƒCƒhƒ‰ƒCƒ“‚ɑ΂µ‚Ä: ”]_ŒoŠO‰È‚Ì—§ê‚©‚çD˜V”NˆãŠw  40: 1767-1769, 2002

67.     ¬Š}Œ´–Mº: Œã“ªŠWâ|‹•ŒŒ«•a•Ï‚ɑ΂·‚éSTA-SCA•«‡D”]ŠO‘¬•ñ 12: 222-223, 2002

68.     ‹y씎•¶C²X–Ø^—C]Œ´–Î: Mesial temporal sclerosisD—Õ°ˆã  29isupplj: 832-833, 2003

69.     ²X–Ø^—C]Œ´–Î: ‹•ŒŒ«”]Ž¾Š³‚Ì•a‘Ô‚ÆŽ¡—à \ CT, MRI \DŒ»‘ãˆã—à 24: 466-472, 2003

70.     ²X–Ø^—C‰“ŽRe“ñ˜YC]Œ´–Î: 3 Tesla MRI‚É‚æ‚é”÷×”]\‘¢‚Ì•`oD”]ŠO‘¬•ñ 13: 973-977, 2003

71.     ²X–Ø^—C]Œ´–Î: _ŒoŒn‚É‚¨‚¯‚éƒ}ƒ‹ƒ`ƒXƒ‰ƒCƒXCT‚ÌV‹Zp‚Æ—Õ°‰ž—pD“úàÕˆã•ñ  48: 128-138, 2003

72.     •Ð“c˜aœAC²X–Ø^—C‚Œ´‘¾˜YC¬—ёהVCˆÀ–ì‘׎jC¼–Ø[: ƒ}ƒ‹ƒ`ƒXƒ‰ƒCƒXCT‚ÌŒ»ó‚Æ«—ˆD‰f‘œî•ñƒƒfƒBƒJƒ‹35: 24-47, 2003

73.     ²X–Ø^—C]Œ´–Î: 16—ñMSCT‚Ì—L—p« \ ”]_ŒoŒn‚ւ̉ž—p \D Innerviaion  18: 11-13, 2003

74.     ²X–Ø^—: ƒ}ƒ‹ƒ`ƒfƒBƒeƒNƒ^CT‚Ì—Õ°•]‰¿ \ “ª•”?“ªèò•” \D CLINICIAN  340: 113-116, 2003

75.     ˆäãŒhC¬ì²: 3ƒeƒXƒ‰MRI‚Ì—Õ°‰ž—pDVˆã—Ã6: 70-72, 2003

76.     ²X–Ø^—C]Œ´–Î: V‚µ‚¢”]‚Ìf’f–@‚͂ǂ̂悤‚É–ð‚É—§‚‚̂© \ MRI \D ‰æ‘œf’f 23, 2003iin pressj

77.     ²X–Ø^—CˆäãŒhC]Œ´–Î: ‚±‚ê‚©‚ç‚Ì”]Žîᇂ̉摜f’f: ’´‚Ž¥êMRID—Õ°‰æ‘œ, 2003iin pressj


’˜‘i•ÒW‘ÐE’P’˜j

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         ²“¡—mˆêCÒŽR—m‰E: ‘B‘gD‚ÌŽOŽŸŒ³ŒuŒõƒCƒ[ƒWƒ“ƒOCƒoƒCƒIƒCƒ[ƒWƒ“ƒO‚ÌÅæ’[Cpp 176-181, Îìt—¥ ed, æ’[ˆã—Ã, “Œ‹žC1999

2.         ²“¡—mˆêC‹{“cß–çCâV–ì’©K: ‚‘¬‹¤Å“_ƒŒ[ƒU[Œ°”÷‹¾‚É‚æ‚éCa2+‚̃}ƒbƒsƒ“ƒO, pp 152-157, ‘gD×–E‰»Šw2000C“ú–{‘gD×–E‰»Šw‰ï edCŠwÛŠé‰æ, “Œ‹ž, 2000

3.         —§ì‰pˆêC‚‹´‰hŽi: –ò—pläóƒTƒ|ƒjƒ“‚Ì–ò•¨Žó—e‘Ì‚Ö‚Ìì—p‚Æ–òŒø \ “`’B•¨Ž¿Žó—e‘Ì‚Ö‚Ìì—p \, pp 58-63, –ò—pläó 2000, ŒF’J˜N ed, ‹¤—§o”Å, “Œ‹ž, 2000

4.         ‰“ŽRe“ñ˜YC²X–Ø^—: V”]‰ð–UƒAƒgƒ‰ƒX, ‹´–{ˆóü, ·‰ª, 2001

5.         ²X–ؘa•FCìè•qC–Ø‘ºáÁŒáC‚“‡_ˆê˜Y: ƒAƒƒtƒ‰ƒV_Œoß×–E‚ÌD1Žó—e‘ÌŽhŒƒ‚ňø‚«‹N‚±‚³‚ê‚é“àŒü‚«“d—¬‰ž“š‚ÍGTPƒÁS‘¶Ý‰º‚ÅŠOŒü‚«“d—¬‰ž“š‚É‹t“]‚·‚éCpp 41-48, ”]‹@”\‚̉𖾠\¶–½‰ÈŠw‚ÌŽå’ª—¬ \,  Ô’r‹I•} ed, ƒKƒCƒAo”ʼnïC‹ãB‘åŠw,  2002

6.         “¡“c—æŽqC–Ø‘ºáÁŒáCìè•qC‚“‡_ˆê˜YC¼–{Œõ”äŒÃC•½–ì_ŽqC²X–ؘa•F: ƒAƒfƒmƒVƒ“Žó—e‘Ì‹y‚ÑFSHŽó—e‘̉ž“š‚ɑ΂·‚éATPŽó—e‘ÌŽhŒƒ‚É‚æ‚é—}§ì—pC pp 83-89, ”]‹@”\‚̉𖾠\ ¶–½‰ÈŠw‚ÌŽå’ª—¬ \CÔ’r‹I•} edCƒKƒCƒAo”ʼnï, ‹ãB‘åŠw, 2002

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

7.         —é–Ø–ž, ˆäŒ´—T: ‚ŽŸ”]‹@”\‹Çݘ_‚Ì“WŠJ‚Æ‹@”\C•œ“IŽ¡—ÃŒ¤‹†‚Ì—ðŽjC pp 297-309,  —Õ°¸_ˆãŠwuÀspecial issue, ¼‰º³–¾C’‹“cŒ¹Žl˜Y edC’†ŽR‘“X, “Œ‹žC1999

8.         Ø‘ÖÆ—YCƒAƒ“ƒiƒXƒxƒ‹ƒcƒRC•½“c—¤³C•½ˆä‹`ˆêCŒE“c’B–çC’†–ì¹N: ƒvƒƒeƒEƒXLPS‚̶•¨Šˆ«, p 97,  ƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†II V‚µ‚¢“WŠJC‰¶“c¹•F‘¼ edCتo”Å, “Œ‹ž,  1999

9.         ˆî“c·–çF ƒqƒgƒŠƒ“ƒp‹…‚̃Gƒ“ƒhƒgƒLƒVƒ“‚ɑ΂·‚锽‰ž«C pp 129-135CƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†2 V‚µ‚¢“WŠJ, “ú–{ƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†‰ï‘¼•ÒedCتo”Å, “Œ‹žC1999

10.     àVˆä‚ŽuC“n•Ó‚Ý‚©C¯Žiˆê•v: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[jŒ»ó‚Æ¡Œã‚̉ۑèCpp 1691-198, ŠO‰È•a—Šw‘æ3”Å, Îì‰h¢C‰“鎛@’medC•¶Œõ“°C“Œ‹žC1999

11.     Ž—’¹“OC“àŽRˆÀ’j: S‘Ÿ‚ƃAƒ|ƒg[ƒVƒX,  pp 86-89C‘ŸŠí•ÊƒAƒ|ƒg[ƒVƒXØ–¾–@C ‘å’Ο‹IC¬˜H••FC“n•ÓŒcˆê edC“ì]“°C“Œ‹žC2000

12.     Sawai T, Uzuki M: In situ hybridization for RNA: Radioactive DNA probe, pp 100-114,  Molecular Histochemical Techniques, Koji T ed, Springer-Verlag Tokyo, Tokyo,  2000

13.     •½“c—¤³C“c‘ºOŽuC“c’†d‘¥C¬ŒFŒb“ñC’·‰ªŒ÷: CAP18ƒyƒvƒ`ƒh‚É‚æ‚éƒGƒ“ƒhƒgƒLƒVƒ“ƒVƒ‡ƒbƒN‚Ì–hŒäCp 141,  ƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†III V‚µ‚¢‹Ç–Ê, ŽR–{r•ã‘¼edCتo”ÅC“Œ‹žC2000

14.     ˆî“c·–ç: ƒGƒ“ƒhƒgƒLƒVƒ“‘ª’è–@‚ÌŒ»ó‚Æ–â‘è“_,  pp 37-49,  ƒGƒ“ƒhƒgƒLƒVƒ“‹z’…—Ö@‚ÌŠî‘b‚Æ—Õ°C ¬‹Ê³’qedCŽ©‘R‰ÈŠwŽÐC“Œ‹žC2000

15.     ˆî“c·–çC‹v•Û‹^“Þ”üC‰““¡dŒú: ƒŠƒ€ƒ‹ƒXƒeƒXƒg‚É‚æ‚錌’†ƒGƒ“ƒhƒgƒLƒVƒ“‘ª’è–@‚Ì–â‘è“_C“Á‚ɃJƒCƒlƒeƒBƒbƒN–@‚É‚¨‚¯‚é”ñ“ÁˆÙ“I”½‰ž‚Ì”­¶‚Æ‚»‚Ì—vˆöC pp 203-209, ƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†3 V‚µ‚¢‹Ç–ÊC“ú–{ƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†‰ï‘¼ edCتo”ÅC“Œ‹žC2000

16.     ‹g“c“nCàVˆä‚Žu: ŠÖ߉Š‚̉ð–UŠwCpp 3-6,  ŠÖ߉Šƒ‚ƒfƒ‹,  ˆÀ”{ç”VCàVˆä‚Žu edC“ú–{ˆãŠwŠÙC“Œ‹žC2000

17.     ‹g“c“nCàVˆä‚Žu: ŠÖ߉Š‚̶‰»Šw,  pp 7-16,  ŠÖ߉Šƒ‚ƒfƒ‹CˆÀ”{ç”VCàVˆä‚Žu edC“ú–{ˆãŠwŠÙC“Œ‹žC2000

18.     ‰FŒŽ”ü˜aCàVˆä‚Žu:  ŠÖ߉Š‚Ì•a—ŠwCpp 17-24,  ŠÖ߉Šƒ‚ƒfƒ‹CˆÀ”{ç”VCàVˆä‚Žu ed, “ú–{ˆãŠwŠÙC“Œ‹žC2000

19.     àVˆä‚Žu: ‰ä‚ª‘‚É‚¨‚¯‚éƒeƒŒƒpƒ\ƒƒW[‚ÌŒ»óCpp 29-32,  —Õ°ŒŸ¸•Ö——CŒŽŠ§Vˆã—à ed, ƒGƒ€EƒC[U‹»‹¦‰ïC“Œ‹ž,  2000

20.     •£Œ°CàVˆä‚Žu: ŒŒŠÇ‰Š‚É‚¨‚¯‚é‘gDŠQ‹@˜Cpp 49-54,  ŒŒŠÇ‰ŠC‹´–{”ŽŽj ed, ’©‘q‘“X, “Œ‹ž,  2001

21.     •½“c—¤³: šM“û—Þ‚ª‚‚­‚éR‹Û’`”’Ž¿iCAP18j‚̃Šƒ|‘½“œ’†˜aŠˆ«‚ƶ‘Ì–hŒäCp 575,  ’`EŠjEyi—ÕŽž‘Š§†jC“àŽR’|•FC’†“ˆôçZC–¼Žær“ñC³–Ø°•F•Ò ed, ‹¤—§o”Å, “Œ‹ž,  2001

22.     àVˆä‚Žu: ‰“Šuˆã—Ẩۑè‚Æ‚±‚ê‚©‚ç‚Ì“WŠJCpp 116-124C’nˆæˆã—Âð•Ï‚¦‚éƒeƒŒƒƒfƒBƒVƒ“C—ìƒeƒŒƒƒfƒBƒVƒ“Œ¤‹†‰ï ed, “Œ—mŒoÏV•ñŽÐ, “Œ‹ž,  2001

23.     àVˆä‚Žu: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚ÌŒ»ó‚Æ–â‘è“_Cpp 3-9,  ƒeƒŒƒpƒ\ƒƒW[2002-ŽÀ—p‰»‚Æ”­“W‚ð‚ß‚´‚µ‚Ä-CàVˆä‚ŽuCˆä“¡‹v—Y edCˆãŽ•–òo”Å, “Œ‹ž,  2001

24.     ‰FŒŽ”ü˜aCàVˆä‚Žu: ƒeƒŒƒpƒ\ƒƒW[‚ÌŒ¤‹†–ʂւ̉ž—pCpp  71-78, •ÊûEˆãŠw‚Ì‚ ‚ä‚Ý@ƒeƒŒƒpƒ\ƒƒW[2002 \ ŽÀ—p‰»‚Æ”­“W‚ð‚ß‚´‚µ‚Ä \CàVˆä‚ŽuCˆä“¡‹v—Yed, ˆãŽ•–òo”ÅC“Œ‹žC2002

25.     àVˆä‚ŽuC‰FŒŽ”ü˜aCˆÉ“¡‹gŒ«: ŠÖ߃ŠƒEƒ}ƒ`‚Ì•a—Šw-ŠŠ–Œ‚̉ŠÇ‚©‚眔j‰ó‚Ü‚ÅC pp 22-33, ÅVˆãŠw•Êû@V‚µ‚¢f’f‚ÆŽ¡—ÂÌABC8/–Ɖu1ŠÖ߃ŠƒEƒ}ƒ`, ‹{âM”V ed, ÅVˆãŠwŽÐ, “Œ‹ž,  2002

26.     àVˆä‚ŽuCŠâè^‹|: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[jCpp 43-46CÅ‹ß‚Ì“®Œü‚Æ¡Œã‚̉ۑèC—Õ°ŒŸ¸•Ö——02, ŒŽŠ§Vˆã—à ed, iŠ”jƒGƒ€EƒC[U‹»‹¦‰ï, “Œ‹ž, 2002

27.     àVˆä‚Žu: ŠÖ߃ŠƒEƒ}ƒ`‚Ì•a—E•a‘ÔC pp 112-122,  ƒŠƒEƒ}ƒ`Šî–{ƒeƒLƒXƒgià’c–@l“ú–{ƒŠƒEƒ}ƒ`@à’c‹³ˆçŒ¤CˆÏˆõ‰ï•ÒjC“ú–{ƒŠƒEƒ}ƒ`à’c‹³ˆçŒ¤CˆÏˆõ‰ï ed, “ú–{ƒŠƒEƒ}ƒ`à’c, “Œ‹ž,  2002

 

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

28.     ²X–Ø^—: Fast spin echo–@‚É‚¨‚¯‚éŽB‘œðŒ‚ÌÝ’èCpp 116-117C—Õ°•úŽËü‰È‚̃Rƒc‚Æ—Ž‚Æ‚µŒŠ‚QC¬’Ë—²O edC’†ŽR‘“XC“Œ‹žC1999

29.     ²X–Ø^—: Mesial temporal sclerosis‚ÌMRIf’f‚Æ—Ž‚Æ‚µŒŠCpp 46-47,  —Õ°•úŽËü‰È‚̃Rƒc‚Æ—Ž‚Æ‚µŒŠ‚PC¬’Ë—²O edC’†ŽR‘“XC“Œ‹žC1999

30.     ²X–Ø^—: _Œo”畆njóŒQCpp 385-396C”]Ò‘‚ÌMRI, ŽRŒûVˆêC‹{â˜a’j edCˆãŠw‘‰@, “Œ‹ž,  1999

31.     ²X–Ø^—C‹Tˆä~: ‚Ä‚ñ‚©‚ñCpp 375-384,  ”]Ò‘‚ÌMRICŽRŒûVˆêC‹{â˜a’j ed, ˆãŠw‘‰@, “Œ‹ž,  1999

32.     ²X–Ø^—: ‰ºƒIƒŠ[ƒuŠj‹U”ì‘å,  pp 397-400,  ”]Ò‘‚ÌMRICŽRŒûVˆêC‹{â˜a’j ed, ˆãŠw‘‰@, “Œ‹ž,  1999

33.     ²X–Ø^—: ‘å”]”玿‘wó‰óŽ€Cpp 404-407C”]Ò‘‚ÌMRICŽRŒûVˆêC‹{â˜a’j ed, ˆãŠw‘‰@, “Œ‹ž,  1999

34.     ²X–Ø^—: AlzheimerŒ^’s•ðCpp 201-208,  MRIC —Õ°¸_ˆãŠwuÀS10: ¸_‰È—Õ°‚É‚¨‚¯‚é‰æ‘œf’fC¼‰º³–¾ ed, ’†ŽR‘“X, “Œ‹ž,  2000

35.     ²X–Ø^—: 3 Tesla MRI: ŽB‘œã‚Ì“Á’¥‚Æ’ˆÓ“_C pp 80-83,  MRI‰ž—pŽ©Ý,  ‚Œ´‘¾˜Y ed, ƒƒWƒJƒ‹ƒrƒ…[C“Œ‹žC 2001

36.     ²X–Ø^—: ŠC”nC‘Ñó‰ñC”]—ÀCpp 27-32,  CTCMRIƒAƒgƒ‰ƒX \ ³í‰ð–U‚Ɠlje‚̃|ƒCƒ“ƒg C”ª‘ã’¼•¶C‘å—F–MC–ؖΎ÷ ed, ˆãŠw‘‰@C“Œ‹žC2001

37.     ‘¾“cŒ´N¬C¬ì²: Ž¸ŒêÇCpp 127-133Cƒi[ƒX‚Ì‚½‚ß‚Ì”]_ŒoŠO‰È@‰ü’ù‘æ2”ÅC 2001

38.     ‰œŽ›—˜’jC²X–Ø^—C—é–ØGŒ›C”¨àV‡CˆÉ“¡Žõ‰îCYun Peng Huang: “à‘å”]Ö¬‚¨‚æ‚уKƒŒƒ“Ö¬‚̉ð–U \ •úŽËüŠw“IƒAƒvƒ[ƒ`C pp 69-80,  Œ°”÷‹¾‰ºŽèp‚Ì‚½‚ß‚Ì”]_ŒoŠO‰È‰ð–UXIV-”]ŽºŒn‚Ì—§‘̉ð–U \C”÷¬”]_ŒoŠO‰È‰ð–UƒZƒ~ƒi[C“Œ‹žC2001

39.     ˆäãŒh: 3.0 Tesla MRI ‚É‚æ‚é”]ŒŒŠÇ«áŠQ‚Ìf’f‚¨‚æ‚Ñp‘O•]‰¿,  pp 86-89,  •Êû@ˆãŠw‚Ì‚ ‚ä‚Ý,  “Œ‹V‰p•v ed, ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐC“Œ‹ž,  2001

40.     ¬Š}Œ´–MºC¬ì²: ”]ŽåŠ²“®–¬•ÂÇ«•a•Ï–«Šú‚ɑ΂·‚éƒoƒCƒpƒXp‚ÌŒ»óC pp 175-176, •Êû@ˆãŠw‚Ì‚ ‚ä‚Ý, “Œ‹V‰p•v edCˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐ, “Œ‹ž,  2001

41.     ²X–Ø^—C‹y씎•¶: ¬Ž™‚Ì”]ŒŒŠÇáŠQ,”]ŒŒŠÇáŠQ‚̉摜f’fCpp 297-307,   ‚‹´ºŠì ed, ’†ŠOˆãŠwŽÐ, “Œ‹ž,  2002

42.     ²X–Ø^—: MDCT‘ÎMRICpp 26-27, MDCT“O’êU—ªƒ}ƒjƒ…ƒAƒ‹C²X–Ø^— edCƒƒWƒJƒ‹ƒrƒ…[, “Œ‹ž,  2002

43.     ²X–Ø^—C‰º–쑾˜Y: ”]_Œo: ŠïŒ`C•Ï«C‘ãŽÓˆÙíC’E‘C‰ŠÇCŠOCpp 27-33,  •úŽËü‰ÈŠw \ f’f \C“ú–{•úŽËü‰Èê–åˆã‰ï ed, ƒƒfƒBƒJƒ‹‹³ˆçŒ¤‹†ŽÐC“Œ¼ŽRŽsC2003

44.     ²X–Ø^—C‹y씎•¶: ¬Ž™‚Ì”]ŒŒŠÇáŠQCpp 297-307C”]ŒŒŠÇáŠQ‚̉摜f’fC‚‹´ºŠì ed, ’†ŠOˆãŠwŽÐ, “Œ‹ž,  2003

45.     ²X–Ø^—: ‰æ‘œf’f?ŒŸ¸: MDCT, pp 333-336C”]ŽîᇂÌÅVˆã—Ã,  ‰ÃŽRF³ ed, æ’[ˆã—ËZpŒ¤‹†ŠC“Œ‹žC2003

46.     –؉º—dzC‰œŽ›—˜’jC‰¡“cW: ‘ÙŽ™”]‚Ì”­’B,  ”]MRI 1. ³í‰ð–U,  ‚‹´ºŠìed, GŽÐ, “Œ‹ž iin pressj

47.     ²X–Ø^—C]Œ´–Î: MRI‚ÌV‚µ‚¢ŽB‘œ–@CAnnual Review_Œo2003C–öàVM•vC‘¼ ed, ’†ŠOˆãŠwŽÐC“Œ‹žiin pressj

 


‘“àƒVƒ“ƒ|ƒWƒEƒ€

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         ²“¡—mˆê: ‘gD•W–{‚É‚¨‚¯‚é×–E“àî•ñ“`’BŒn‚̉Ž‹‰»FƒŠƒAƒ‹ƒ^ƒCƒ€‹¤Å“_Œ°”÷‹¾‚É‚æ‚éƒJƒ‹ƒVƒEƒ€ƒCƒ[ƒWƒ“ƒOC‘æ7‰ñƒRƒ“ƒtƒH[ƒJƒ‹488ƒTƒ}[ƒVƒ“ƒ|ƒWƒEƒ€, 1999, 7, ‘O‹´

2.         ²“¡—mˆê: ‘gD•W–{‚É‚¨‚¯‚é×–E“àî•ñ“`’BŒn‚̉Ž‹‰»FƒŠƒAƒ‹ƒ^ƒCƒ€‹¤Å“_Œ°”÷‹¾‚É‚æ‚éƒJƒ‹ƒVƒEƒ€ƒCƒ[ƒWƒ“ƒOC ‘æ7‰ñƒRƒ“ƒtƒH[ƒJƒ‹488ƒTƒ}[ƒVƒ“ƒ|ƒWƒEƒ€, 1999, 7, ‘O‹´

3.         ‹{“cß–çCÖ–ì’©KC²“¡—mˆê: DAF-2 DA‚É‚æ‚éˆêŽ_‰»’‚‘f‚̃Cƒ[ƒWƒ“ƒO \ V¶Ž™ƒ‰ƒbƒg”|—{S‹Ø×–E‚É‚¨‚¯‚錟“¢ \C‘æ8‰ñ“ú–{ƒoƒCƒIƒCƒ[ƒWƒ“ƒOŠw‰ï, 1999, 10, ‚‚­‚Î

4.         ’†ìGKC²“¡•¶•FCAmbreena SiddiqC—ÑOŽOC—§ì‰pˆêC•xŒ´–õ”ŽCVéˆÀ“N: ƒEƒj“ŃŒƒNƒ`ƒ“‚Ì×–E”½‰ž‚ɂ‚¢‚ÄC‘æ47‰ñ“Å‘fƒVƒ“ƒ|, 2000, 7, ‘q•~

5.         ²“¡—mˆê: •ª”å×–E‚ÌŠJŒû•úoC‘æ56‰ñ“ú–{“dŽqŒ°”÷‹¾Šw‰ïŠwpu‰‰‰ïƒVƒ“ƒ|ƒWƒEƒ€, 2000, 5, “Œ‹ž

6.         ²“¡—mˆêC‹{“cß–ç: ‚m‚n‚̉Ž‹‰»C‘æ56‰ñ“ú–{“dŽqŒ°”÷‹¾Šw‰ïŠwpu‰‰‰ïƒVƒ“ƒ|ƒWƒEƒ€, 2000, 5, “Œ‹ž

7.         ²“¡—mˆêC‹{“cß–çCâV–ì’©K: ‚‘¬‹¤Å“_ƒŒ[ƒU[Œ°”÷‹¾‚É‚æ‚éCa2+‚̃}ƒbƒsƒ“ƒOC‘æ25‰ñ‘gD×–E‰»Šw‰ï, 2000, 8, ’¬“c

8.         “¡“c—æŽqC–Ø‘ºáÁŒáCìè•qC‚“‡_ˆê˜YC¼–{Œõ”äŒÃC²X–ؘa•F: ƒAƒtƒŠƒJƒcƒƒKƒGƒ‹‚Ì—‘–E×–E–Œã‚ÌATPŽó—e‘ÌŽhŒƒ‚É‚æ‚éFSHŽó—e‘̉ž“š‚ƃAƒfƒmƒVƒ“Žó—e‘̉ž“š‚Ì—}§,•½¬12”N“x¶—ŠwŒ¤‹†ŠŒ¤‹†‰ï, 2000, 8, ‰ªè

9.         ¼ì‘׳C“y”ìŽçC“n•Ó”üŠì—YC—é–Ø—Ï•ÛC¬ì²C–Ø‘ºáÁŒáC²X–ؘa•F: ƒXƒtƒBƒ“ƒSƒŠƒ“Ž‰Ž¿Sphingosylphosphorylcholin‚É‚æ‚é”]ŒŒŠÇ‚ÌŽ‘±“IŽûk‚Ì”­¶‹@˜C‘æ15‰ñƒXƒpƒYƒ€ƒVƒ“ƒ|ƒWƒEƒ€, 2000, 7, ‹ž“s

10.     “n•Ó”üŠì—YC“y”ìŽçC¼ì‘׳C—é–Ø—Ï•ÛC¬ì²Cìè•qC²X–ؘa•F: ”]ŒŒŠÇ‚ÌŽ‘±“IŽûk‚ɑ΂·‚éRho kinase inhibitor Y-27632‚Ì—}§Œø‰ÊC‘æ15‰ñƒXƒpƒYƒ€ƒVƒ“ƒ|ƒWƒEƒ€, 2000, 7, ‹ž“s

11.     “y”ìŽçC¼ì‘׳C“n•Ó”üŠì—YC—é–Ø—Ï•ÛC¬ì²C–Ø‘ºáÁŒáC²X–ؘa•F: Rho kinase activator‚É‚æ‚éŽûk‚ɑ΂·‚éŠeŽí”]ŒŒŠÇŠg’£–ò‚Ì—}§Œø‰ÊC‘æ15‰ñƒXƒpƒYƒ€ƒVƒ“ƒ|ƒWƒEƒ€, 2000, 7, ‹ž“s

12.     ‹{“cß–çC²“¡—mˆê: V¶Ž™ƒ‰ƒbƒg”|—{S‹Ø×–E‚É‚¨‚¯‚éˆêŽ_‰»’‚‘f‚̃Cƒ[ƒWƒ“ƒOC‘æ56‰ñ“ú–{“dŽqŒ°”÷‹¾Šw‰ïŠwpu‰‰‰ïƒVƒ“ƒ|ƒWƒEƒ€, 2000, 5, “Œ‹ž

13.     ²“¡—mˆê: ×–E“àî•ñ“`’BŒn‚Ö‚¨‚æ‚Ú‚·ƒŒ[ƒU[Œõ‚̉e‹¿C‘æ57‰ñ“ú–{“dŽqŒ°”÷‹¾Šw‰ïŠwpW‰ï, 2001, 5, •Ÿ‰ª

14.     Satoh Y, Saino T: Calcium signaling in cytoplasm and nucleusC‘æ107‰ñ“ú–{‰ð–UŠw‰ï‘‰ï, 2002, 3, •l¼

15.     —§ì‰pˆêCH“¡Œ«ŽOCŠ~–{ˆÐŽu: ƒXƒeƒƒCƒhŒ^–ò—pläóƒTƒ|ƒjƒ“‘ãŽÓ•¨‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‘jŠQì—pC‘æ2‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€, 2002, 2, ·‰ª

16.     H“¡Œ«ŽOC—§ì‰pˆêCŠ~–{ˆÐŽu: ƒjƒ…[ƒƒXƒeƒƒCƒh‚É‚æ‚éƒJƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‘jŠQC‘æ2‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€, 2002, 2, ·‰ª

17.     Ö–ì’©KC¼‰Y½C²“¡—mˆêFŒŒŠÇ•Ç‚ÌŒoŽž“IƒJƒ‹ƒVƒEƒ€“®‘ÔD‚»‚̃Cƒ[ƒWƒ“ƒO‚ƈӋ`C‘æ108‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï, 2003, 4, •Ÿ‰ª

18.     —§ì‰pˆêCH“¡Œ«ŽOC…ŠÔŒªŽOC‹ß“¡‚ä‚«ŽqCŠ~–{ˆÐŽu: –ò—pläó‚Ì•›t‹@”\—}§F”|—{×–E‚Å‚ÌŒŸ“¢C‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ï, 2003, 3, •Ÿ‰ª

 

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

19.     ›Œ´~C—é–Ø—Ï•ÛC‹v•ÛŒc‚C‹g“cŒ¤“ñC¬ì²CàVˆä‚Žu: ƒ‰ƒbƒg‘¹”]‚É‚¨‚¯‚éE-selectin‚Ì”­Œ» \ Thrombin‚ÌŠÖ—^‚ɂ‚¢‚Ä \C‘æ11‰ñ_Œo‘¹‚ÌŠî‘bƒVƒ“ƒ|ƒWƒEƒ€, 1999, 12, “Œ‹ž

20.     ˆ¢•”—²ŽuCˆé•”ç–¾CÎèŒb—C‘º“c—²•FC“Œ‹V‰p•v: ’s•ð‚ƃ‚ƒmƒAƒ~ƒ“ì“®ŒnáŠQC‘æ52‰ñ“ú–{Ž©—¥_ŒoŠw‰ï, 1999, 11, L“‡

21.     àVˆä‚ŽuC“n•Ó‚Ý‚©C‰FŒŽ”ü˜aC’†‘ºáÁˆê: –{–M‚É‚¨‚¯‚éf’f•a—ˆã‚Ì•Î݂ƃeƒŒƒpƒ\ƒƒW[‚Ì’nˆæˆã—Âɂ¨‚¯‚é—L—p«C‘æ88‰ñ“ú–{•a—Šw‰ï, 1999, 4, “Œ‹ž

22.     “n•Ó‚Ý‚©CàVˆä‚Žu: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚Ìp’†v‘¬f’f‚É‚¨‚¯‚é—¿‹à‘ÌŒn‚ÉŠÖ‚·‚é’ñˆÄC‘æ88‰ñ“ú–{•a—Šw‰ï, 1999, 4, “Œ‹ž

23.     ›Œ´~C—é–Ø—Ï•ÛC‹v•ÛŒc‚C‹g“cŒ¤“ñC¬ì²CàVˆä‚Žu: Rƒgƒƒ“ƒrƒ“ÜiƒAƒ‹ƒKƒgƒƒoƒ“j‚̃‰ƒbƒg‚Ì‘¹”]‚É—^‚¦‚é‰e‹¿‚ɂ‚¢‚Ä \ ŒŒŠÇ‚É‚¨‚¯‚éÚ’…•ªŽqiintercellular adhesion molecule (ICAM)-1j‚Ì”­Œ»‚ÆMac-1—z«×–E‚ÌZ \C‘æ12‰ñ_Œo‘¹‚ÌŠî‘bƒVƒ“ƒ|ƒWƒEƒ€, 2000, 12, “Œ‹ž

24.     •£Œ°CàVˆä‚Žu: ‘ŸŠí•Êu‹`‚ւ̉摜‰ž—pC‘æ89‰ñ“ú–{•a—Šw‰ï‘‰ï, 2000, 4, ‘åã

25.     ‰FŒŽ”ü˜aCàVˆä‚Žu: _ŒoE“à•ª”åŒn‚Æ–«ŠÖ߃ŠƒEƒ}ƒ`C‘æ44‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïEŠwpW‰ï, 2000, 5, ‰¡•l

26.     ‰FŒŽ”ü˜aCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‰Šú‚ÌŠŠ–Œ•a•ÏC‘æ44‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïEŠwpW‰ï, 2000, 5, ‰¡•l

27.     “c’†^ŠóCàVˆä‚ŽuC’Ò”ü’qŽqC“¡ˆäŽ”V: –«ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚鉊ú“a•Ï \ MRL/lƒ}ƒEƒX‚ðŽ¾Š³ƒ‚ƒfƒ‹‚Æ‚µ‚½•a—‘gDŠw“IŒŸ“¢C‘æ44‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïEŠwpW‰ï, 2000, 5, ‰¡•l

28.     ‰FŒŽ”ü˜aCù–ìŒöLCŒËP˜alC‘º¼N¬C‚‹´˜aLC‰«—²C”Ñ–ì˜a”üCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`iRAjŠŠ–Œ‘gD‚ÆŠÖ߉t‚É‚¨‚¯‚éurocortinCCRF‚ÆCRF receptor‚Ì”­Œ»C‘æ10‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2000, 10, ·‰ª

29.     “c‘º‘¥’jC‰FŒŽ”ü˜aC¼–{•s“ñ•vC—ÍŠÛöC‘•ª³ˆêCàVˆä‚Žu: ‹}‘¬”j‰óŒ^ŒÒŠÖßÇ‚Ì‘å‘Úœ“ª‚É‚¨‚¯‚éurokinase‚¨‚æ‚Ñurokinase-receptor‚Ì”­Œ»‚Æœ”j‰ó‚ÌŠÖ˜AC ‘æ10‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2000, 10, ·‰ª

30.     ›Œ´~C—é–Ø—Ï•ÛC‹v•ÛŒc‚C‹g“cŒ¤“ñC¬ì²CàVˆä‚Žu: Rƒgƒƒ“ƒrƒ“܂̃‰ƒbƒg‚Ì‘¹”]‚É—^‚¦‚é‰e‹¿‚ɂ‚¢‚Ä \ Ú’…•ªŽq‚Ì”­Œ»‚ƉŠÇ«×–EZ‚Ì‘gDŠw“I•]‰¿ \C ‘æ‚P‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€C2001, 2, ·‰ª

31.     ˆ¢•”—²Žu: ƒp[ƒLƒ“ƒ\ƒ“•a‚ÌŽ¡—ÃAƒ‹ƒSƒŠƒYƒ€C‘æ42‰ñ“ú–{_ŒoŠw‰ï‘‰ï, 2001, 5, “Œ‹ž

32.     •½“c—¤³: “à“Å‘f‚Ìì—p‹@\‚ÆCAP18‚É‚æ‚é‚»‚ÌŽ¡—Ö@‚ÌŠJ”­CƒVƒ“ƒ|ƒWƒEƒ€: ׋ۓőfŒ¤‹†‚ÌŠî‘b‚Æ‚»‚̉ž—pC‘æ74‰ñ“ú–{׋ۊw‰ï‘‰ï, 2001, 4, ‰ªŽR

33.     Pan LH, Beppu T, Kurose, Yamauchi K, Sugawara, Ogawa A, Sawai T: Neoplastic cells and proliferating endothelial cells express connective tissue growth factoriCTGFj in glioblastoma,  ‘æ2‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€ From Cell Biology to Neuropathology, 2002, 2, ·‰ª

34.     Kobayashi T, Kurose A, Sawai T: Expression of connective tissue growth factor and its relationship to angiogenesis in glioma,  ‘æ2‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€@From Cell Biology to Neuropathology, 2002, 2, ·‰ª

35.     Uzuki M, Sasano H, Muramatsu Y, Takahashi K, Totsune K, Oki Y and Sawai T: Corticotropin releasing factoriCRFj family neuropeptides and CRF receptors in inflammatory disease,  ‘æ2‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€ From Cell Biology to Neuropathology, 2002, 2, ·‰ª

36.     Sugawara A, Suzuki M, Sawai T, Ogawa A: Therapeutic effects of an antithrombin agent 'argatroban' on the expression of intercellular adhesion moleculeiICAMj-1 positive vessels and Mac-1 positive cells in the experimental brain injury of rat, ‘æ2‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€ From Cell Biology to Neuropathology, 2002, 2, ·‰ª

37.     ‰FŒŽ”ü˜aCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‚ƃqƒAƒ‹ƒƒ“Ž_C‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

38.     àVˆä‚Žu: ŠâŽèŒ§‚̉“Šuˆã—Âɂ¨‚¯‚éŠâŽèˆã‰È‘åŠw‚̉ʂ½‚·–ðŠ„C‘æ56‰ñ“Œ–kˆãŽt‰ï˜A‡‰ï‘‰ï, 2002, 9, H“c

39.     Γc‹Ó“ñC‰Ôâ’qlC—ÑGˆê˜YC‰“ŽRe“ñ˜Y: “€Œ‹’´”–؂̬‚³‚Èi•àC“ú–{“dŽqŒ°”÷‹¾Šw‰ï‘æ‚S7‰ñƒVƒ“ƒ|ƒWƒEƒ€, 2002, 11, å‘ä

40.     ‰“ŽRe“ñ˜YC—ÑGˆê˜YCÔ–ØIC‹´–{’B–ç: ‰t‘̃wƒŠƒEƒ€‚É‚æ‚é‹}‘¬“€Œ‹’uŠ·C“ú–{“dŽqŒ°”÷‹¾Šw‰ï‘æ‚S7‰ñƒVƒ“ƒ|ƒWƒEƒ€, 2002, 11, å‘ä

 

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

41.     ˆäãŒhC¬ì²C¬Š}Œ´–MºC•Ê•{‚–¾C®–ìL: 3 ƒeƒXƒ‰ MRI ‚É‚æ‚é”÷×”]\‘¢‚¨‚æ‚Ñ”’Ž¿_ŒoüˆÛ•]‰¿F‚‰ð‘œ“x‰æ‘œEŠgŽUƒeƒ“ƒ\ƒ‹‰æ‘œ‚ð—p‚¢‚½ŒŸ“¢C“ú–{”]_ŒoCIŠw‰ï, 2001, 3, •Ÿˆä

42.     ²X–Ø^—: ƒAƒ‹ƒcƒnƒCƒ}[•a‚̉摜f’fC‘æ97‰ñ“ú–{¸__ŒoŠw‰ï‘‰ï, 2001, 5, ‘åã

43.     ²X–Ø^—: ’´‚Ž¥êMRI‚ð—p‚¢‚½”]‚Ì”÷׉ð–UC‘æ30‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ï‘å‰ï, 2002, 9, “Œ‹ž

44.     ²X–Ø^—: ‚‰ð‘œ“xMRI‚ð—p‚¢‚½‚Ä‚ñ‚©‚ñ‚̉摜f’fC‘æ19‰ñƒuƒŒƒCƒ“ƒtƒ@ƒ“ƒNƒVƒ‡ƒ“ƒCƒ[ƒWƒ“ƒOƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX, 2003, 9, _ŒË

 


‘“àŠw‰ï

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         Miyata S, Saino T, Satoh Y: The imaging of nitric oxide on neonatal rat cardiomyocytes, ‘æ105‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï, 2000, 3, ‰¡•l

2.         Saino T, Matsuura M, Satoh Y: Digital imaging analysis on intracellular calcium ion dynamics of rat arterioles, ‘æ105‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï, 2000, 3, ‰¡•l

3.         “nç³´ŽqC‹{“cß–çCÖ–ì’©KC²“¡—mˆê: Intracellular calcium ion dynamics in the rabbit corneal epithelium, ‘æ105‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï, 2000, 3, ‰¡•l

4.         Koji T, Nishikawa Y, Doi M, Kimura S, Kawasaki S, Sasaki K, Ogawa A: Involvement of Rho-kinase activation in the thromboxane A2-induced contraction in the middle cerebral artery of bovine, ‘æ78‰ñ“ú–{¶—Šw‰ï‘å‰ï, 2001, 3, ‹ž“s

5.         Kawasaki S, Kimura S, Fujita R, Takashima K, Sasaki K: Role of small G-protein Rho in 5-HT-induced facilitation of voltage-dependent Ca2+ channel, ‘æ78‰ñ“ú–{¶—Šw‰ï‘å‰ï, 2001, 3, ‹ž“s

6.         Kimura S, Kawasaki S, Fujita R, Takashima K, Sasaki K: CaM-kinase II and protein phosphatase 2A regulate quisqualic acid-induced K+-current response in the ganglion cells of Aplysia,  ‘æ78‰ñ“ú–{¶—Šw‰ï‘å‰ï, 2001, 3, ‹ž“s

7.         —§ì‰pˆêCH“¡Œ«ŽOCŠ~–{ˆÐŽuC…ŠÔŒªŽOCŠ~–{ˆÐŽu C‹{Žè‹`˜aCŠaè~C‚‹´Ÿ—YC’·’JìG•v: –ò—pläóƒXƒeƒƒCƒhƒTƒ|ƒjƒ“‘ãŽÓ•¨‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚ɑ΂·‚éŒø‰ÊC‘æ52‰ñ“ú–{–ò—Šw‰ï–k•”‰ï, 2001, 10, ŽD–y

8.         H“¡Œ«ŽOC—§ì‰pˆêC‹ß“¡‚ä‚«ŽqCŠ~–{ˆÐŽu: ƒjƒRƒ`ƒ“«ƒAƒZƒ`ƒ‹ƒRƒŠƒ“Žó—e‘ÌŽhŒƒ‚É‚æ‚éƒJƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚ɑ΂·‚éƒvƒŒƒOƒlƒmƒƒ“—°Ž_‚Ì—}§‹@\C‘æ52‰ñ“ú–{–ò—Šw‰ï–k•”‰ï, 2001, 10, ŽD–y

9.         Kawasaki S, Kimura S, Fujita R, Takashima K, Sasaki K: Rho-kinase regulates 5-HT-induced facilitation of voltage dependent Ca2+ channel, ‘æ24‰ñ“ú–{_Œo‰ÈŠw‘å‰ï, 2001, 9, ‹ž“s

10.     ¼ì‘׳CKŽ¡F—TC“n•Ó”üŠì•vC“y”ìŽçC²X–ؘa•FC¬ì²: Serotonin‚É‚æ‚é”]ŒŒŠÇ•½ŠŠ‹Ø‚ÌŽûk‚É‚¨‚¯‚é’ᕪŽq—Ê’`”’‚f’`”’Rho‚ÌŠÖ—^C‘æ17‰ñƒXƒpƒYƒ€EƒVƒ“ƒ|ƒWƒEƒ€, 2001, 3, ‘åã

11.     KŽ¡F—TC¼ì‘׳Cìè•qC–Ø‘ºáÁŒáC“y”ìŽçC¬ì²C²X–ؘa•F: ƒgƒƒ“ƒ{ƒLƒTƒ“‚`‚QŽó—e‘ÌŽhŒƒ‚Å”­¶‚·‚é”]ŒŒŠÇŽûk‚É‚¨‚¯‚éRho-kinase‚É‚æ‚éŽûk‘‹­‹@\C‘æ17‰ñƒXƒpƒYƒ€EƒVƒ“ƒ|ƒWƒEƒ€, 2001, 3, ‘åã

12.     H“¡Œ«ŽOC—§ì‰pˆêC‹ß“¡‚ä‚«ŽqCŠ~–{ˆÐŽuFƒjƒRƒ`ƒ“«ƒAƒZƒ`ƒ‹ƒRƒŠƒ“Žó—e‘ÌŽhŒƒ‚É‚æ‚éƒJƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚ɑ΂·‚éƒvƒŒƒOƒlƒmƒƒ“—°Ž_‚Ì—}§‹@\C‘æ52‰ñ“ú–{–ò—Šw‰ï–k•”‰ï, 2001, 10, ŽD–y

13.     —§ì‰pˆêCH“¡Œ«ŽOC…ŠÔŒªŽOCŠ~–{ˆÐŽuC‹{Žè‹`˜aCŠaè~C‚‹´Ÿ—YC’·’JìG•v: –ò—pläóƒXƒeƒƒCƒhƒTƒ|ƒjƒ“‘ãŽÓ•¨‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚ɑ΂·‚éŒø‰ÊC‘æ52‰ñ“ú–{–ò—Šw‰ï–k•”‰ï, 2001, 10, ŽD–y

14.     ²“¡—mˆêCÖ–ì’©K: Bio-imaging techniques showing morphological and functional changes in living tissue specimens: application of confocal microscopy, ‘æ106‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï, 2001, 3, ‚’m

15.     ²“¡—mˆêCÖ–ì’©K: Imaging of intracellular calcium dynamics of intestine: with special reference to crypt cells, ‘æ106‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï, 2001, 3, ‚’m

16.     Watanabe S, Miyata S, Saino T, Satoh Y: ATP-stimulated [Ca2+]i dynamics in the cultured human corneal epithelial cells, ‘æ106‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï, 2001, 4, ‚’m

17.     …ŠÔŒªŽOC—§ì‰pˆêCH“¡Œ«ŽOC‹ß“¡‚ä‚«ŽqC‹g“cà†CŠ~–{ˆÐŽu: ‹ÇŠ–ƒŒ–ò‚ªƒEƒV•›t‘Ž¿×–E‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚É—^‚¦‚é‰e‹¿C‘æ75‰ñ“ú–{–ò—Šw‰ï”N‰ï, 2002, 3, ŒF–{

18.     —§ì‰pˆêC‹{Žè‹`˜aCåyè~C’·’JìG•vCH“¡Œ«ŽOC‚‹´Ÿ—YCŠ~–{ˆÐŽu: –ò—pläóƒTƒ|ƒjƒ“‚Æ‚»‚ê‚ç‘ãŽÓ•¨‚Ì•›t”玿ƒRƒ‹ƒ`ƒ]ƒ‹ŽY¶‚ɑ΂·‚éŒø‰ÊC‘æ122‰ñ“ú–{–òŠw‰ï, 2002, 3, ç—t

19.     H“¡Œ«ŽOC—§ì‰pˆêCŠ~–{ˆÐŽu: ƒEƒV•›t‘Ž¿×–E‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚ÉŠÖ‚·‚éƒjƒRƒ`ƒ“«ƒAƒZƒ`ƒ‹ƒRƒŠƒ“Žó—e‘̃Tƒuƒ^ƒCƒv‚̃ŠƒKƒ“ƒh‚É‚æ‚铯’èC‘æ122‰ñ“ú–{–òŠw‰ï, 2002, 3, ç—t

20.     —§ì‰pˆêC’·’JìG•vCH“¡Œ«ŽOC…ŠÔŒªŽOC‹ß“¡‚ä‚«ŽqCŠ~–{ˆÐŽu: –ò—pläóƒXƒeƒƒCƒhŒ^ƒTƒ|ƒjƒ“‘ãŽÓ•¨‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‘jŠQC75‰ñ“ú–{–ò—Šw‰ï”N‰ï, 2002, 3, ŒF–{

21.     …ŠÔŒªŽOC—§ì‰pˆêCH“¡Œ«ŽOC‹ß“¡‚ä‚«ŽqC‹g“cà†CŠ~–{ˆÐŽu: ‹ÇŠ–ƒŒ–ò‚ª‹•›t‘Ž¿×–E‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚É—^‚¦‚é‰e‹¿C75‰ñ“ú–{–ò—Šw‰ï”N‰ï, 2002, 3, ŒF–{

22.     —§ì‰pˆêC‹{Žè‹`˜aCŠaè~C’·’JìG•vCH“¡Œ«ŽOC‚‹´Ÿ—YCŠ~–{ˆÐŽu: –ò—pläóƒTƒ|ƒjƒ“‚Æ‚»‚ê‚ç‘ãŽÓ•¨‚Ì•›t”玿ƒRƒ‹ƒ`ƒ]ƒ‹ŽY¶‚ɑ΂·‚éŒø‰ÊC‘æ122‰ñ”N‰ï–òŠw‰ï, 2002, 3, ç—t

23.     H“¡Œ«ŽOC—§ì‰pˆêCŠ~–{ˆÐŽu: ƒEƒV•›t‘Ž¿×–E‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚ÉŠÖ—^‚·‚éƒjƒRƒ`ƒ“«ƒAƒZƒ`ƒ‹ƒRƒŠƒ“Žó—e‘̃Tƒuƒ^ƒCƒv‚̃ŠƒKƒ“ƒh‚É‚æ‚铯’èC‘æ122‰ñ”N‰ï–òŠw‰ï, 2002, 3, ç—t

24.     Koji T, Nishikawa Y, Doi M, Ogawa A, Sasaki K: Augmenting mechanism of slowly developing contractile response to the stimulation of thromboxane A2-receptor in the middle cerebral artery of bovine, ‘æ79‰ñ“ú–{¶—Šw‰ï, 2002, 3, L“‡

25.     Fujita R, Kimura S, Kawasaki S, Takashima K, Hirano H, Matsumoto M, Sasaki K: Mechanism of P2Y-receptor induced inhibition of K+-current responses to FSH and adenosine in the follicular cells of Xenopus oocyte, ‘æ79‰ñ“ú–{¶—Šw‰ï, 2002, 3, L“‡

26.     Takashima K, Kawasaki S, Kimura S, Fujita R, Sasaki K: Accute modulation of ionotropic receptor responses by progesterone and estradiol in the ganglion cells of Aplysia,  ‘æ79‰ñ“ú–{¶—Šw‰ï, 2002, 3, L“‡

27.     Kimura S, Kawasaki S, Fujita R, Sasaki K: Regulatory mechanism of K+-current response produced by AMPA-like receptor in the ganglion cells of Aplysia,  ‘æ25‰ñ“ú–{_Œo‰ÈŠw‘å‰ï, 2002,7, “Œ‹ž

28.     Kawasaki S, Kimura S, Fujita R, Sasaki K: Reversal of an inward current response induced by dopamine to an outward current response after the intracellular application og GTPgammaS in the ganglion cells of Aplysia,  ‘æ25‰ñ“ú–{_Œo‰ÈŠw‘å‰ï, 2002,7, “Œ‹ž

29.     Koji T, Nishikawa Y, Kawasaki S, Kimura S, Ogawa, Sasaki K: Regulatory role of PI3-kinase and Rho-kinase in the slowly developing contraction induced by stimulation of TXA2-receptor in the cerebral artery of bovine, ‘æ25‰ñ“ú–{_Œo‰ÈŠw‘å‰ï, 2002,7, “Œ‹ž

30.     Kawasaki S, Kimura S, Fujita R, Sasaki K: D1-receptor-induced response reverses from inward current to outward current after the injection of guanosinethiophosphate in the ganglion cells of Aplysia,  ‘æ80‰ñ“ú–{¶—Šw‰ï‘å‰ï, 2003, 3, •Ÿ‰ª

31.     Fujita R, Kimura S, Kawasaki S, Hirano H, Matsumoto M, Sasaki K: P2Y-receptor induced inhibition of K+-current resposes to FSH and adenosine in the follicular cells of Xenopus oocyte, ‘æ80‰ñ“ú–{¶—Šw‰ï‘å‰ï, 2003, 3, •Ÿ‰ª

32.     H“¡Œ«ŽOC—§ì‰pˆêC‹ß“¡‚ä‚«ŽqC…ŠÔŒªŽOCŠ~–{ˆÐŽu: ƒfƒqƒhƒƒGƒsƒAƒ“ƒhƒƒXƒeƒƒ“‚Æ‚»‚Ì—°Ž_‘Ì‚Ì•›t‘Ž¿×–E‚©‚ç‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚ɑ΂·‚é—}§Œø‰ÊC ‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ï, 2003, 3, •Ÿ‰ª

33.     …ŠÔŒªŽOC—§ì‰pˆêCH“¡Œ«ŽOC‹ß“¡‚ä‚«ŽqCŠ~–{ˆÐŽu: ‹ÇŠ–ƒŒ–ò‚ª‹•›t‘Ž¿×–E‚̃JƒeƒR[ƒ‹ƒAƒ~ƒ“•ª”å‚É‹y‚Ú‚·Œø‰ÊC‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ï, 2003, 3, •Ÿ‰ª

34.     —§ì‰pˆêCH“¡Œ«ŽOC’·’JìG•vCŠ~–{ˆÐŽuC‹{è‰ë—YC•½G°: –ò—pläóƒTƒ|ƒjƒ“‚ª’°“à׋ۂɂæ‚Á‚Ä‚½‚½‚©‚ꂽ‘ãŽÓ•¨‚̓jƒRƒ`ƒ“«ƒAƒZƒ`ƒ‹ƒRƒŠƒ“Žó—e‘Ì‚ðƒuƒƒbƒN‚·‚éC“ú–{–òŠw‰ï123”N‰ï, 2003, 3, ’·è

35.     H“¡Œ«ŽOC—§ì‰pˆêCŠ~–{ˆÐŽuCTu AT: ƒwƒriAgkistrodon contortrix contortrixj‚̓ʼnt‚©‚番—£‚µ‚½ƒqƒAƒ‹ƒƒjƒ_[ƒ[C“ú–{–òŠw‰ï123”N‰ï, 2003, 3, ’·è

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

1.         ŒF’JƒC²“¡Ž–¤CàVˆä‚ŽuCì–”•ü–›C²–씎‚C‘•ª³ˆê: äF”‘a•”‘¹‚Ì•a—‘gDŠŒ© \ ŠŠ–Œ‚¨‚æ‚ÑŠÖß•ï‚Ì‘B«‚ƉŠÇ«×–E‚Ì‹ÇÝ \C‘æ14‰ñ“ú–{®Œ`ŠO‰ÈŠî‘bŠwpW‰ï, 1999, 10, “Þ—Ç

2.         ŒF’JƒCì–”•ü–›C²–씎‚C²“¡Ž–¤CàVˆä‚Žu: Š®‘S’f—ô‚É‚¨‚¯‚éäF”Â’f’[‚Ì‘gD•ª—ÞC ‘æ26‰ñ“ú–{Œ¨ŠÖߊw‰ï, 1999, 11, ‘å‹{

3.         ²–씎‚CŒF’JƒCàVˆä‚Žu: Ž©‰Æ‘å‘Ú‹Ø–Œpatch–@‚É‚¨‚¯‚éäF‘gD‚¨‚æ‚ÑäFœ•t’…•”‚ÌÄŒ`¬‰ß’ö \ ŽÀŒ±“IŒ¤‹†C‘æ26‰ñ“ú–{Œ¨ŠÖߊw‰ï, 1999, 11, ‘å‹{

4.         ˆî“c·–çC‹v•Û‹^“Þ”üC²“¡¬‘åC‰““¡dŒú: ƒxƒ“Å‘fVTI‚̃qƒgD’†‹…‚Ö‚ÌŒ‹‡‚ÆŠˆ«‰»C ‘æ4‰ñ’°ŠÇoŒŒ«‘å’°‹ÛƒVƒ“ƒ|ƒWƒEƒ€, 1999, 6, ‘åã

5.         ˆî“c·–çC²“¡¬‘åC‰““¡dŒú: ƒxƒ“Å‘f‚É‚æ‚éƒqƒgD’†‹…‚ÌŠˆ«‰»FÚ’…•ªŽq”­Œ»‚¨‚æ‚уTƒCƒgƒJƒCƒ“ŽY¶‚Ì‘£iC‘æ72‰ñ“ú–{׋ۊw‰ï, 1999, 3, “Œ‹ž

6.         —é–Ø–ž, –k”©Œ°_, 쑺—@: ‘–¸Œ^“dŽqŒ°”÷‹¾‚É‚æ‚éƒOƒŠƒAŽ²õŠÔ‘ŠŒÝŠÖŒW‚ÌŠÏŽ@C‘æ4‰ñƒOƒŠƒAŒ¤‹†‰ï, 1999, 11, å‘ä

7.         ŽO‰YNGC•£Œ°CàVˆä‚Žu: ‰E‘¤“ª—t‚É”­¶‚µ‚½¬Ž™”]ŽîᇂÌ1—áC‘æ1‰ñ“ú–{•a—Šw‰ï“Œ–kŽx•”ŠwpW‰ïE‘æ35‰ñ“ú–{•a—ˆã‹¦‰ï“Œ–kVŠƒŽx•”ŒðŒ©‰ï, 1999, 2, å‘ä

8.         •£Œ°CàVˆä‚Žu: ”ñ’èŒ^“I‚ÈS‹ØÇ‚Ì2—áC‘æ1‰ñ“ú–{•a—Šw‰ï“Œ–kŽx•”ŠwpW‰ïE‘æ35‰ñ“ú–{•a—ˆã‹¦‰ï“Œ–kVŠƒŽx•”ŒðŒ©‰ï, 1999, 2, å‘ä

9.         ‹g“c_ŽqCˆÉ“¡°•ûC‹àŽqŽqCŽR“àL•½CΓc—z“ñC~Mˆê˜YCˆäã—m¼CÄ“¡—§‰ØCàVˆä‚Žu: œ‘ˆÙŒ`¬ÇŒóŒQ‚ɇ•¹‚µCNSIP‚ª‹^‚í‚ꂽŠÔŽ¿«”x‰Š‚Ì1—áC‘æ68‰ñ“ú–{ŒÄ‹zŠíŠw‰ï“Œ–k’n•û‰ïE‘æ98‰ñ“ú–{Œ‹Šj•aŠw‰ï“Œ–k’n•û‰ï, 1999, 2, H“c

10.     ‰FŒŽ”ü˜a: –«ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚éƒqƒAƒ‹ƒƒ“Ž_iHAj‚Ì“®‘Ô-ƒqƒAƒ‹ƒƒ“Ž_Œ‹‡’`”’(HABP)‚ð—p‚¢‚½ŒŸ“¢C‘æ1‰ñŠâŽè“¤‹†‰ï, 1999, 3, ·‰ª

11.     ‰FŒŽ”ü˜aCù–ìŒöLC‘º¼N¬CŒËŠ_˜alC‰«—²C‚‹´˜aLC”Ñ–ì˜a”üCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`ŠŠ–Œ‘gD‚ÆŠÖ߉t‚É‚¨‚¯‚é urocortin ‚¨‚æ‚Ñ CRF receptor‚Ì”­Œ»C‘æ88‰ñ“ú–{•a—Šw‰ï, 1999, 4, “Œ‹ž

12.     àN—§‰ØCŽR“àL•½C‹g“c_ŽqC’†¼“OC‘êì³tC‰FŒŽ”ü˜aCˆäã—m¼CàVˆä‚Žu: ”xüˆÛÇ‚É‚¨‚¯‚é connective tissue growth factoriCTGFj‚Ì”­Œ»C‘æ88‰ñ“ú–{•a—Šw‰ï, 1999, 4, “Œ‹ž

13.     àVˆä‚ŽuC‰FŒŽ”ü˜aC“n•Ó‚Ý‚©CŠâè^‹|C{ŽR‹ŽO: ’e«Œ^ƒGƒ‰ƒXƒ`ƒ“‚̉ˋ´ƒAƒ~ƒmŽ_‚̉ðÍ  \ ”x“®–¬‚Æ‘å“®–¬‚Ì”äŠr \C ‘æ88‰ñ“ú–{•a—Šw‰ï, 1999, 4, “Œ‹ž

14.     ¼–씎–¾C‰FŒŽ”ü˜aC—V“¹˜a—YC’†‘ò•s“ñ—YC“n•Ó‘×—TC•ÄŒ´LCàVˆä‚ŽuC–Ø‘º—FŒú: RA‚ÌŠÖߓj‰ó‚É‚¨‚¯‚éapoptosisC‘æ43‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 1999, 5, ŽD–y

15.     ‹g“c¹–¾CˆêŒË’啶C¼“c~C‹g“c—FŽjC“ˆ‘º³CàVˆä‚ŽuC•£Œ°C‰FŒŽ”ü˜aCˆÀ“¡‹MMC‰““¡N“ñ˜YC¬ŽR“cŠìŒh: A‚Ì•GŠÖß‹ß–T‚É‚Ý‚ç‚ê‚鋑圔XŽî‚Ì”­¶‹@˜‚ɂ‚¢‚Ä \ ‰æ‘œ‚¨‚æ‚Ñ•a—‘gDŠw“I‰ðÍ \C‘æ43‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 1999, 5, ŽD–y

16.     ‰FŒŽ”ü˜aCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`iRAjŠŠ–Œ‘gD‚ÆŠÖ߉t‚É‚¨‚¯‚éurocortin‚Ì”­Œ»C ‘æ43‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 1999, 5, ŽD–y

17.     òŽR•ü­C”©ŽR–¾CÖ“¡‹PMCàVˆä‚Žu: ‹ÃŒÅ˜´ió‘ԂƔ畆’×ᇂð’悵‚½ˆ««ŠÖ߃ŠƒEƒ}ƒ`‚Ì1Ç—áC‘æ43‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 1999, 5, ŽD–y

18.     àVˆä‚ŽuC“n•Ó‚Ý‚©C‰FŒŽ”ü˜aCŠâè^‹|C”~“c‰pKC{ŽR‹ŽO: HPLC‚É‚æ‚éƒqƒg‘匌ŠÇƒGƒ‰ƒXƒ`ƒ“‚̉ˋ´ƒAƒ~ƒmŽ_‚̉ðÍC‘æ31‰ñ“ú–{Œ‹‡‘gDŠw‰ï, 1999, 6, –¼ŒÃ‰®

19.     àN—§‰ØCŽR“àL•½C‰FŒŽ”ü˜aC‹g“c_ŽqC ’†¼“OC‘êì³tCˆäã—m¼CàVˆä‚Žu: ”xüˆÛÇ‚É‚¨‚¯‚éconnective tissue growth factor iCTGFj‚Ì”­Œ»C‘æ31‰ñ“ú–{Œ‹‡‘gDŠw‰ï, 1999, 6, –¼ŒÃ‰®

20.     ›Œ´–õ‘¥C“c“‡ˆç˜NCŒã“¡—S³C’¹‰H—LC‘ºãGŽ÷C“ˆ‘º³CàVˆä‚ŽuC…àV“TŽqC–x“àŽO˜Y: ƒEƒTƒMŠÖߓ|—{Œn‚É‚¨‚¯‚éƒqƒAƒ‹ƒƒ“Ž_ƒŒƒZƒvƒ^[ˆâ“`Žq”­Œ»‚É‹y‚Ú‚·IL-1ƒÀ‚̉e‹¿C ‘æ31‰ñ“ú–{Œ‹‡‘gDŠw‰ï, 1999, 6, –¼ŒÃ‰®

21.     ‰FŒŽ”ü˜aCù–ìŒöLC‘º¼N¬CŒËP˜alC‚‹´˜aLC‰«—²C”Ñ–ì˜a”üCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`ŠŠ–Œ‘gD‚ÆŠÖ߉t‚É‚¨‚¯‚éurocortin‚¨‚æ‚Ñ CRF receptor‚Ì”­Œ»C‘æ31‰ñ“ú–{Œ‹‡‘gDŠw‰ï, 1999, 6, –¼ŒÃ‰®

22.     •£Œ°CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‚Ì×–EŒv—ÊŠw“I‰ðÍC ‘æ9‰ñ“ú–{ƒTƒCƒgƒƒgƒŠ[Šw‰ï, 1999, 6, ŽD–y

23.     àVˆä‚ŽuC‰FŒŽ”ü˜aC¼–씎–¾: –«ŠÖ߃ŠƒEƒ}ƒ`iRAj‚Ì•a‘Ô‰ðÍ‚©‚玡—Â̌ø‰Ê”»’è‚ÉŽŠ‚é•a—‘gDŠw‚̉ž—p, ‘æ20‰ñ“ú–{‰ŠÇŠw‰ï, 1999, 7, å‘ä

24.     àN—§‰ØCŽR“àL•½C‰FŒŽ”ü˜aC’†¼“OC‘êì³tCˆäã—m¼CàVˆä‚ŽuF”xüˆÛÇ‚É‚¨‚¯‚éconnective tissue growth factoriCTGFj‚Ì”­Œ», ‘æ20‰ñ“ú–{‰ŠÇŠw‰ï, 1999, 7, å‘ä

25.     ‹g“c¹–¾CˆêŒË’啶C@‘œF‰ÀC“ˆ‘º³C‰FŒŽ”ü˜aC•£Œ°C‹g“c“nCàVˆä‚Žu: RA‚Ì‹‘圔XŽî‚É‚¨‚¯‚éMMP‚Æ‚»‚Ì‘jŠQy‘f‚Ì”­Œ»‚ɂ‚¢‚ÄC‘æ504‰ñŠâŽèˆãŠw‰ï—á‰ï, 1999, 8, ·‰ª

26.     •£Œ°CàVˆä‚Žu: AIDS‚Ì•a—FƒƒVƒAAIDSƒZƒ“ƒ^[‚̃GƒCƒY–UŒŸ—á‚ɂ‚¢‚ÄC‘æ505‰ñŠâŽèˆãŠw‰ï—á‰ï, 1999, 9, ·‰ª

27.     àN—§‰ØCŽR“àL•½C‰FŒŽ”ü˜aC ’†¼“OC‘êì³tCˆäã—m¼CàVˆä‚Žu: üˆÛ‰»”x‚É‚¨‚¯‚éconnective tissue growth factoriCTGFj‚Ì”­Œ»‚Æ‚»‚Ì‹ÇÝC ‘æ7‰ñ”xƒŠƒ‚ƒfƒŠƒ“ƒOŒ¤‹†‰ï, 1999, 10, “Œ‹ž

28.     •£Œ°C‹g“c¹–¾CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ”|—{×–E‚Ì‘B“®‘ԂƃAƒ|ƒg[ƒVƒX‚Ì—U“±C‘æ9‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 1999, 10, ŒSŽR

29.     ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC’†‘ò•s“ñ—YC•ÐŽR—ŒbC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`“gD‚É‚¨‚¯‚éƒAƒ|ƒg[ƒVƒXC‘æ9‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 1999, 10, ŒSŽR

30.     @‘œF‰ÀC‰FŒŽ”ü˜aC‹g“c¹–¾C‹g“c“nC“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚É‚¨‚¯‚éinterleukiniILj-18‚Ì“®‘Ô, ‘æ9‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 1999, 10, ŒSŽR

31.     ‹g“c¹–¾CˆêŒË’啶C@‘œF‰ÀC“ˆ‘º³C‰FŒŽ”ü˜aC•£Œ°C‹g“c“nCàVˆä‚ŽuCˆÀ“¡‹MMC‰““¡N“ñ˜Y: RA‚Ì‹‘圔XŽî‚É‚¨‚¯‚éMMP‚ÆTIMP mRNA‚Ì”­Œ»‚ɂ‚¢‚ÄC‘æ9‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 1999, 10, ŒSŽR

32.     “c‘º‘¥’jC‰FŒŽ”ü˜aC¼–{•s“ñ•vC—ÍŠÛöC‘•ª³ˆêCàVˆä‚Žu: ‹}‘¬”j‰óŒ^ŒÒŠÖßÇ‚ÌŠŠ–Œ‚É‚¨‚¯‚éplasminogen activatoriPAj‚Æ‚»‚Ìreceptor‚Ì”­Œ»‚Æœ”j‰ó‚ÌŠÖ˜AC ‘æ9‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 1999, 10, ŒSŽR

33.     ‹g“c“nC‰FŒŽ”ü˜aC•£Œ°C²“¡FC‹g“c¹–¾C¼“c~C“ˆ‘º³CàVˆä‚Žu: F‘f«ãO–ÑŒ‹ß«ŠŠ–Œ‰ŠiPVSj‚Ì×–EŠw“I“Á’¥C‘æ9‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 1999, 10, ŒSŽR

34.     àN—§‰ØCŽR“àL•½C‰FŒŽ”ü˜aC’†¼“OC‘êì³tCˆäã—m¼CàVˆä‚Žu: üˆÛ‰»”x‚É‚¨‚¯‚éconnective tissue growth factoriCTGFj ‚Ì”­Œ»‚Æ‚»‚Ì‹ÇÝC‘æ9‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 1999, 10, ŒSŽR

35.     —é–Ø—zŽqC”©ŽR–¾CòŽR•ü­C‰FŒŽ”ü˜aCàVˆä‚Žu: ‘½”­«’P_Œo‰Š‚ðŽåÇó‚Æ‚µ‚½ANCAŠÖ˜AŒŒŠÇ‰Š‚Ì1—áC‘æ9‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 1999, 10, ŒSŽR

36.     •£Œ°C‹g“c¹–¾C‹g“c“nCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ”|—{×–E‚Ì‘B“®‘ԂƃAƒ|ƒg[ƒVƒX‚Ì—U“±CŠâŽè–Ɖu§˜b‰ï, 1999, 11, ·‰ª

37.     ¼–씎–¾C—V“¹˜a—YC‰FŒŽ”ü˜aC•ÄŒ´LC‘å’ι•FC¼‰ª‹vŽõŽ÷CàVˆä‚Žu: V‹Kƒqƒg‰»RFasR‘Ì R-125224ih-HFE7Aj‚Ì–«ŠÖ߃ŠƒEƒ}ƒ`Ž¡—Öò‚Æ‚µ‚Ẳ”\«C‘æ29‰ñ“ú–{–ƉuŠw‰ï‘‰ïEŠwpW‰ï, 1999, 12, ‹ž“s

38.     @‘œF‰ÀC‰FŒŽ”ü˜aC‹g“c¹–¾C‹g“c“nC“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚É‚¨‚¯‚é InterleukiniILj-18‚Ì“®‘ÔC‘æ14‰ñ“ú–{—Õ°ƒŠƒEƒ}ƒ`Šw‰ï‘‰ï, 1999, 12, ‹ž“s

39.     ‰FŒŽ”ü˜aCù–ìŒöLCŒËP˜alC‘º¼N¬C‚‹´˜aLC‰«—²C”Ñ–ì˜a”üCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`iRAjŠŠ–Œ‘gD‚ÆŠÖ߉t‚É‚¨‚¯‚éurocortin‚Æ CRF receptor‚Ì”­Œ»C ‘æ14‰ñ“ú–{—Õ°ƒŠƒEƒ}ƒ`Šw‰ï‘‰ï, 1999, 12, ‹ž“s

40.     àVˆä‚Žu: ƒqƒg”x“®–¬CƒGƒ‰ƒXƒ`ƒ“‰Ë‹´ƒAƒ~ƒmŽ_—ʂ̉Á—‚æ‚Ñ•a“Ió‘Ô‚É”º‚¤•Ï‰»CThe Meeting for Elastin Research  1999, 1999, 12, “Œ‹ž

41.     ‹v•ÛŒc‚C—é–Ø—Ï•ÛCH“¡–¾C‹g“cŒ¤“ñC›Œ´~C¬ì²: ƒ‰ƒbƒg”]‘¹‚É‚¨‚¯‚鉊ǫזE‚ɑ΂·‚éRthrombinÜ‚ÌŒø‰ÊC‘æ58‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ï‘‰ï, 1999, 10, “Œ‹ž

42.     ˆî“c·–çC‰““¡dŒú: ƒqƒg‚ÌŽ¾Š³‚ƃGƒ“ƒhƒgƒLƒVƒ“ \ Å‹ß12”NŠÔ‚̬т©‚ç \C ‘æ46‰ñ“Å‘fƒVƒ“ƒ|ƒWƒEƒ€, 1999,7, ·‰ª

43.     ’†‘ºáÁˆêCàVˆä‚Žu: ‰“Šu•a—f’f‚É]Ž–‚·‚é•a—ˆã‚̃Aƒ“ƒP[ƒg’²¸ \ ˜J“­‰ßd‚ɂ‚¢‚ÄC‘æ88‰ñ“ú–{•a—Šw‰ï, 1999, 4, “Œ‹ž

44.     ›Œ´~C—é–Ø—Ï•ÛC‹v•ÛŒc‚C‹g“cŒ¤“ñCH“¡–¾C¬ì²CàVˆä‚Žu: Rƒgƒƒ“ƒrƒ“ÜiƒAƒ‹ƒKƒgƒƒoƒ“j‚̃‰ƒbƒg‚Ì‘¹”]‚É—^‚¦‚é‰e‹¿‚ɂ‚¢‚Ä \ Ú’…•ªŽqiIntercellular Adhesion Molecule iICAMj-1j‚Ì”­Œ»‚ƉŠÇ«×–E”‚Ì‘gDŠw“I•]‰¿ \C‘æ21‰ñ“ú–{‰ŠÇŠw‰ï, 2000,7, “Œ‹ž

45.     ŽO‰YNGC•£Œ°CàVˆä‚ŽuC•Ê•{‚–¾: Dysembryoplastic neuroeptitherial tumoriDNTj‚Ì1—áC‘æ3‰ñ“ú–{•a—Šw‰ï“Œ–kŽx•”ŠwpW‰ïE‘æ37‰ñ“ú–{•a—ˆã‹¦‰ï“Œ–kVŠƒŽx•”ŒðŒ©‰ï, 2000, 2, å‘ä

46.     •£Œ°C›Œ´~CàVˆä‚Žu: “ªŒz•”ŽîᇂÌ1—áC‘æ4‰ñ“ú–{•a—Šw‰ï“Œ–kŽx•”ŠwpW‰ï, 2000,7, O‘O

47.     ›Œ´~C—é–Ø—Ï•ÛC‹v•ÛŒc‚C‹g“cŒ¤“ñC¬ì²CàVˆä‚Žu: Š£‘‡”ZklRƒgƒƒ“ƒrƒ“III»ÜŽ‘±“I• o“à“Š—^‚É‚æ‚é”]‘¹‚ɑ΂·‚鎡—ÃŒø‰Ê \ ”]‘¹ƒ‚ƒfƒ‹‚É‚æ‚é‘gDŠw“I‰ðÍ \C ‘æ59‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ï‘‰ï, 2000, 10, “Œ‹ž

48.     àN—§‰ØCàVˆä‚ŽuCˆÉ“¡°•û: ”x‚É‘½”­«‹CŽî‚Ì‚Ý‚ç‚ꂽ1—áC ‘æ3‰ñ“ú–{•a—Šw‰ï“Œ–kŽx•”ŠwpW‰ïE‘æ37‰ñ“ú–{•a—ˆã‹¦‰ï“Œ–kVŠƒŽx•”ŒðŒ©‰ï, 2000, 2, å‘ä

49.     •£Œ°CàVˆä‚Žu: ƒŒƒU[ƒXƒLƒƒƒjƒ“ƒOƒTƒCƒgƒƒgƒŠ[ \ Œ`‘ÔŠÏŽ@‚ð‰Â”\‚É‚µ‚½ƒTƒCƒgƒƒgƒŠ[C‘æ510‰ñŠâŽèˆãŠw‰ï—á‰ï, 2000, 3, ·‰ª

50.     ‰FŒŽ”ü˜aC“n•Ó’mKCŒj‘דTCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`ŠŠ–Œ‘gD‚É‚¨‚¯‚éƒqƒAƒ‹ƒƒ“Ž_‡¬y‘f \ ‰æ‘œ‰ðÍ‘•’u‚ð—p‚¢‚½y‘fŠˆ«‚Ì’è—ʉ» \C‘æ510‰ñŠâŽèˆãŠw‰ï—á‰ï, 2000, 3, ·‰ª

51.     “c‘º‘¥’jC‰FŒŽ”ü˜aC¼–{•s“ñ•vC—ÍŠÛöC‘•ª³ˆêCàVˆä‚Žu: ‹}‘¬”j‰óŒ^ŒÒŠÖßÇiRDCj‚ÌŠŠ–Œ‘gD‚É‚¨‚¯‚éurokinaseiURasej‚¨‚æ‚Ñurokinase-receptoriUR/Rcj‚Ì”­Œ»‚Æœ”j‰ó‚ÌŠÖ˜AC‘æ2‰ñŠâŽè“¤‹†‰ï, 2000, 3, ·‰ª

52.     àVˆä‚ŽuC‰FŒŽ”ü˜aC“n•Ó‚Ý‚©CŠâè^‹|C{ŽR‹ŽO: ”x“®–¬ƒGƒ‰ƒXƒ`ƒ“‚̉ˋ´ƒAƒ~ƒmŽ_‚̉ðÍi2j \ ”x“®–¬‚̉Á—‚æ‚Ñ”x‚ŒŒˆ³Ç‚É‚¨‚¯‚é•Ï‰» \C‘æ89‰ñ“ú–{•a—Šw‰ï‘‰ï, 2000, 4, ‘åã

53.     •£Œ°C‹g“c“nC‹g“c¹–¾CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ”|—{×–E‚Ìpaclitaxel‚É‚æ‚é×–E“®‘ԂƃAƒ|ƒg[ƒVƒX‚Ì—U“±C ‘æ89‰ñ“ú–{•a—Šw‰ï‘‰ï, 2000, 4, ‘åã

54.     ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC’†‘ò•s“ñ—YC•ÐŽR—ŒbC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`“îœ×–E‚É‚¨‚¯‚éƒAƒ|ƒg[ƒVƒX‚Æ’`”’•ª‰ðy‘fC‘æ89‰ñ“ú–{•a—Šw‰ï‘‰ï, 2000, 4, ‘åã

55.     ‹g“c“nC‰FŒŽ”ü˜aC•£Œ°C²“¡FC@‘œF‰ÀC‹g“c¹–¾C¼“c~C“ˆ‘º³CàVˆä‚Žu: F‘f«ãO–ÑŒ‹ß«ŠŠ–Œ‰ŠiPVSj‚Ì×–EŠw“I“Á’¥C‘æ89‰ñ“ú–{•a—Šw‰ï‘‰ï, 2000, 4, ‘åã

56.     –ì“c—TC“¡“c’¼FC¬—Ñ„C–Ø‘ºŽ–¤CˆÉ“¡Œ[C¼‰iŒú¶CŒ‹é–L•FCàVˆä‚ŽuC‰FŒŽ”ü˜aC“n•Ó‚Ý‚©: äX’_ŠÇ‡—¬ˆÙí‚É‚¨‚¯‚é’_”X‚¨‚æ‚Ñ’_ŠÇ‚Ì•a—‘gDŠw“IŒŸ“¢C ‘æ89‰ñ“ú–{•a—Šw‰ï‘‰ï, 2000, 4, ‘åã

57.     ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC’†‘ò•s“ñ—YC•ÐŽR—ŒbC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`“gD‚É‚¨‚¯‚éƒAƒ|ƒg[ƒVƒX‚Æ’`”’•ª‰ðy‘fC‘æ44‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïEŠwpW‰ï, 2000, 5, ‰¡•l

58.     “c‘º‘¥’jC‰FŒŽ”ü˜aC¼–{•s“ñ•vC—ÍŠÛöC‘•ª³ˆêCàVˆä‚Žu: ‹}‘¬”j‰óŒ^ŒÒŠÖßÇ‚ÌŠŠ–Œ‚É‚¨‚¯‚éurokinase‚¨‚æ‚Ñ‚»‚Ìreceptor‚Ì”­Œ»‚Æœ”j‰ó‚ÌŠÖ˜AC‘æ44‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïEŠwpW‰ï, 2000, 5, ‰¡•l

59.     ‹g“c¹–¾CˆêŒË’啶C@‘œF‰ÀC“ˆ‘º³C‰FŒŽ”ü˜aC•£Œ°CàVˆä‚ŽuC‰““¡N“ñ˜YCˆÀ“¡‹MMC¬ŽR“cŠìŒh: RA‚Ì‹‘圔XŽî‚É‚¨‚¯‚éMMP-2‚ÆMMP-9 mRNA‚Ì”­Œ»C‘æ44‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïEŠwpW‰ï, 2000, 5, ‰¡•l

60.     @‘œF‰ÀC‰FŒŽ”ü˜aC‹g“c¹–¾C‹g“c“nC“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚É‚¨‚¯‚éInterleukiniILj-18‚Ì“®‘ÔC‘æ44‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïEŠwpW‰ï, 2000, 5, ‰¡•l

61.     •£Œ°C‹g“c¹–¾C‹g“c“nCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ”|—{×–E‚ÌRƒKƒ“Ü‚É‚æ‚é‘B“®‘ԂƃAƒ|ƒg[ƒVƒX‚Ì—U“±C ‘æ44‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïEŠwpW‰ï, 2000, 5, ‰¡•l

62.     ‹g“c“nC‰FŒŽ”ü˜aC•£Œ°C²“¡FC@‘œF‰ÀC‹g“c¹–¾C¼“c~C“ˆ‘º³CàVˆä‚Žu: F‘f«ãO–ÑŒ‹ß«ŠŠ–Œ‰ŠiPVSj‚Ì×–EŠw“I“Á’¥C‘æ44‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïEŠwpW‰ï, 2000, 5, ‰¡•l

63.     ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC’†‘ò•s“ñ—YC•ÐŽR—ŒbC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`“îœ×–E‚É‚¨‚¯‚éƒAƒ|ƒg[ƒVƒX‚Æ’`”’•ª‰ðy‘fC‘æ32‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ï, 2000, 5, “Œ‹ž

64.     àVˆä‚ŽuC‰FŒŽ”ü˜aCŠâè^‹|C“n•Ó’mKCŒj‘דTC{ŽR‹ŽO: ƒqƒg”x“®–¬ƒGƒ‰ƒXƒ`ƒ“‚̉ˋ´ƒAƒ~ƒmŽ_‚ÌHPLC‚É‚æ‚é‰ð͂Ɖ摜‰ðÍ‘•’u‚ð—p‚¢‚½’e«üˆÛ‚Ì”äŠrC‘æ32‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ï, 2000, 5, “Œ‹ž

65.     @‘œF‰ÀC‰FŒŽ”ü˜aC‹g“c¹–¾C‹g“c“nC“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚É‚¨‚¯‚éInterleukiniILj -18 ‚Ì“®‘ÔC‘æ21‰ñ“ú–{‰ŠÇŠw‰ï, 2000,7, “Œ‹ž

66.     àN—§‰ØCŽR“àL•½C‰FŒŽ”ü˜aC’†¼“OC‘êì³tCˆäã—m¼CàVˆä‚Žu: ”xüˆÛÇ‚É‚¨‚¯‚éconnective tissue growth factor iCTGFj‚Ì”­Œ»C‘æ71‰ñ“ú–{ŒÄ‹zŠíŠw‰ï“Œ–k’n•û‰ïE‘æ101‰ñ“ú–{Œ‹Šj•aŠw‰ï“Œ–k’n•û‰ï, 2000, 9, å‘ä

67.     àN—§‰ØCàVˆä‚ŽuCˆÉ“¡°•ûCŽR“àL•½Cˆäã—m¼: ”x‚É‘½”­«‹CŽî‚Ì‚Ý‚ç‚ꂽ1—áC ‘æ71‰ñ“ú–{ŒÄ‹zŠíŠw‰ï“Œ–k’n•û‰ïE‘æ101‰ñ“ú–{Œ‹Šj•aŠw‰ï“Œ–k’n•û‰ï, 2000, 9, å‘ä

68.     ‹g“c“nC‰FŒŽ”ü˜aC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚éƒ}ƒgƒŠƒbƒNƒXƒƒ^ƒƒvƒƒeƒA[ƒ[‚Ì”­Œ»‚ɂ‚¢‚Ä, ‘æ10‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2000, 10, ·‰ª

69.     ‹g“c¹–¾C‰FŒŽ”ü˜aC‹g“c“nC•£Œ°C@‘œF‰ÀCàVˆä‚ŽuCˆÀ“¡‹MMC‰““¡N“ñ˜YC¬ŽR–¾ŽqCˆêŒË’啶C“ˆ‘º³: ƒ€ƒ`ƒ‰ƒ“ƒXŒ^ŠÖ߉Š‚É‚¨‚¯‚éMMP-2‚ÆMMP-9 mRNA‚Ì”­Œ»C‘æ10‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2000, 10, ·‰ª

70.     ¬ŽR–¾ŽqC‹g“c¹–¾CˆÀ“¡‹MMC“c“‡Ž–¤C‰““¡N“ñ˜YC@‘œF‰ÀC‹g“c“nC“ˆ‘º³: –«ŠÖ߃ŠƒEƒ}ƒ`‚ɑ΂·‚é•IŠÖߊŠ–ŒØœp‚ÌpŒã¬Ñ‚ɂ‚¢‚ÄC‘æ10‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2000, 10, ·‰ª

71.     •£Œ°CàVˆä‚Žu: MCTDŠ³ŽÒŒŒ´‚Ì”|—{ŒŒŠÇ“à”ç×–E‚ւ̉e‹¿C ‘æ10‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2000, 10, ·‰ª

72.     ŽO‰YNGC•£Œ°CŽÄ“c—S“ñCàVˆä‚ŽuC²“¡—F—º: œ‘ˆÙŒ`¬ÇŒóŒQiMDSj‚ÌŒo‰ß’†‚É–«EBƒEƒCƒ‹ƒXŠ´õ‚É‚Ä”­Ç‚µŽíX‚ÌŽ©ŒÈR‘Ì‚Ì㸋y‚Ñ”x–Eã”ç‚ٌ̈^‚ðŽ¦‚µ‚½ŒŒ‹…æÃHÇŒóŒQiVAHSj‚Ì1Ç—áC‘æ10‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2000, 10, ·‰ª

73.     àVˆä‚ŽuC‰FŒŽ”ü˜aCŠâè^‹|: ”x“®–¬•ÇC\¬¬•ª‚̉Á—î‚É”º‚¤•Ï‰»C‘æ517‰ñŠâŽèˆãŠw‰ï—á‰ï, 2000, 12, ·‰ª

74.     ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC’†‘ò•s“ñ—YC•ÐŽR—ŒbC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`“îœ×–E‚É‚¨‚¯‚éƒAƒ|ƒg[ƒVƒX‚Æ’`”’•ª‰ðy‘fC‘æ15‰ñ“ú–{—Õ°ƒŠƒEƒ}ƒ`Šw‰ï‘‰ï, 2000, 12, •Ê•{

75.     àVˆä‚ŽuC‰FŒŽ”ü˜aCŠâè^‹|: ƒqƒg”x“®–¬•ÇC\¬¬•ª‚̉Á—î•Ï‰»CThe Meeting for Elastin Research 2000, 2000, 12, “Œ‹ž

76.     àVˆä‚ŽuCˆ°Œ´ŽiCˆä“¡‹v—YCˆÉ“¡‰ë•¶C“y‹´N¬C’†‘ºáÁˆêC’†•õŠ°˜aC–ì’Ã’·CŒüˆä´C“n•Ó‚Ý‚©: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚É‚¨‚¯‚év‘¬f’fŽÀ—p‰»‚Ì–â‘è“_, ‘æ89‰ñ“ú–{•a—Šw‰ï‘‰ï, 2000, 4, ‘åã

77.     ›Œ´~C—é–Ø—Ï•ÛC‹v•ÛŒc‚C‹g“cŒ¤“ñC¬ì²CàVˆä‚Žu: Š£‘‡”ZklRƒgƒƒ“ƒrƒ“III»ÜŽ‘±“I• o“à“Š—^‚É‚æ‚é”]‘¹‚ɑ΂·‚鎡—ÃŒø‰Ê \ ”]‘¹ƒ‚ƒfƒ‹‚É‚æ‚é‘gDŠw“I‰ðÍ \C ‘æ24‰ñ“ú–{_ŒoŠOŠw‰ï, 2001, 3, ì

78.     àN—§‰ØC•Ê•{‚–¾C•£Œ°C›Œ´~C—é–Ø—Ï•ÛC¬ì²CàVˆä‚Žu: Glioma‚É‚¨‚¯‚éconnective tissue growth factoriCTGFj‚Ì–ðŠ„C‘æ520‰ñŠâŽèˆãŠw‰ï—á‰ï, 2001, 3, ·‰ª

79.     ŽO‰YNGC•£Œ°CŽÄ“c—S“ñCàVˆä‚ŽuC‰ª“cMˆê˜Y: ”x‚É”­¶‚µ‚½d‰»«ŒŒŠÇŽî‚Ì1Ç—áC‘æ518‰ñŠâŽèˆãŠw‰ï—á‰ï, 2001, 1, ·‰ª

80.     ŽO‰YNGC•£Œ°CàVˆä‚ŽuC‰ª“cMˆê˜Y: ‰E”x’†—t‚É”­¶‚µ‚½d‰»«ŒŒŠÇŽî‚Ì1—áC‘æ52‰ñ“ú–{•a—Šw‰ï“Œ–kŽx•”ŠwpW‰ï, 2001, 2, å‘ä

81.     ¬’r—mˆêC‰FŒŽ”ü˜aC”ª”¦‡ˆê˜YC‘•ª³ˆêCàVˆä‚Žu: ’ŊԔƒwƒ‹ƒjƒA‚Ì•a— \ ‰ŠÇ×–EZ‚Ɠ‚Ì•Ï« \C‘æ3‰ñŠâŽè“¤‹†‰ï, 2001, 2, ·‰ª

82.     •£Œ°C²X–ØMlCàVˆä‚Žu: ¬‡«Œ‹‡‘gD•aŠ³ŽÒŒŒ´‚Ì”|—{ŒŒŠÇ“à”ç×–E“®‘Ԃւ̉e‹¿, ‘æ520‰ñŠâŽèˆãŠw‰ï—á‰ï, 2001, 3, ·‰ª

83.     ŽO‰YNGC•£Œ°CŽÄ“c—S“ñCàVˆä‚ŽuC²“¡—F—ºCˆäã—m¼: œ‘ˆÙŒ`¬ÇŒóŒQiMDSjŒo‰ß’†‚É–«EBƒEƒCƒ‹ƒXŠ´õ‚É‚Ä”­Ç‚µCŽíX‚ÌŽ©ŒÈR‘Ì‚Ìã¸‚ðŽ¦‚µ‚½ŒŒ‹…æÃHÇŒóŒQiVAHSj‚Ì1Ç—áC ‘æ520‰ñŠâŽèˆãŠw‰ï—á‰ï, 2001, 3, ·‰ª

84.     ŽO‰YNGC•£Œ°CŽÄ“c—S“ñCàVˆä‚ŽuC‰ª“cMˆê˜Y: ‰E”x’†—t‚É”­¶‚µ‚½d‰»«ŒŒŠÇŽî‚Ì1Ç—áC‘æ78‰ñŠâŽè”xŽ¾Š³Œ¤‹†‰ï, 2001, 3, ·‰ª

85.     Šâè^‹|C‰FŒŽ”ü˜aCàVˆä‚Žu: ”x“®–¬•ÇC‰Á—î•Ï‰»‚Ì‘gDŒv‘ª‚ð—p‚¢‚½ŒŸ“¢C‘æ90‰ñ“ú–{•a—Šw‰ï‘‰ï, 2001, 4, “Œ‹ž

86.     ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC’†àV•s“ñ—YC•ÐŽR—ŒbC‘å’ι•FC¬ìKŒbC’†ŽR~ˆêC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ‘gD‚ÌSCIDƒ}ƒEƒX‚ւ̈ÚAŒã‚Ì•a—‘œ‚ɂ‚¢‚ÄC‘æ90‰ñ“ú–{•a—Šw‰ï‘‰ï, 2001, 4, “Œ‹ž

87.     ‹g“c“nC‰FŒŽ”ü˜aC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚éƒ}ƒgƒŠƒbƒNƒXƒƒ^ƒƒvƒƒeƒA[ƒ[‚Ì”­Œ»‚ɂ‚¢‚ÄC ‘æ90‰ñ“ú–{•a—Šw‰ï‘‰ï, 2001, 4, “Œ‹ž

88.     ŽO‰YNGC•£Œ°C²“¡—F—ºCàVˆä‚Žu: œ‘ˆÙŒ`¬ÇŒóŒQ‚ÌŒo‰ß’†‚ÉŽíX‚ÌŽ©ŒÈR‘Ì‚Ìã¸‚ðŽ¦‚µ‚½ŒŒ‹…æÃHÇŒóŒQ‚Ì1Ç—áC ‘æ90‰ñ“ú–{•a—Šw‰ï‘‰ï, 2001, 4, “Œ‹ž

89.     ¬—Ñ‹MŽ÷C›Œ´ŠxŽjCŒã“¡Žõ—TC“càV–LC‰FŒŽ”ü˜aCàVˆä‚Žu: “œ”A•aŠá‚É‚¨‚¯‚éŠá“àƒTƒCƒgƒJƒCƒ“”Z“x‚̕ω»‚ɂ‚¢‚Ä‚ÌŒŸ“¢C‘æ521‰ñŠâŽèˆãŠw‰ï—á‰ï, 2001, 4, ·‰ª

90.     ‹g“c“nC‰FŒŽ”ü˜aC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚éƒ}ƒgƒŠƒbƒNƒXƒƒ^ƒƒvƒƒeƒA[ƒ[‚Ì”­Œ»‚ɂ‚¢‚ÄC‘æ45‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2001, 5, “Œ‹ž

91.     ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC’†àV•s“ñ—YC•ÐŽR—ŒbC‘å’ι•FC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ‘gD‚ÌSCIDƒ}ƒEƒX‚ւ̈ÚAŒã‚Ì•a—‘œ‚ɂ‚¢‚ÄC‘æ45‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2001, 5, “Œ‹ž

92.     •£Œ°C²X–ØMlCàVˆä‚Žu: MCTDŠ³ŽÒŒŒ´‚Ì”|—{ŒŒŠÇ“à”ç×–E“®‘Ԃւ̉e‹¿C ‘æ45‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2001, 5, “Œ‹ž

93.     “c‘º‘¥’jC‰FŒŽ”ü˜aC¼–{•s“ñ•vC—ÍŠÛöC‘•ª³ˆêCàVˆä‚Žu: ‹}‘¬”j‰óŒ^ŒÒŠÖßÇ‚Ì‘å‘Úœ“ª‚É‚¨‚¯‚éurokinase‚¨‚æ‚Ñurokinase-receptor‚Ì”­Œ»‚Æœ”j‰ó‚ÌŠÖ˜AC‘æ45‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2001, 5, “Œ‹ž

94.     ‹g“c¹–¾C‰FŒŽ”ü˜aC‹g“c“nC•£Œ°CˆêŒË’啶CàVˆä‚ŽuC“ˆ‘º³: ƒ€ƒ`ƒ‰ƒ“ƒXŒ^ŠÖ߉Š‚Ìœ—n‰ð•”‚É‚¨‚¯‚éMMP-9 mRNA‚Ì”­Œ»‚ɂ‚¢‚ÄC‘æ45‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2001, 5, “Œ‹ž

95.     ¬’r—mˆêC‰FŒŽ”ü˜aCàVˆä‚Žu: ’ŊԔƒwƒ‹ƒjƒA“à‚̓•Ï«‚Æ“îœ×–E‚Ì‘BCŒ¸­C‘æ45‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2001, 5, “Œ‹ž

96.     —é–Ø—zŽqC”©ŽR–¾CòŽR•ü­CM“ciŒáC‰FŒŽ”ü˜aCàVˆä‚Žu: ƒŠƒEƒ}ƒ`«‘½”­‹Ø’ÉÇ‚Ì—Õ°‘œ‚ð’悵‹Ø‰Š‚Ì•a—ŠŒ©‚ð”F‚ß‚½3Ç—áC‘æ45‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2001, 5, “Œ‹ž

97.     àVˆä‚ŽuC‰FŒŽ”ü˜aCŠâè^‹|: ‰æ‘œ‰ðÍ‘•’u‚ð—p‚¢‚½”x“®–¬•Ç‚̉Á—î•Ï‰»‚̉ðÍC‘æ33‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ï, 2001, 6, “Œ‹ž

98.     ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC’†àV•s“ñ—YC•ÐŽR—ŒbC‘å’ι•FC¬ìKŒbC•½“c–œç‘ãC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ‘gD‚ÌSCIDƒ}ƒEƒX‚ւ̈ÚAŒã‚Ì•a—‘gD‘œ‚ɂ‚¢‚ÄC‘æ33‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ï, 2001, 6, “Œ‹ž

99.     ‹g“c“nC‰FŒŽ”ü˜aCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚éƒ}ƒgƒŠƒbƒNƒXƒƒ^ƒƒvƒƒeƒA[ƒ[‚Ì”­Œ»‚¨‚æ‚Ñ’`”’•ª‰ð”\‚ɂ‚¢‚ÄC‘æ33‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ï, 2001, 5, “Œ‹ž

100.  ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC’†àV•s“ñ—YC•ÐŽR—ŒbC‘å’ι•FC¬ìKŒbC•½“c–œç‘ãC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ‘gD‚ÌSCIDƒ}ƒEƒX‚ւ̈ÚAŒã‚Ì•a—‘gD‘œ‚ɂ‚¢‚ÄC‘æ22‰ñ“ú–{‰ŠÇEĶˆãŠw‰ï, 2001,7, “Œ‹ž

101.  ˆÉ“¡’C‰FŒŽ”ü˜aC‹g“c“nC“ˆ‘º³C²“¡¬‘åCàVˆä‚Žu: «ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŒŒ´CŠÖ߉t’†‚ÌMMPsiMMP-1, -9, -13j‚Ì”Z“x‚ÆŠˆ«Œ^‚Æ‚ÌŠÖŒWC‘æ22‰ñ“ú–{‰ŠÇEĶˆãŠw‰ï, 2001,7, “Œ‹ž

102.  —é–Ø–žC–k”©Œ°_C쑺—@CˆÀ“cdCŠÔ“¡ŒõˆêC‰œŽR—YC‘¾“c‘CŽðˆä–¾•vC¬ì“o‹IŽqC¬Œ´ƒPƒCŽqC²X–Ø—R‰ÀC²X–ØŽ–ç: _ŒoŒn×–E‚̉‘ã”|—{‚ƖƉu‘gD‰»ŠwõF‚É‚æ‚éƒOƒŠƒA×–E‚Ì“¯’èC‘æ522‰ñŠâŽèˆãŠw‰ï, 2001, 5, ·‰ª

103.  ŽO‰YNGC•£Œ°CŽÄ“c—S“ñCàVˆä‚ŽuC‰ª“cMˆê˜Y: ‰E”x’†—t‚É”­¶‚µ‚½d‰»«ŒŒŠÇŽî‚Ì‚PÇ—áC‘æ78‰ñŠâŽè”xŽ¾Š³Œ¤‹†‰ï, 2001, 3, ·‰ª

104.  ‰FŒŽ”ü˜aC“n•Ó’mKCŒj‘דTCàVˆä‚Žu: ƒeƒŒƒpƒ\ƒƒW[ŽóM‰æ‘œ‚Å‚¨‚±‚È‚Á‚½‰æ‘œ‰ðÍiIPAP‚ð—p‚¢‚½’è—Ê“IŒŸõjC‘æ90‰ñ“ú–{•a—Šw‰ï‘‰ï, 2001, 4, “Œ‹ž

105.  ŽO‰YNG: ‰EãŠ{“´‚É”­¶‚µ‚½Inverted papillioma‚Ì1—áC‘æ53‰ñ“ú–{•a—Šw‰ï“Œ–kŽx•”ŠwpW‰ï, 2001, 7, •Ÿ“‡

106.  Ä“¡‰_–QC–Ñ—˜FC’J“¡K•vC¬—ÑmCŽR“àL•½Cˆäã—m¼C“ì‰_•üŽ÷C’J“c’B’jCàN—§‰ØCàVˆä‚Žu: —¼ã—t‘½”­«”x”X–E‚Æ‹C‹¹‚ð‚«‚½‚µ‚½ƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—áC‘æ73‰ñ“ú–{ŒÄ‹zŠíŠw‰ï“Œ–k’n•û‰ï/‘æ103‰ñ“ú–{Œ‹Šj•aŠw‰ï“Œ–k’n•û‰ï, 2001, 9, ÂX

107.  ²X–ØMlC•£Œ°CÎXÍ‘¾˜YC‰ª“cMˆê˜YC²“¡³rC²“¡¸ˆêCàVˆä‚Žu: ”µ‚É‚æ‚é‰ß•q«”x‘Ÿ‰Š‚Ì1—áC‘æ3‰ñ“Œ–k‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï, 2001, 9, åŽs

108.  Ä“¡‰_–QC–Ñ—˜FC’J“¡K•vC¬—ÑmCŽR“àL•½Cˆäã—m¼CàN—§‰ØCàVˆä‚Žu: —¼ã—t‘½”­«”x”X–E‚Æ‹C‹¹‚ð‚«‚½‚µ‚½ƒTƒ‹ƒRƒCƒh[ƒVƒX‚ÆŽv‚í‚ê‚é1—áC‘æ3‰ñ“Œ–k‚Ñ‚Ü‚ñ«”xŽ¾Š³Œ¤‹†‰ï, 2001, 9, å‘ä

109.  ˆÉ“¡‹gŒ«CàVˆä‚Žu: ŠŠ–Œ‚É‚¨‚¯‚éCTGFiconnective tissue growth factorj‚Ì”­Œ» \ –«ŠÖ߃ŠƒEƒ}ƒ`‚Æ•ÏŒ`«•GŠÖßÇ‚Æ‚Ì”äŠrEŒŸ“¢ \C‘æ525‰ñŠâŽèˆãŠw‰ï—á‰ï, 2001, 9, ·‰ª

110.  ˆÉ“¡’C‰FŒŽ”ü˜aC“ˆ‘º³C²“¡¬‘åCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`ŒŒ´CŠÖ߉t’†‚ÌMMP-1, -9, -13‚Ì”Z“x‚ÆŠˆ«Œ^‚Æ‚ÌŠÖŒWC‘æ525‰ñŠâŽèˆãŠw‰ï—á‰ï, 2001, 9, ·‰ª

111.  ‘å“à’¼‹vC‰FŒŽ”ü˜aCàVˆä‚Žu: Ä”­«‘½”­“Š‚Ì•a—‘gDŠw“IŒŸ“¢ \ “j‰ó‚ÉŠÖ—^‚·‚é’`”’•ª‰ðy‘fŒQ‚ƃAƒ|ƒg[ƒVƒX‚Ì”­Œ» \C‘æ525‰ñŠâŽèˆãŠw‰ï—á‰ï, 2001, 9, ·‰ª

112.  ˆÉ“¡’C‰FŒŽ”ü˜aC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`ŒŒ´CŠÖ߉t’†‚ÌMMP-1C  -9C-13‚Ì”Z“x‚ÆŠˆ«C‘æ11‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2001, 10, ŽRŒ`

113.  ‹g“c“nC‰FŒŽ”ü˜aC•£Œ°CˆÉ“¡’C‘å“à’¼‹vC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: ‰æ‘œ‰ðÍ‘•’u‚É‚æ‚é–«ŠÖ߃ŠƒEƒ}ƒ`‚Ì’`”’•ª‰ð”\‚ÌŒŸ“¢C‘æ11‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2001, 10, ŽRŒ`

114.  ‹g“c¹–¾C‰FŒŽ”ü˜aC‹g“c“nC‘å“à’¼‹vCˆÉ“¡’CàVˆä‚ŽuC¬ŽR–¾ŽqCˆêŒË’啶C“ˆ‘º³: RA‚Ìœ”j‰ó•”‚É‚¨‚¯‚éRANKL mRNA‚Ì”­Œ»C‘æ11‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2001, 10, ŽRŒ`

115.  ˆÉ“¡‹gŒ«C‰FŒŽ”ü˜aC•£Œ°C’Ò”ü’qŽqC“¡ˆäŽ”VCàVˆä‚Žu: ŠŠ–Œ‚É‚¨‚¯‚錋‡‘gD¬’·ˆöŽqiCTGFj‚Ì”­Œ»C‘æ11‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2001, 10, ŽRŒ`

116.  ŠLŽRC‰FŒŽ”ü˜aC‘O“c˜aÍCŽODÆŽOC“ˆ‘º³CàVˆä‚Žu: •ÏŒ`«ŠÖßÇiOAjŠ³ŽÒŠÖ߉t’†‚̃qƒAƒ‹ƒƒ“Ž_iHAj‚Ì•ªŽq—Ê‚Æ”Z“x‚ɂ‚¢‚ÄC‘æ11‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2001, 10, ŽRŒ`

117.  ‘å“à’¼‹vC‰FŒŽ”ü˜aC‹g“c“nC‹g“c¹–¾C—é–Ø—zŽqCòŽR•ü­C“ˆ‘º³CàVˆä‚Žu: Ä”­«‘½”­“Š‚É‚¨‚¯‚é“j‰ó‹@˜‚ÉŠÖ‚·‚é•a—‘gDŠw“IŒŸ“¢ \ ’`”’•ª‰ðy‘fŒQ‚ƃAƒ|ƒg[ƒVƒX‚Ì”­Œ» \C‘æ11‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2001, 10, ŽRŒ`

118.  ‹g“c“nC‰FŒŽ”ü˜aC•£Œ°CˆÉ“¡’C‘å“à’¼‹vC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: F‘f«ãO–ÑŒ‹ß«ŠŠ–Œ‰Š‚É‚¨‚¯‚é‹×–E‚Ì“Á’¥‚ɂ‚¢‚ÄC‘æ11‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2001, 10, ŽRŒ`

119.  ¬”¦ŽjŽqCó‰ªL‘¾C’ç—æŽqC‚‹´´ŽÀC•½“c—¤³C²“¡¬‘å: ’°ŠÇoŒŒ«‘å’°‹Û‚Ì“Å‘fStx2‚ªƒ}ƒEƒX”]‚É‹y‚Ú‚·‰e‹¿C ‘æ55‰ñ“ú–{׋ۊw‰ï“Œ–kŽx•”‘‰ï, 2001, 8, å‘ä

120.  Šâ“®‚¿‚¸ŽqC¬ŽR—ŒbC¼“c‘s³C—˜•”‹P—YC‰FŒŽ”ü˜aCàVˆä‚Žu: ”DP‰ŠúãO–Ñ‚ÌhCG •ª”å”\‚ÆAgNORs ‚Ì”­Œ»‚ɂ‚¢‚Ä \ IPAP; Image Processor for Analytical Pathology‚ð—p‚¢‚½ŒŸ“¢ \C‘æ528‰ñŠâŽèˆãŠw‰ï—á‰ï, 2002, 1, ·‰ª

121.  ŠLŽRC‰FŒŽ”ü˜aC‘O“c˜aÍCŽODÆŽOC“ˆ‘º³CàVˆä‚Žu: •ÏŒ`«ŠÖßÇŠ³ŽÒŠÖ߉t’†‚̃qƒAƒ‹ƒƒ“Ž_‚Ì•ªŽq—ÊC”Z“xC”S“x‚ɂ‚¢‚Ä‚ÌŒŸ“¢C‘æ1‰ñBiomatrix Forum, 2002, 1, “Œ‹ž

122.  –ì“c—TC“¡“c’¼FC¬—Ñ„C–Ø‘ºŽ–¤CˆÉ“¡Œ[C›Œ´rŽ÷C‰F–ì—vC¬“‡‰pŒåC“n•Ó‚Ý‚©CàVˆä‚Žu: L”Í‚Èi“W‚ðŽ¦‚µ‚½’_“¹Šà‚Ì1—áC ‘æ54‰ñ“ú–{•a—Šw‰ï“Œ–kŽx•”ŠwpW‰ï, 2002, 2, å‘ä

123.  ‰FŒŽ”ü˜aC•½“c–œç‘ãCàVˆä‚Žu: ƒ}ƒCƒNƒƒEƒF[ƒuˆ—‚ð‚­‚í‚¦‚½’EŠD–@‚ƖƉu‘gD‰»ŠwCin situ hybridization‚ւ̉e‹¿C ‘æ5‰ñˆãŠwƒ}ƒCƒNƒƒEƒF[ƒuŒ¤‹†‰ïEŠwpW‰ï, 2002, 3, “Œ‹ž

124.  ‘å“à’¼‹vC‰FŒŽ”ü˜aC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: Ä”­«‘½”­“Š‚É‚¨‚¯‚é•a—‘gDŠw“IŒŸ“¢ \ “j‰ó‚ÉŠÖ—^‚·‚é’`”’•ª‰ðy‘fŒQ‚ƃAƒ|ƒg[ƒVƒX‚Ì”­Œ» \C‘æ4‰ñŠâŽè“¤‹†‰ï, 2002, 3, ·‰ª

125.  ŠLŽRC‰FŒŽ”ü˜aC‘O“c˜aÍCŽODÆŽOC“ˆ‘º³CàVˆä‚Žu: •ÏŒ`«ŠÖßÇŠ³ŽÒ‚ÌŠÖ߉t’†‚̃qƒAƒ‹ƒƒ“Ž_‚Ì•ªŽq—ÊC”Z“xC”Sâf“x‚ɂ‚¢‚Ä‚ÌŒŸ“¢C‘æ530‰ñŠâŽèˆãŠw‰ï—á‰ï, 2002, 3, ·‰ª

126.  ¬—Ñ‹MŽ÷C›Œ´ŠxŽjCŒã“¡Žõ—TC‘â˜NC“càV–LC‰FŒŽ”ü˜aCàVˆä‚Žu: “œ”A•a–Ô–ŒÇ‚É‚¨‚¯‚éŠá“àƒTƒCƒgƒJƒCƒ“”Z“x‚̕ω»@‘æ‚Q•ñC‘æ530‰ñŠâŽèˆãŠw‰ï—á‰ï, 2002, 3, ·‰ª

127.  ¬—Ñ“NlC•£Œ°CàVˆä‚Žu: ƒOƒŠƒI[ƒ}‚É‚¨‚¯‚éconnective tissue growth factor‚Ì”­Œ»‚ÆŒŒŠÇV¶‚Æ‚ÌŠÖ˜AC‘æ91‰ñ“ú–{•a—Šw‰ï‘‰ï, 2002, 3, ‰¡•l

128.  •£Œ°C²X–ØMlCàVˆä‚Žu: ¬‡«Œ‹‡‘gD•aiMCTDj‚É‚¨‚¯‚é”x‚ŒŒˆ³ÇiPHj”­¶‹@˜‚̉ð–¾C‘æ91‰ñ“ú–{•a—Šw‰ï‘‰ï, 2002, 3, ‰¡•l

129.  ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC‹g“c¹–¾C‹g“c“nC•½“c–œç‘ãC‘å’ι•FC¬ìKŒbC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ‘gD‚ÌSCIDƒ}ƒEƒX‚ւ̈ÚAŒã‚Ì•a—‘œ‚ɂ‚¢‚ÄiˆÚA–@‚ÆŽžŠúCŒŒŠÇ‚Æ‚ÌŠÖŒWjC ‘æ91‰ñ“ú–{•a—Šw‰ï‘‰ï, 2002, 3, ‰¡•l

130.  Šâè^‹|C‰FŒŽ”ü˜aC”~“c‰pKCàVˆä‚Žu: ‘gDŒv‘ª‚ð—p‚¢‚½”x“®–¬‚ð\¬‚·‚鬕ª‚̉Á—î“I•Ï‰»‚ÌŒŸ“¢C‘æ91‰ñ“ú–{•a—Šw‰ï‘‰ï@, 2002, 3, ‰¡•l

131.  ŽO‰YNGC‰FŒŽ”ü˜aC•£Œ°CŽÄ“c—S“ñC‰ª“cMˆê˜YCàVˆä‚Žu: d‰»«ŒŒŠÇŽî2—á‚̖Ɖu‘gD‰»ŠwõF‚É‚æ‚é‘gDŠw“I“Á’¥‚ÌŒŸ“¢C‘æ91‰ñ“ú–{•a—Šw‰ï‘‰ï, 2002, 3, ‰¡•l

132.  àN—§‰ØCŽR“àL•½C‰FŒŽ”ü˜aC‘å’J–¾•vC–¼‘qGCàVˆä‚Žu: üˆÛ‰»”x‘gD‚É‚¨‚¯‚éconnective tissue growth factoriCTGFj‚Ì”­Œ»C ‘æ91‰ñ“ú–{•a—Šw‰ï‘‰ï, 2002, 3, ‰¡•l

133.  ‹g“c“nC‰FŒŽ”ü˜aC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: In situ zymography‚ð—p‚¢‚½–«ŠÖ߃ŠƒEƒ}ƒ`ŠŠ–Œ‘gD‚Ì‚¨‚¯‚éƒ[ƒ‰ƒ`ƒ“•ª‰ð”\‚ÌŒŸ“¢C‘æ34‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ï, 2002, 4, •l¼

134.  ˆÉ“¡’C‰FŒŽ”ü˜aC“ˆ‘º³C‹g“c¹–¾CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`ŒŒ´CŠÖ߉t’†‚ÌMatrix metalloproteinase-13‚Ì“®‘ÔC ‘æ34‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ï, 2002, 4, •l¼

135.  ˆÉ“¡‹gŒ«C‰FŒŽ”ü˜aC“¡ˆäŽ”VCàVˆä‚Žu: ŠŠ–Œ‚É‚¨‚¯‚錋‡‘gD¬’·ˆöŽqiCTGFj‚Ì”­Œ»C‘æ34‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ï, 2002, 4, •l¼

136.  ‹g“c“nC‰FŒŽ”ü˜aC•£Œ°C‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: ‰æ‘œ‰ðÍ‘•’u‚É‚æ‚é–«ŠÖ߃ŠƒEƒ}ƒ`iRAjŠŠ–Œ‚̃[ƒ‰ƒ`ƒ“•ª‰ð”\‚ÌŒŸ“¢C‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

137.  àN—§‰ØCŽR“àL•½C‰FŒŽ”ü˜aC’†¼“OC‘êì³tCˆäã—m¼CàVˆä‚Žu: ”xüˆÛÇ‚É‚¨‚¯‚éconnective tissue growth factoriCTGFj‚Ì”­Œ»C‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

138.  ŠLŽRC‰FŒŽ”ü˜aC‘O“c˜aÍCŽODÆŽOC“ˆ‘º³CàVˆä‚Žu: •ÏŒ`«ŠÖßÇŠ³ŽÒŠÖ߉t’†‚̃qƒAƒ‹ƒƒ“Ž_‚Ì•ªŽq—ÊC”Z“x‚Æ”S“x‚ɂ‚¢‚Ä‚ÌŒŸ“¢C‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

139.  ‰FŒŽ”ü˜aC¼–씎–¾C—V“¹˜a—YC‹g“c¹–¾C‹g“c“nC‘å’ι•FC–Ø‘º—FŒúCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒŠŠ–Œ‘gD‚ÌSCIDƒ}ƒEƒX‚ւ̈ÚAŒã‚Ì•a—‘œ‚ɂ‚¢‚ÄiˆÚA•û–@‚ÆŠÏŽ@ŽžŠúC‚¨‚æ‚ÑŒŒŠÇ‚Æ‚ÌŠÖŒW‚ÌŒŸ“¢jC ‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

140.  ˆÉ“¡’C‰FŒŽ”ü˜aC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`ŒŒ´EŠÖ߉t’†‚ÌMatrix metalloproteinaseiMMPj-13‚Ì“®‘ÔC‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

141.  ‹g“c¹–¾C‰FŒŽ”ü˜aC‹g“c“nCˆÉ“¡’C‘å“à’¼‹vC¬ŽR–¾ŽqC•£Œ°CàVˆä‚ŽuC“ˆ‘º³: ƒ€ƒ`ƒ‰ƒ“ƒXŒ^ŠÖ߉Š‚É‚¨‚¯‚霉è×–E‚Æ”jœ×–E‚Ì‘gDŠw“I“Á’¥C‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

142.  ‘å“à’¼‹vC‰FŒŽ”ü˜aC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: Ä”­«‘½”­“Š‚Ì•a—‘gDŠw“IŒŸ“¢ \“j‰ó‚ÉŠÖ—^‚·‚é’`”’•ª‰ðy‘fŒQ‚ƃAƒ|ƒg[ƒVƒX‚Ì”­Œ» \C‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

143.  •£Œ°C²X–ØMlCàVˆä‚Žu: ¬‡«Œ‹‡‘gD•aiMCTDj‚É‚¨‚¯‚é”x‚ŒŒˆ³ÇiPHj”­¶‹@˜‚̉ð–¾C‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

144.  ˆÉ“¡‹gŒ«C‰FŒŽ”ü˜aC•£Œ°C’Ò”ü’qŽqC“¡ˆäŽ”VCàVˆä‚Žu: ŠŠ–Œ‚É‚¨‚¯‚錋‡‘gD¬’·ˆöŽqiCTGFj‚Ì”­Œ»C‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

145.  ‹v‰ä–FºC’JŒûŒ°C“à“cÙŽ¢C“à“c—²C‰FŒŽ”ü˜aCàVˆä‚ŽuCD“cO”üC’†‘ºkŽO: ”jœ×–E•ª‰»ˆöŽq‚Ì‹ÇÝC‘æ46‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ïŠwpW‰ï, 2002, 4, _ŒË

146.  ¬—Ñ“NlC•£Œ°CàVˆä‚Žu: ƒOƒŠƒI[ƒ}‚É‚¨‚¯‚éconnective tissue growth factor‚Ì”­Œ»C“ú–{”]Žîᇕa—Šw‰ï, 2002, 5, L“‡

147.  ŽO‰YNGCŠ™“cŠì”ŽCŽÄ“c—S“ñC‹à“c—SŽ¡C‘ºˆä˜a•vCàVˆä‚Žu: ¶Š{‰º‘B‚É”­¶‚µ‚½leiomyosarcoma‚Ì1—áC ‘æ55‰ñ“ú–{•a—Šw‰ï“Œ–kŽx•”ŠwpW‰ï, 2002, 7, ŽRŒ`

148.  àVˆä‚ŽuC‹g“c“nCŠâè^‹|: Film In Situ ZymographyiFIZj‚É‚æ‚éŠÔÚ‰t’†‚̃[ƒ‰ƒ`ƒ“•ª‰ð”\‚ÌŒŸ“¢C ‘æ534‰ñŠâŽèˆãŠw‰ï—á‰ï, 2002, 8, ·‰ª

149.  àN—§‰ØCàVˆä‚Žu: Pulmonary Sarcoidosis‚É‚¨‚¯‚éconnective tissue growth factoriCTGFj‚Ì”­Œ»C ‘æ534‰ñŠâŽèˆãŠw‰ï—á‰ï, 2002, 8, ·‰ª

150.  ˆÉ“¡‹gŒ«C‰FŒŽ”ü˜aC•£Œ°CŽR“àL•½C•–ìÂC“¡ˆäŽ”VCàVˆä‚Žu: ƒŠƒEƒ}ƒ`‚ł͉ŠÇ‚Ì–«‰»‚É”º‚¢ŠÖߊŠ–Œ‚É‚¨‚¯‚éCTGFmRNA‚Ì”­Œ»‚͒ቺ‚·‚é \ Real-time quantitative PCR‚¨‚æ‚ÑFlow cytometry‚É‚æ‚é‰ðÍ \C‘æ534‰ñŠâŽèˆãŠw‰ï—á‰ï, 2002, 8, ·‰ª

151.  Š™“cŠì”ŽC¬—Ñ—R‰ÀC‹à“c—TŽ¡C²“¡GºC‘ºˆä˜a•vC’†—¢—´•FCŽO‰YNGC›–ì—SK: ¬Ž™‚É‚Ý‚ç‚ꂽ㪕”_ŒoâŽî‚Ì1—áC‘æ17‰ñ–k‰œ‰HŽOŒ§’n•û•”‰ï‡“¯Šwpu‰‰‰ï, 2002, 9, O‘O

152.  ‹g“c“nC‰FŒŽ”ü˜aCŠâè^‹|C‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: Film in situ zymographyiFIZj‚ð—˜—p‚µ‚½ŠÖߎ¾Š³‚É‚¨‚¯‚銊–Œ‘gD‚¨‚æ‚ÑŠÖ߉t‚̃[ƒ‰ƒ`ƒ“•ª‰ð”\‚ÌŒŸ“¢C‘æ12‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2002, 9, ŽD–y

153.  ‰FŒŽ”ü˜aCŠLŽRCŽODÆŽOC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚ÌŠŠ–Œ‘gD‚É‚¨‚¯‚éƒqƒAƒ‹ƒƒ“Ž_‡¬y‘fiHAS1, 2, 3j‚ÌmRNA‚Ì”­Œ»‚ƃqƒAƒ‹ƒƒ“Ž_‡¬y‘fŠˆ«C‘æ12‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2002, 9, ŽD–y

154.  •£Œ°C²X–ØMlCàVˆä‚Žu: RŒŒŠÇ“à”ç×–ER‘Ì‚ÌŽ¾Š³“ÁˆÙ«‚ÆŽ¾Š³Šˆ“®«‚Æ‚ÌŠÖŒW \MCTD‚ÆSSc‚ð’†S‚É \C‘æ12‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2002, 9, ŽD–y

155.  ŠLŽRC‰FŒŽ”ü˜aC‘O“c˜aÍCŽODÆŽOC“ˆ‘º³CàVˆä‚Žu: •ÏŒ`«•GŠÖßÇŠÖ߉t’†‚̃qƒAƒ‹ƒƒ“Ž_‚Ì”Z“xC•ªŽq—Ê‚¨‚æ‚ÑŠÖ߉t‚Ì”S“xC”S’e«‚ɂ‚¢‚Ä‚ÌŒŸ“¢C‘æ12‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2002, 9, ŽD–y

156.  –xˆä‚•¶C‹g“c¹–¾C¬ŽR–¾ŽqC‘å“à’¼‹vC‹g“c“nCˆÀ“¡‹MMC“ˆ‘º³C“ñ‹{—R—¢: œ”Õ—Ö‚Ì”j‰ó‚ð‚«‚½‚µ‚½ÆŽã«œÜ‚Ì1—áC‘æ12‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï–kŠC“¹E“Œ–kŽx•”ŠwpW‰ï, 2002, 9, ŽD–y

157.  ¬—Ñ‘ô–çC“c’†‹v•qC’Ž–{‰hŽqCç—tWCàVˆä‚ŽuC‰FŒŽ”ü˜a: ƒ‰ƒbƒg‚É‚¨‚¯‚éŽÀŒ±“I™ù‡Š±Â‚ª”]“àc-Fos mRNA”­Œ»‚É‹y‚Ú‚·‰e‹¿C‘æ108‰ñ“ú–{•â’ÔŽ•‰ÈŠw‰ïŠwp‘å‰ï, 2002, 10, –¼ŒÃ‰®

158.  ¬”¦ŽjŽqC’ç—æŽqC•½“c—¤³C²“¡¬‘å: R‹Ûƒyƒvƒ`ƒhmCRAMP‚Ì‘å’°‹Û“à‘å—Ê”­Œ»Œn‚Ì\’zC‘æ75‰ñ“ú–{׋ۊw‰ï‘‰ï, 2002, 4, ‰¡•l

159.  ó‰ªL‘¾C¬”¦ŽjŽqC‚‹´´ŽÀC’ç—æŽqCˆî“c·–çC²“¡¬‘å: Stx1 ‚ɑ΂·‚é’†˜aR‘Ì‚ÍBƒTƒuƒ†ƒjƒbƒg’P—Ê‘Ì‚æ‚è‚à‘½—Ê‘Ì‚ÉŒø—¦“I‚ÉŒ‹‡‚·‚é«Ž¿‚ðŽ‚ÂC‘æ6‰ñ’°ŠÇoŒŒ«‘å’°‹ÛŠ´õǃVƒ“ƒ|ƒWƒEƒ€, 2002, 6, “Œ‹ž

160.  H“¡–΂C‘å“à~C’ç—æŽqC¬”¦ŽjŽqC‚‹´´ŽÀCˆî“c·–çC²“¡¬‘åC’·’J쓹•FC—é–Ø‘×C“¡‰ª’mº: ƒ}ƒEƒXt×–EŠà‚ɑ΂·‚éBAIibrain-specific angiogenesis inhibitor 1jˆâ“`Žq‚ð—p‚¢‚½RŽîᇌø‰Ê‚ÌŠî‘b“IŒŸ“¢C‘æ56‰ñ“ú–{׋ۊw‰ï“Œ–kŽx•”‘‰ï, 2002, 8, ·‰ª

161.  ˆî“c·–çC”ªdŠ~‘×–@C²“¡M”ŽC²“¡¬‘åC‰““¡dŒú: ‚Š´“xƒGƒ“ƒhƒgƒLƒVƒ“‘ª’è–@‚Ì”sŒŒÇf’f‚É‚¨‚¯‚é—L—p«‚ÌŒŸ“¢C‘æ77‰ñ“ú–{Š´õÇŠw‰ï‘‰ï, 2003, 4, •Ÿ‰ª

162.  ‰FŒŽ”ü˜aCŠLŽRCŽODÆŽOCàVˆä‚Žu: ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚ÌŠŠ–Œ‘gD‚É‚¨‚¯‚éƒqƒAƒ‹ƒƒ“Ž_‡¬y‘fiHAS1, 2, 3j‚ÌmRNA‚Ì”­Œ»‚Ƈ¬y‘fŠˆ«C‘æ2‰ñBiomatrix Forum, 2003, 1, “Œ‹ž

163.  ›–ì—SKC¬–쎛‰pŒbC‰““¡Š²–çCç“cŸˆêCÔâr‰pCàVˆä‚Žu: –«Šˆ“®«EBƒEƒCƒ‹ƒXŠ´õÇ‚É”º‚¤‰á‰ß•qÇ’ŽŽh•”‚É‚¨‚¯‚錌ŠÇ‰Š•a•ÏC‘æ538‰ñŠâŽèˆãŠw‰ï—á‰ï, 2003, 1, ·‰ª

164.  ›–ì—SK: ƒEƒCƒ‹ƒXŽ¾Š³‚ƖƉuˆÙíC‘æ6‰ñ–Ɖu‚ÆŽ¾Š³Œ¤‹†‰ï, 2003, 1, å‘ä

165.  •Ê•{‚–¾CˆäãŒhCŽÄ“c—S“ñC•£Œ°C’†‘ºáÁˆêCrˆäŒ[ŽjC¬Š}Œ´–MºC¬ì²: ƒOƒŠƒI[ƒ}‚Ìp‘Of’f‚É‚¨‚¯‚éŠgŽUƒeƒ“ƒ\ƒ‹MRI‚ð—p‚¢‚½fractional anisotropy’l‚Ì—L—p«C ‘æ539‰ñŠâŽèˆãŠw‰ï—á‰ï, 2003, 2, ·‰ª

166.  ˆÉ“¡‹gŒ«C‰FŒŽ”ü˜aCŽR“àL•½C•–ìÂC“¡ˆäŽ”VCàVˆä‚Žu: ŠÖ߃ŠƒEƒ}ƒ`‚ÌŠŠ–ŒŒŒŠÇV¶‚É‚¨‚¯‚éCTGF‚ÌŠÖ—^C‘æ5‰ñŠâŽè“¤‹†‰ï, 2003, 2, ·‰ª

167.  àVˆä‚ŽuC›–ì—SKC‹g“c“nCŠâè^‹|: Film In Situ ZymographyiFIZj‚É‚æ‚éŠÖ߉t’†‚̃[ƒ‰ƒ`ƒ“•ª‰ð”\‚ÌŒŸ“¢i‘æ2•ñj \ Šˆ«‰»‚ÆŠˆ«—}§‚ɂ‚¢‚Ä \C‘æ540‰ñŠâŽèˆãŠw‰ï—á‰ï, 2003, 3, ·‰ª

168.  ¬—Ñ“NlC•£Œ°C•Ê•{‚–¾CrˆäŒ[ŽjCàVˆä‚ŽuC¬ì²: _ŒoäPŽî‚É‚¨‚¯‚éconnective tissue growth factoriCTGFj‚Ì”­Œ»‚ÆŒŒŠÇV¶‚Ö‚ÌŠÖ—^C‘æ540‰ñŠâŽèˆãŠw‰ï—á‰ï, 2003, 3, ·‰ª

169.  ŽO‰YNGC›–ì—SKCŠ™“cŠì”ŽCŽÄ“c—S“ñC‹îˆä‰xŽqC‹à“c—TŽ¡C‘ºˆä˜a•vC‘å’J–¾: Žîá‡×–E‚̈ꕔ‚ªmyofibroblast‚Ö‚Ì•ª‰»‚ðŽ¦‚µ‚½¶Š{‰º‘Bfibrosarcoma‚Ì1Ç—áC ‘æ540‰ñŠâŽèˆãŠw‰ï—á‰ï, 2003, 3, ·‰ª

170.  ›–ì—SKC‹îˆä‰xŽqCàVˆä‚Žu: ƒq ƒgT×–EŠ”‚É‚¨‚¯‚éEBƒEƒCƒ‹ƒX‚̬RNA EBER‚É‚æ‚éŽîᇉ󎀈öŽq‚Ì”­Œ»—U“±C‘æ92‰ñ“ú–{•a—Šw‰ï‘‰ï, 2003, 4, •Ÿ‰ª

171.  ›–ì—SKC¬–쎛‰pŒbC‰““¡Š²–çC‹îˆä‰xŽqCç“cŸˆêCÔâr‰pCàVˆä‚Žu: –«Šˆ“®«EBƒEƒCƒ‹ƒXŠ´õÇ‚É”º‚¤‰á‰ß•qÇ’ŽŽh•”‚É‚¨‚¯‚錌ŠÇ‰Š•a•ÏC‘æ92‰ñ“ú–{•a—Šw‰ï‘‰ï, 2003, 4, •Ÿ‰ª

172.  ‰FŒŽ”ü˜aCŠLŽRCŽODÆŽOC‹g“c¹–¾C“ˆ‘º³C•½“c–œç‘ãCàVˆä‚Žu: ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚ÌŠŠ–Œ‘gD‚É‚¨‚¯‚éƒqƒAƒ‹ƒƒ“Ž_‡¬y‘fiHAS1, 2, 3j‚ÌmRNA‚Ì”­Œ»‚Ƈ¬y‘fŠˆ«C ‘æ92‰ñ“ú–{•a—Šw‰ï‘‰ï, 2003, 4, •Ÿ‰ª

173.  ŽO‰YNGC›–ì—SKCŠ™“cŠì”ŽCŽÄ“c—S“ñC‹îˆä‰xŽqC‹à“c—TŽ¡C‘ºˆä˜a•vC‘å’J–¾•vCàVˆä‚Žu: Žîá‡×–E‚̈ꕔ‚ªmyofibroblast‚Ö‚Ì•ª‰»‚ðŽ¦‚µ‚½¶Š{‰º‘Bfibrosarcoma‚Ì1Ç—áC‘æ92‰ñ“ú–{•a—Šw‰ï‘‰ï, 2003, 4, •Ÿ‰ª

174.  ‘å“à’¼‹vC‰FŒŽ”ü˜aCŠâè^‹|C‹g“c¹–¾C›–ì—SKCàVˆä‚Žu: Ä”­«‘½”­“Š‚É‚¨‚¯‚é•a—‘gDŠw“IŒŸ“¢ \ “j‰ó‚É‚¨‚¯‚é’`”’•ª‰ðy‘fŒQ‚ƃAƒ|ƒg[ƒVƒX‚ÌŠÖ—^ \C‘æ92‰ñ“ú–{•a—Šw‰ï‘‰ï, 2003, 4, •Ÿ‰ª

175.  àN—§‰ØC•Ê•{‚–¾C¬—Ñ“NlC•£Œ°CŽR“àL•½C¬ì²CàVˆä‚Žu: Glioblastoma‚É‚¨‚¯‚éConnective tissue growth factoriCTGFj”­Œ»C ‘æ92‰ñ“ú–{•a—Šw‰ï‘‰ï, 2003, 4, •Ÿ‰ª

176.  ¬—Ñ“NlC•£Œ°C¬ì²CàVˆä‚Žu: _ŒoäPŽî‚É‚¨‚¯‚éconnective tissue growth factoriCTGFj‚Ì”­Œ»‚ÆŒŒŠÇV¶‚Ö‚ÌŠÖ˜AC‘æ92‰ñ“ú–{•a—Šw‰ï‘‰ï, 2003, 4, •Ÿ‰ª

177.  ‹g“c“nC‰FŒŽ”ü˜aCŠâè^‹|C‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: ‰æ‘œ‰ðÍ‘•’u‚ð—p‚¢‚½ŠÖ߃ŠƒEƒ}ƒ`ŠÖ߉t‚É‚¨‚¯‚éƒ[ƒ‰ƒ`ƒ“•ª‰ð”\‚ÌŒŸ“¢C‘æ47‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2003, 4, “Œ‹ž

178.  ‹g“c¹–¾C‰FŒŽ”ü˜aCˆêŒË’啶C‹g“c“nC‘å“à’¼‹vC‰““¡N“ñ˜YC¬ŽR–¾ŽqCˆÀ“¡‹MMCàVˆä‚ŽuC“ˆ‘º³: RA‚Ì•GŠÖß‹ß–T‚É”­¶‚·‚鋑圔XŽî‚Ì”­¶‹@˜C ‘æ47‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2003, 4, “Œ‹ž

179.  ˆÉ“¡‹gŒ«C‰FŒŽ”ü˜aC•£Œ°C“¡ˆäŽ”VCàVˆä‚Žu: ŠŠ–Œ”|—{×–E‚É‚¨‚¯‚éCTGFmRNA‚Ì”­Œ»@\ Real-time quantitative PCR–@‚É‚æ‚é‰ðÍ \C‘æ47‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2003, 4, “Œ‹ž

180.  ŠLŽRC‰FŒŽ”ü˜aCŽODÆŽOC‘O“c˜aÍC“ˆ‘º³CàVˆä‚Žu: •ÏŒ`«•GŠÖßÇŠÖ߉t‚Ì”S’e«‚ɂ‚¢‚ÄC‘æ47‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2003, 4, “Œ‹ž

181.  ‰FŒŽ”ü˜aCŠLŽRCŽODÆŽOC‹g“c¹–¾C“ˆ‘º³CàVˆä‚Žu: ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚ÌŠŠ–Œ‘gD‚É‚¨‚¯‚éƒqƒAƒ‹ƒƒ“Ž_‡¬y‘fiHAS1, 2, 3j‚ÌmRNA‚Ì”­Œ»‚Ƈ¬y‘fŠˆ«C‘æ47‰ñ“ú–{ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï, 2003, 4, “Œ‹ž

182.  ¬—Ñ‘ô–çC“c’†‹v•qC’Ž–{‰hŽqCç—tWCàVˆä‚ŽuC‰FŒŽ”ü˜a: ™ðšŽž‚É‚¨‚¯‚éŽÀŒ±“I™ù‡Š±Â‚ƃ‰ƒbƒg”]“àƒXƒgƒŒƒX‰ž“šC‘æ109‰ñ“ú–{•â’ÔŽ•‰ÈŠw‰ïŠwp‘å‰ï, 2003, 5, “Œ‹ž

183.  ç—tWC“c’†‹v•qC’Ž–{‰hŽqC¬—Ñ‘ô–çCàVˆä‚ŽuC‰FŒŽ”ü˜a: ƒ‰ƒbƒg‚É‚¨‚¯‚é™ù‡Š±Â‚ªHPAŒnƒXƒgƒŒƒX”½‰ž‚É‹y‚Ú‚·‰e‹¿C‘æ109‰ñ“ú–{•â’ÔŽ•‰ÈŠw‰ïŠwp‘å‰ï, 2003, 5, “Œ‹ž

 

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

184.  ²X–Ø^—C‹y씎•¶C]Œ´–ÎC‹Êì–Ft: Œz•”“®–¬‚Ì•¡”‰ñ‘¢‰e3D MRC‘æ101‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï–k“ú–{’n•û‰ï, 1999, 11, •Ÿ“‡

185.  ²X–Ø^—C‹y씎•¶C]Œ´–ÎC‹Êì–Ft: Fast STIR‚É‚æ‚éŠÔ”]‚ÌMRŠŒ©C‘æ27‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ï‘å‰ï, 1999, 9, “Œ‹ž

186.  ²X–Ø^—C‹y씎•¶C]Œ´–ÎC‹Êì–Ft: Fast STIR‚É‚æ‚鎋°“àˆŸŠj‚Ì•`oC‘æ100‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï–k“ú–{’n•û‰ï, 1999, 6, å‘ä

187.  ‹yì_C‹Êì–Ft: Proton MRS‚©‚ç‚Ý‚½”]ŒŒŠÇ«’s•ð‚ƃAƒ‹ƒcƒnƒCƒ}[Œ^’s•ð‚̈Ⴂ‚ɂ‚¢‚Ä \ ”’Ž¿‚Ɣ玿‚É‚¨‚¯‚é‘ãŽÓ‚̈Ⴂ‚ɂ‚¢‚Ä \C‘æ27‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ï‘å‰ï, 1999, 9, “Œ‹ž

188.  ‹y씎•¶C²X–Ø^—C]Œ´–ÎC‹Êì–Ft: •Ž¿‚̳íMRŠŒ©C‘æ100‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï–k“ú–{’n•û‰ï, 1999, 6, å‘ä

189.  ˆÀ“cd, “¹–”—˜, —é–Ø–ž, ¬Œ´ƒPƒCŽq, ¬–ì’¼”V, Žðˆä–¾•v: ‘½Ê‚ȸ_Çó‚ð’悵‚½Binswanger•a‚Ì2—áC‘æ53‰ñ“Œ–k¸__ŒoŠw‰ï, 1999, 9, ·‰ª

190.  ²X–Ø^—C‹y씎•¶C]Œ´–ÎC‹Êì–Ft:  3 Tesla MRI‚É‚¨‚¯‚é’†”]’áM†‚Æ•Ž¿‚ÌŠÖŒWC‘æ103‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï–k“ú–{’n•û‰ï, 2000, 12, å‘ä

191.  ²X–Ø^—C‹y씎•¶C]Œ´–ÎC‹Êì–Ft: Šî’êŠj‚ÌMRI : • ‘¤üð‘ÌC• ‘¤’W‘“‹…CŽ‹°‰ºŠj‚̳튌©C‘æ28‰ñ “ú–{Ž¥‹C‹¤–ˆãŠw‰ï‘å‰ï, 2000, 10, ‹ž“s

192.  ‹yì_C‹Êì–Ft: ƒAƒ‹ƒcƒnƒCƒ}[Œ^’s•ðŠ³ŽÒ‚ÌdÇ“x‚Æ”]“à‚̗̈æ•Ê‘ãŽÓ•Ï‰»‚ɂ‚¢‚ÄC ‘æ28‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ï‘å‰ï, 2000, 10, ‹ž“s

193.  ‹y씎•¶C²X–Ø^—C]Œ´–ÎC‹Êì–Ft: •Ž¿•a•Ï‚ÌMRŠŒ©C‘æ103‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï–k“ú–{’n•û‰ï, 2000, 10, å‘ä

194.  ²X–Ø^—C‹y씎•¶C]Œ´–ÎC‹Êì–Ft:  3 Tesla‘•’u‚É‚¨‚¯‚é•Ž¿‚ÌMRŠŒ©C ‘æ60‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïŠwp”­•\‰ï, 2001, 4, _ŒË

195.  ˆÀ“cd, —é–Ø–ž, ¬Š}Œ´–Mº, ¬—ѳ˜a, ¬ì², Žðˆä–¾•v: ¸_•ª—ô•a‚É‚¨‚¯‚鉹ŠyŒ¶’®‚Ì•a‘ƒ‹ÇÝC‘æ8‰ñNMCC‹¤“¯—˜—pŒ¤‹†¬‰Ê”­•\‰ï, 2001, 5, ·‰ª

196.  ˆÀ“cd, —é–Ø–ž, ¬Š}Œ´–Mº, ¬—ѳ˜a, ¬ì², Žðˆä–¾•v:¸_•ª—ô•a‚É‚¨‚¯‚鉹ŠyŒ¶’®‚Ì•a‘ƒ‹ÇÝ: PET‚É‚æ‚錟“¢, ‘æ21‰ñŠâŽèŒ§ŠjˆãŠw§˜b‰ï, 2001, 7, ·‰ª

197.  ˆäãŒhC¬Š}Œ´–MºC²X–Ø^—C¬ì²C‹Êì–FtCŠ‘‘òG”VCLouis Lauzon: ”]_ŒoŠO‰È—Õ°‚É‚¨‚¯‚é3.0 tesla MRI‚Ì—L—p«: ‚‰ð‘œ“x‰æ‘œCŠgŽU‹­’²‰æ‘œC‘¢‰e MRI ‚É‚æ‚錟“¢, ‘æ29‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ï‘å‰ï, 2001, 9, ’}”g

198.  ˆäãŒhC•Ê•{‚–¾C¬Š}Œ´–MºC¬ì²F 3DAC‚Å_ŒoüˆÛáŠQ‚ð”F‚ß‚È‚©‚Á‚½”]—À•” glioma‚Ì1—á, ‘æ36‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ï“Œ–k’n•û‰ï, 2001, 9, ÂX

199.  ˆäãŒhC¬ì²C¬Š}Œ´–MºC®–ìL: 3ƒeƒXƒ‰ MRI ‚ð—p‚¢‚½”]ŒŒ—¬•]‰¿C ‘æ25‰ñ–k“ú–{”]_ŒoŠO‰È˜A‡‰ï, 2001, 6, •xŽR

200.  ˆäãŒhC¬Š}Œ´–MºC®–ìLC¬ì²: ”]‹•ŒŒŠ³ŽÒ‚É‚¨‚¯‚é’´‚Ž¥êMRI‚É‚æ‚é”]ŒŒ—¬•]‰¿FSPECT‚Æ‚Ì”äŠrC‘æ8‰ñ“Œ–k”]zŠÂƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX, 2001, 10, å‘ä

201.  ˆäãŒhC¬Š}Œ´–MºC¬ì²CLouis LauzonCŠ‘‘òG”V: ”]_ŒoŠO‰Èp‘O•]‰¿‚É‚¨‚¯‚é3.0ƒeƒXƒ‰MRI‚Ì—L—p«C‘æ60‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ï‘‰ï, 2001, 10, ‰ªŽR

202.  ¼‰YGŽ÷C®–ìLC¬ì²C²X–Ø^—CˆäãŒhC¬Š}Œ´–Mº: ‰º“‚–©r•F,”]_Œo—̈æ‚É‚¨‚¯‚鶑ÌÞ—¿‚ÌMRI‰æ‘œ‚É‹y‚Ú‚·‰e‹¿C‘æ60‰ñ“ú–{”]_ŒoŠO‰ÈŠw‰ï‘‰ï, 2001, 10, ‰ªŽR

203.  ²X–Ø^—C¼‰iŒåC•yàVLsC‹Êì–FtC¬ì”Ž”VCˆäãŒhC¬ì²:  3 Tesla‘•’u‚ð—p‚¢‚½ƒqƒgCƒCƒkCƒlƒRŠC”n‘Ì‚ÌMR”äŠr‰ð–UC‘æ29‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ï‘å‰ï, 2001, 9, ‚‚­‚Î

204.  ²X–Ø^—C¼‰iŒåC•yàVLsC‰“ŽRe“ñ˜YC‹Êì–FtC¬ì”Ž”V: 3 Tesla‘•’u‚ð—p‚¢‚½ƒCƒkCƒlƒR”]‚ÌMRŠŒ©C‘æ29‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ï‘å‰ï, 2001, 9, ‚‚­‚Î

205.  ²X–Ø^—C‹y씎•¶C]Œ´–ÎC‹Êì–Ft: 3 Tesla MRI‚É‚¨‚¯‚éGd-DTPA‘¢‰e‘‹­Œø‰Ê‚ÌŠî‘b“IŒŸ“¢C‘æ105‰ñ“ú–{ˆãŠw•úŽËüŠw‰ï–k“ú–{’n•û‰ï, 2001, 11, å‘ä

206.  ˆäãŒhC¬Š}Œ´–MºC¬ì²CŽµð•¶—YC‰iœAMŽ¡: “ú–{ƒMƒKƒrƒbƒgƒlƒbƒgƒ[ƒN‚ð—˜—p‚µ‚½Ç—ጟ“¢C‘æ11‰ñ“ú–{”]_ŒoŠO‰ÈƒRƒ“ƒsƒ…[ƒ^Œ¤‹†‰ï, 2002, 1, ‘åã

207.  ˆäãŒhC¬Š}Œ´–MºC¬ì²: ”]_ŒoŠO‰Èp‘Of’f‚É‚¨‚¯‚é3.0Tesla MRI‚Ì—L—p«C‘æ‚Q‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€, 2002, 2, ·‰ª

208.  ¼‰YGŽ÷CˆäãŒhC¬Š}Œ´–MºC®–ìLC¬ì²: ”]_ŒoŠO‰È¶‘ÌÞ—¿‚É—R—ˆ‚·‚éMRIƒA[ƒ`ƒtƒ@ƒNƒg‚Ì0.5, 1.5, 3.0Tesla‘•’u‚É‚¨‚¯‚é’è—Ê“I•]‰¿C‘æ‚Q‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€, 2002, 2, ·‰ª

209.  ˆäãŒhC¬Š}Œ´–MºC¬ì²C²X–Ø^—C‹Êì–Ft:  3.0Tesla MRI ‚É‚æ‚é‰ð–UŠw“I\’z‚©‚ç‚Ì’†Sa“¯’è: fMRI‚ð’´‚¦‚ç‚ê‚é‚©H ‘æ11‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ïŠwpW‰ïiCNTTj, 2002, 2, b•{

210.  ¼‰YGŽ÷C®–ìLC²X–Ø^—CˆäãŒhC¬Š}Œ´–MºC¬ì²: ”]_Œo—̈æ‚É‚¨‚¯‚鶑ÌÞ—¿‚ÌMRI‰æ‘œ‚É‹y‚Ú‚·‰e‹¿ \ 0.5TC1.5T‹y‚Ñ3.0T MR‘•’u‚ð—p‚¢‚½’è—Ê•]‰¿ \C‘æ11‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ïŠwpW‰ïiCNTTj, 2002, 4, b•{

211.  ®–ìLC¼‰YGŽ÷C²X–Ø^—CˆäãŒhC¬Š}Œ´–MºC¬ì²C‰º“‚–©r•F: Ž•‰ÈÞ—¿‚ÌŽ¥‰»—¦‚Æ3.0ƒeƒXƒ‰[MRIŽB‘œƒA[ƒ`ƒtƒ@ƒNƒgC ‘æ11‰ñ”]_ŒoŠO‰ÈŽèp‚Æ‹@ŠíŠw‰ïŠwpW‰ïiCNTTj, 2002, 4, b•{

212.  ˆäãŒhC¬Š}Œ´–MºC®–ìLC¬ì²:  3.0Tesla MRI‚É‚æ‚é”]zŠÂ—\”õ”\•]‰¿C ‘æ31‰ñ“ú–{”]‘²’†‚ÌŠO‰ÈŠw‰ï, 2002, 4, å‘ä

213.  Sasaki M, Oikawa H, Tamakawa Y: Internal structures of cerebral gray matter at 3 Tesla: MR imaging using fast short inversion-time inversion-recovery technique, ‘æ2‰ñŠâŽèˆã‰È‘åŠwæ’[ˆã—ÃŒ¤‹†ƒZƒ“ƒ^[ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€, 2002, 2, ·‰ª

214.  ŽÄ“cŒb—C‘å’Ëk‘¾˜YCŽðˆä–¾•vC‰œŽ›—˜’jCŠÔ“¡ŒõˆêC‹à‘ò‚ЂÂéCŽR“c‘“ÖCŠÛ“c^Ž÷C‚’J—FŠóC쑺—@: ‰º‚‘ÌŽî‘å‚Æ‚ƒvƒƒ‰ƒNƒ`ƒ“ŒŒÇ‚𔺂Á‚½ŽüŠú«¸_•aC“ú–{¸__ŒoŠw‰ï‘‰ï, 2003, 5, “Œ‹ž

215.  ŽR“c‘“ÖC‚’J—FŠóC‹à‘ò‚ЂÂéC‹yì‹ÅCŽðˆä–¾•v: _Œo“à‰ÈC–ƒŒ‰È‚ւ̃Rƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“‚É‚æ‚Á‚ĉü‘P‚µ‚½ˆ««i’vŽ€«j‹Ù’£•a‚Ì1—áC“ú–{¸__ŒoŠw‰ï‘‰ï, 2003, 5, “Œ‹ž

216.  ‹y씎•¶C²X–Ø^—C‰“ŽRe“ñ˜YC]Œ´–Î:  3 Tesla MRI‚É‚æ‚é“®•¨”]‚ÌGd-DTPAŠÒ—¬ŒÅ’èMR microscopyC ‘æ31‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ï‘å‰ï, 2003, 9, •xŽm‹g“c


u‰‰

•a‘ԉ𖾕”–åi¶—•”–åj@

1.         —§ì‰pˆê: –ò—pläó‚Ì•›t‚ɑ΂·‚é–òŒø \ ƒXƒeƒƒCƒhŒ^ƒTƒ|ƒjƒ“‚ƃzƒ‹ƒ‚ƒ“•ª”å \C132‰ñ“ú–{bˆãŠw‰ï, 2001, 10, ·‰ª

 

Ž¡—Ö@ŒŸ“¢•”–åi•a—•”–åj

2.         Inada K: Diagnostic value of endotoxin levels measured by endotoxin-specific limulus test. IBC (International Business Communications) Congress, 1999, 1, Baltimore (USA)

3.         —é–Ø–ž: ‘å”]”’Ž¿‚̶Œã”­’B‰ß’ö\ƒOƒŠƒA•¡‡‘Ì‚Ì‘½Å“_“I”­’B‚ɂ‚¢‚Ä\C“Œ–k˜V”NŠú”]áŠQŒ¤‹†‰ï, 1999, 3, å‘ä

4.         àVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‚Ì•a—Šw“I“Á’¥CŒQ”n’n‹æƒŠƒEƒ}ƒ`‹³ˆçŒ¤C‰ï, 1999, 6, ‚è

5.         àVˆä‚Žu: ŠÖ߉Š‚Ì•a—Šw“I“Á’¥C‘æ25‰ñƒŠƒEƒ}ƒ`’†‰›‹³ˆçŒ¤C‰ï, 1999, 7, –¼ŒÃ‰®

6.         •½“c—¤³: “«Š´õÇŽ¡—ÂւÌVí—ª@©’Ž‚©‚çƒqƒg‚ÉŽŠ‚鶑̖hŒäŒn‚ð—˜—p‚µ‚ÄC‘æ3‰ñŠâŽèNMCƒNƒ‰ƒu “Á•Êu‰‰, 1999, 2, ŠâŽè

7.         •½“c—¤³: “«Š´õÇŽ¡—ÂւÌV‚µ‚¢í—ª@¶‘Ì‚Ì‚à‚–hŒä”\‚ð—˜—p‚µ‚ÄC‘æ22‰ñƒzƒmƒ~Š¿•û‰ï‚Ý‚¿‚Ì‚­’n‹æ‘å‰ï, 1999, 4, å‘ä

8.         ˆî“c·–ç: ƒGƒ“ƒhƒgƒLƒVƒ“CƒÀ-ƒOƒ‹ƒJƒ“‘ª’è‚̈Ӌ`C—Õ°”÷¶•¨Œ¤‹†‰ï, 1999, 5, “Œ‹ž

9.         àVˆä‚Žu: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚ÌŒ»‹µ‚Æ–â‘è“_C‘æ25‰ñ“ú–{ˆãŠw‰ï‘‰ï, 1999, 4, “Œ‹ž

10.     àVˆä‚Žu: ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚ÉŠÖ‚·‚鉓Šuˆã—ÔÇE•a—•ª‰È‰ï‚Ì3”NŠÔ‚ÌŠˆ“®“à—e‚Æ¡Œã‚ÌŽÀ—p‰»‚ɑ΂·‚錩’Ê‚µC‘æ3‰ñ‰“Šuˆã—ÃŒ¤‹†‰ï, 1999, 4, “Œ‹ž

11.     àVˆä‚Žu: Lˆæ“I•a—f’fŠw‚Ì“W–]@ƒ}ƒ‹ƒ`ƒƒfƒBƒAŽž‘ã‚Ì•a—f’f \ ‰“Šu•a—f’fiƒeƒŒƒpƒ\ƒƒW[j‚ÌŒ»ó‚Æ–â‘è“_C‘æ46‰ñ“ú–{—Õ°•a—Šw‰ï‘‰ï, 1999, 11, ŒF–{

12.     ‰FŒŽ”ü˜aCàVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`ŠŠ–Œ‘gD‚ÆŠÖ߉t‚É‚¨‚¯‚éurocortin‚Æ CRF receptor‚Ì”­Œ»C‘æ3‰ñ–Ɖu‚ÆŽ¾Š³Œ¤‹†‰ï, 2000, 2, å‘ä

13.     àVˆä‚Žu: •a—Šw“I‚É‚Ý‚½–«ŠÖ߃ŠƒEƒ}ƒ`iRAj‚Ì“îœEœ”j‰ó‚Ì“Á’¥C‘æ4‰ñ“Œ‹žƒŠƒEƒ}ƒ`ƒtƒH[ƒ‰ƒ€, 2000, 2, “Œ‹ž

14.     ‰FŒŽ”ü˜aCàVˆä‚Žu: ‰æ‘œ‰ðÍ‘•’u‚ð—p‚¢‚½•a—‘gD‚Ì’è—Ê“I‰ðÍ‚ÆIPAP‚ð—p‚¢‚½y‘f‘gD‰»Šw‚Ì’è—ʉ»C‘æ89‰ñ“ú–{•a—Šw‰ï‘‰ï, 2000, 4, ‘åã

15.     àVˆä‚Žu: –«ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚é“îœEœ”j‰ó‚Ì•a—C 2000ŠÖߊO‰ÈƒtƒH[ƒ‰ƒ€, 2000, 6, å‘ä

16.     •£Œ°: Laser scanning cytometryC‘æ11‰ñ“ú–{ƒTƒCƒgƒƒgƒŠ[Šw‰ï‹ZpuK‰ï, 2000, 11, “Œ‹ž

17.     •½“c—¤³: “«Š´õÇ‚Ì–hŒä@¶‘Ì–hŒäˆöŽq‚É‚æ‚éVí—ªC—–B¶•¨»•iŒ¤‹†Š, 2000, 5,    —–Bi’†‘j

18.     ˆî“c·–ç: ƒGƒ“ƒhƒgƒLƒVƒ“‚Ì‘ª’è–@‚ð‚ß‚®‚Á‚ÄC‘æ‚S‰ñƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇŽ¡—ÃŒ¤‹†‰ï, 2000, 1, “Œ‹ž

19.     ˆî“c·–ç: ƒGƒ“ƒhƒgƒLƒVƒ“‘ª’è–@C’·èŒ§—Õ°‰q¶ŒŸ¸‹ZŽt‰ïŒ¤C‰ï, 2000, 2, ’·è

20.     àVˆä‚Žu: ‰“Šuˆã—Â̌»ó‚Æ–â‘è“_C‘æ41‰ñ“ú–{Ž•‰Èˆã—ÊǗŠw‰ïŠwp‘å‰ï, 2000, 7, ·‰ª

21.     àVˆä‚ŽuCŠJŒ´¬ˆò: ƒeƒŒƒpƒ\ƒƒW[‚ÌŒ»ó‚Æ–â‘è“_C ‘æ62‰ñ“ú–{—Õ°ŠO‰ÈŠw‰ï‘‰ï, 2000, 11, –¼ŒÃ‰®

22.     àVˆä‚Žu: ‰“Šu•a—f’f‚Ì—LŒø«C•½¬12”N“xŒú¶‰ÈŠwŒ¤‹†iˆã—ËZp•]‰¿‘‡Œ¤‹†j„iŽ–‹Æ@Œ¤‹†¬‰Ê”­•\‰ïŽs–¯ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€, 2000, 11, •l¼

23.     ‰FŒŽ”ü˜aCàVˆä‚ŽuC“n•Ó’mKCŒj‘דT: ƒnƒCƒeƒNƒŠƒT[ƒ`ƒZƒ“ƒ^[‹@Ší—˜—pƒZƒ~ƒi[G•a—‰æ‘œ‰ð̓VƒXƒeƒ€iimage processor for analytical pathology: IPAPj‚ð—p‚¢‚½•a—•W–{i–Ɖu‘gD‰»ŠwCin situ hybridizationj‚Ì’è—ʉ»C‘æ520‰ñŠâŽèˆãŠw‰ï—á‰ï, 2001, 3, ·‰ª

24.     ˆ¢•”—²ŽuC“Œ‹V‰p•v: ƒAƒ‹ƒcƒnƒCƒ}[•a‚ƃtƒŠ[ƒ‰ƒWƒJƒ‹C ‘æ43‰ñ“ú–{˜V”NˆãŠw‰ïŠwpW‰ï, 2001, 6, ‘åã

25.     •£Œ°: ƒŒƒU[ƒXƒLƒƒƒjƒ“ƒOƒTƒCƒgƒƒgƒŠ[  „Ÿ Œ`‘ÔŠÏŽ@‚ð‰Â”\‚É‚µ‚½ƒTƒCƒgƒƒgƒŠ[‚ÌV‹Zp \C‘æ17‰ñ“ú–{—Õ°×–EŠw‰ïŠâŽèŽx•”W’k‰ï, 2001, 2, ·‰ª

26.     ˆî“c·–ç: ƒGƒ“ƒhƒgƒLƒVƒ“Šw2001C‘æ7‰ñ‘å㌌‰tò‰»E‘ÌŠOŠÂ‹«Œ¤‹†‰ï, 2001, 2, ‘åã

27.     àVˆä‚Žu: äPŒ´•a‚É‚Ý‚ç‚ê‚é“Á’¥“I‚È•a—‘gD‘œC‘æ27‰ñƒŠƒEƒ}ƒ`’†‰›‹³ˆçŒ¤C‰ï, 2001, 7, ‘åã

28.     ‰FŒŽ”ü˜aCàVˆä‚Žu: ŠÖߎ¾Š³‚É‚¨‚¯‚é–Ɖu‘gD‰»Šw‚Æ in situ hybridizationC ‘æ10‰ñd‘gD¶•¨Šw‰ï‘‰ï, 2001, 8, ·‰ª

29.     àVˆä‚Žu: ƒeƒŒƒpƒ\ƒƒW[‚ÌŒ»ó‚Æ“W–]C‘æ91‰ñ“ú–{•a—Šw‰ï‘‰ï, 2002, 3, ‰¡•l

30.     àVˆä‚Žu: ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¢‚ÄŠÖß‚Í‚¢‚©‚ɉó‚ê‚Ä‚¢‚­‚©C•½¬14”N“x–kŠC“¹E“Œ–k’n‹æƒŠƒEƒ}ƒ`‚̃PƒAŒ¤C‰ï, 2002, 9, ·‰ª

31.     ˆî“c·–ç: ƒŒƒWƒIƒlƒ‰‘®‹Û‚ÌŠî‘b’mŽ¯CƒŒƒWƒIƒlƒ‰‘ÎôƒZƒ~ƒi[, 2002, 11, ·‰ª

32.     ˆî“c·–ç: ŒŒ’†ƒGƒ“ƒhƒgƒLƒVƒ“—Ê‚ð‚Ç‚¤•]‰¿‚·‚é‚©C‘æ3‰ñbM‹}«ŒŒ‰tò‰»—Ö@Œ¤‹†‰ï“Á•Êu‰‰, 2002, 11, ¼–{

33.     ‰“ŽRe“ñ˜Y: _ŒoĶ—Ö@‚ÌŠî‘b \ _ŒoŒn‚ð\’z‚·‚é×–E‚©‚çl‚¦‚é \C‘æ‚P‚R‚S‰ñ“ú–{bˆãŠw‰ï, 2002, 9, Šò•Œ

34.     ‰“ŽRe“ñ˜Y: _Œo‘gD‚ÌĶ \ ƒOƒŠƒA×–E‚Ì–ðŠ„‚ðl‚¦‚é \C‘æ‚P‚R‰ñ“Œ–kŽÀŒ±“®•¨Œ¤‹†‰ï, 2002, 10, ·‰ª

35.     ‰FŒŽ”ü˜a: ƒ}ƒCƒNƒƒEƒF[ƒu‚ð—p‚¢‚½•W–{ˆ—‚ÌŽÀÛC“ú–{Œ°”÷‹¾Šw‰ï@ŠÖ“ŒŽx•”@‘æ27‰ñu‰‰‰ï, 2003, 3, “Œ‹ž

 

_ŒoĶE•Ï«Œ¤‹†•”–åi‰æ‘œ‰ðÍ•”–åj

36.     ²X–Ø^—: ”]‚ÌMR‰ð–U: updateC‘æ11‰ñVŠƒMR‰æ‘œŒ¤‹†‰ï, 1999, 9, VŠƒ

37.     ²X–Ø^—: ”]Ž¾Š³‚ÌMRI: MRIŒŸ¸–@C•úŽËü‰Èê–åˆã‰ï1999”N“xƒ~ƒbƒhƒTƒ}[ƒZƒ~ƒi[, 1999,7, “Œ‹ž

38.     ²X–Ø^—: “ª•”—̈æ‚ÌŽB‘œ‚É‚¨‚¯‚éT1ƒRƒ“ƒgƒ‰ƒXƒg—˜—p‚Ì—L—p«C ‘æ2‰ñMR Masters, 1999, 4, “Œ‹ž

39.     ²X–Ø^—: ’m‚Á‚Ä‚¨‚«‚½‚¢”]‹@”\‰ð–UC2000”N“x•úŽËü‰Èê–åˆã‰ïƒ~ƒbƒhƒTƒ}[ƒZƒ~ƒi[, 2000,7, “Œ‹ž

40.     ²X–Ø^—: ”]‚ÌMR‰ð–U: updateC‘æ45‰ñɪŒ§MRIŒ¤‹†‰ï, 2000, 6, ɪ

41.     ²X–Ø^—: —Õ°‚ɖ𗧂”]‚ÌMRI‰ð–UC ‘æ60‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïŠwp”­•\‰ï, 2001, 4, _ŒË

42.     ²X–Ø^—: ’´‚Ž¥êMRI‚ÌŒ»ó‚Æ«—ˆC‘æ24‰ñŽl‘MRŒ¤‹†‰ï, 2001, 3, ¼ŽR

43.     Sasaki M: Hippocampal formation and temporal lobe epilepsy, Asian-Oceanian Seminars on Diagnostic and Interventional Radiology, 2001, 6, Sapporo

44.     쑺—@: White matter disease‚ÌŠT”O‚Æ‚»‚ÌŒ`‘ÔŠw“IŠî”ÕC‘æ6‰ñ“Œ–k¸_•ª—ô•aŒ¤‹†‰ï, 2001, 6, å‘ä

45.     ²X–Ø^—: ’´‚Ž¥êMRI‚É‚æ‚é”]‚Ì‹@”\‰ð–UC‘æ4‰ñ–kŠC“¹“®‘Ôf’fƒZƒ~ƒi[, 2001, 6, ŽD–y

46.     ²X–Ø^—: MRI‚É‚æ‚鎋°‰ºŠj‚Ì“¯’èC‘æ16‰ñ“ú–{‘å”]Šî’êŠjŒ¤‹†‰ï, 2001, 7, ŽO“‡

47.     ²X–Ø^—: ‚Ä‚ñ‚©‚ñ‚̉摜f’fC‘æ2‰ñ–k—¢ƒjƒ…[ƒƒTƒCƒGƒ“ƒXƒtƒƒ“ƒeƒBƒA, 2001, 9, ‘Š–ÍŒ´

48.     ²X–Ø^—: 3 Tesla MRI‚ÌŠî‘b‚ÆŽÀÛC‘æ5‰ñMR Masters, 2001, 9, ‚‚­‚Î

49.     ¬ì²: ”]‘²’†ÅV‚ÌŽ¡—ÂƗ\–hC‘æ10‰ñŽs–¯ŒöŠJuÀ, 2001, 8, –¼ŒÃ‰®

50.     ²X–Ø^—: ‚Ä‚ñ‚©‚ñC’s•ðŽ¾Š³‚ÌMRIC ‘æ8‰ñŒF–{ƒƒfƒBƒJƒ‹ƒCƒ[ƒWƒ“ƒOŒ¤‹†‰ï, 2001, 10, ŒF–{

51.     ²X–Ø^—: ’´‚Ž¥êMRI‚ÌŒ»ó‚Æ«—ˆC‘æ8‰ñŒF–{ƒƒfƒBƒJƒ‹ƒCƒ[ƒWƒ“ƒOŒ¤‹†‰ï, 2001, 10, ŒF–{

52.     ²X–Ø^—: 3 Tesla MRI‚ÌŒ»ó‚Æ«—ˆC ‘æ22‰ñŒQ”nMRˆãŠwŒ¤‹†‰ï, 2001, 11, ‘O‹´

53.     ²X–Ø^—: ’´‚Ž¥êMRI‚ÌŒ»ó‚Æ«—ˆC‘æ73‰ñH“c¬Ž™_ŒoǗጟ“¢‰ï, 2001, 11, H“c

54.     Inoue T, Ogasawara K, Ogawa A: Clinical Impacts of 3.0 Tesla MR Imaging in Neurosurgery, MRI 2002 Clinical Update and Practical Applications postgraduate course, 2002, 2, Kauai

55.     ²X–Ø^—: ƒqƒg‚Ì’†•_ŒoŽ¾Š³C“ú–{bˆã—Õ°•a—Šw‰ï2002”N‘å‰ï, 2002, 2, “Œ‹ž

56.     ²X–Ø^—: ‚Ž¥ê3 Tesla MRIC‘æ26‰ñRadiology UpdateŠwpu‰‰‰ï, 2002, 3, “Œ‹ž

57.     ²X–Ø^—: ”]Žîᇉ摜f’f‚ÌpitfallC‘æ4‰ñŽRŒûŒ§”]ŽîᇃVƒ“ƒ|ƒWƒEƒ€, 2002, 5, ‰F•”

58.     ²X–Ø^—: MRIŽž‘ã‚Ì”]CT: ŒŒŠÇáŠQ‚ð’†S‚ÉC‘æ2‰ñŽRŒ`ƒfƒWƒ^ƒ‹‰æ‘œƒZƒ~ƒi[, 2002, 6, ŽRŒ`

59.     ²X–Ø^—: _Œo‰æ‘œ‰ð–U‚Æ_ŒoüˆÛ˜A—‚Ì’mŽ¯F‘¤“ª—tC•Ó‰ŒnC‘æ22‰ñ_Œo•úŽËüƒ[ƒNƒVƒ‡ƒbƒv, 2002, 7, •ÄŽq

60.     ²X–Ø^—: ‰æ‘œƒRƒ“ƒgƒ‰ƒXƒg‚ƃpƒ‹ƒXŒn—ñC‘æ24‰ñ“ú–{Ž¥‹C‹¤–ˆãŠw‰ïMRŠî‘buÀ, 2002, 8, ‹ž“s

61.     ²X–Ø^—: ’´‚Ž¥ê3 Tesla MRI‚ÌŒ»ó‚Æ«—ˆC ‘æ1‰ñ“Œ–kMR‹ZpŒ¤‹†‰ï, 2002, 9, å‘ä

62.     ²X–Ø^—: ”]‘²’†‚É‚¨‚¯‚éMDCT‚Ì–ðŠ„‚Æ«—ˆ“W–]C ‘æ3‰ñŽµŒG_Œo‰æ‘œ•×‹­‰ï, 2002, 12, •Ÿ‰ª

63.     ²X–Ø^—: MDCT‚ÌŒ»ó‚Æ«—ˆ \ _ŒoŒn‚ð’†S‚É \CƒtƒBƒŠƒbƒvƒXIDTƒZƒ~ƒi[, 2002, 11,     •Ÿ‰ª

64.     ²X–Ø^—F T1, T2, T2*‚Ƃ͉½‚©CŠî‘b‚ÌŠî‘bFT1‚Æinversion recoveryC‘æ38‰ñ“ú–{ˆãŠw•úŽËüŠw‰ïH‹G—Õ°‘å‰ï, 2002, 10, H“c

65.     ²X–Ø^—: ƒGƒrƒfƒ“ƒX‚ÉŠî‚­”]ŒŒŠÇáŠQ‚̉摜f’fC“ú–{•úŽËü‰Èê–åˆã‰ï•úŽËüf—ÃKƒCƒhƒ‰ƒCƒ“ô’èˆÏˆõ‰ïƒ[ƒLƒ“ƒOƒOƒ‹[ƒv‰ï‹c, 2002, 9, “Œ‹ž

66.     ²X–Ø^—: _Œo“`’B•¨Ž¿‚ÆŽó—e‘ÌC ‘æ23‰ñ_Œo•úŽËüƒ[ƒNƒVƒ‡ƒbƒv, 2003, 7, “ß{

67.     ²X–Ø^—: MDCT‚Æ’´‚Ž¥êMRI‚ÌŒ»ó‚ƉۑèC“ú—§ƒƒfƒBƒR‹Zpu‰‰‰ï, 2003, 7,

68.     ²X–Ø^—: ”]ŒŒŠÇáŠQ‚̉摜f’f \ ‹}«Šú”][Ç‚ð’†S‚É \C‘æ5‰ñMB”]ŒŒŠÇ“àŽ¡—ÃŒ¤‹†‰ï, 2003, 5, ¼–{

69.     ²X–Ø^—: MDCT‚ÌŒ»ó‚Æ«—ˆ \ ”]ŒŒŠÇáŠQ‚ð’†S‚É \C‘æ27‰ñ‹{èCTŒ¤‹†‰ï, 2003, 5, ‹{è

70.     ²X–Ø^—: ”]ŒŒŠÇáŠQ‚É‚¨‚¯‚éMSCT‚̈Ӌ`: Œ»ó‚Æ«—ˆC2003 Multislice CT advanced seminar, 2003, 3, ‰¡•l

71.     ²X–Ø^—: MDCT‚ÌŒ»ó‚Æ«—ˆ \ ”]ŒŒŠÇáŠQ‚ð’†S‚É \C The 4th CT conference, 2003, 3, ‰ªŽR

72.     ²X–Ø^—: ’´‚Ž¥êMRI‚ÌŒ»ó‚Æ«—ˆC‘æ16‰ñ“È–ØMRˆãŠwŒ¤‹†‰ï, 2003, 3, ‰F“s‹{

73.     ²X–Ø^—F: ’´‚Ž¥êMRI‚ÆMDCT‚ÌŒ»ó‚Æ«—ˆC ‘æ8‰ñ¬Ž™_ŒoǗጟ“¢‰ï, 2003, 2, ŽRŒ`

74.     ²X–Ø^—: 16—ñMDCT‚Æ3Tesla MRI‚̃Cƒ“ƒpƒNƒg \ ‚Ç‚±‚Ü‚Å‚Ý‚¦‚é‚Ì‚© \C‘æ26‰ñ“ú–{”]_ŒoCIŠw‰ï‘‰ï, 2003, 2, –¼ŒÃ‰®

75.     ²X–Ø^—: MELT-Japan‚É‚¨‚¯‚é‰æ‘œf’f‚Ì•W€‰»CzŠÂŠí•aŒ¤‹†ˆÏ‘õ”ï@’´‹}«Šú‹•ŒŒ«”]ŒŒŠÇáŠQ‚ɑ΂·‚é”ñNP“If’f@ƒ‚ƒjƒ^ƒŠƒ“ƒOƒVƒXƒeƒ€‚Ì\’z‚É, 2003, 1, ‹ž“s